## BEFORE THE VETERINARY MEDICAL BOARD DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

## IN THE MATTER OF THE PETITION FOR EARLY TERMINATION OF PROBATION OF KIM LEWIS KUHLMANN

Agency Case No. 4602018000299

## Office of Administrative Hearings Case No. 2025090684

## **HEARING EXHIBITS INDEX**

EX. #	DOCUMENT	I.D.	ADMIT
1	Notices of Hearing and Proofs of Service (Redacted)		
2	Certification of License History		
3	Veterinary Medical Board Case No. 4602018000299 Decision and Order re. Stipulated Settlement, effective December 30, 2022; Stipulated Settlement and Disciplinary Order No. 4602018000299, signed October 15, 2022; and First Amended Accusation, filed April 7, 2022. (Redacted)		
4	Petition for Early Termination of Probation (Redacted)		
5	Petitioner's Narrative Statement		
6	Letters of Recommendation (Redacted)		
7	Continued Education Certificates		
8	Petitioner's Resume (Redacted)		
9	Probation Compliance Report		

10	Probation Violation Letter, dated January 30, 2023 (Redacted)	
11	Probation Supervisor Approval Form (Redacted)	
12	Probation Violation Letter, dated May 26, 2023 (Redacted)	
13	Quarterly Probation Report (Redacted)	
14	Probation Violation Letter, dated June 25, 2024 (Redacted)	
15	Emails, Monthly Supervision Reports, and Supervision Review Logs (Redacted)	

## Exhibit 1



BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY • GAVIN NEWSOM, GOVERNOR
DEPARTMENT OF CONSUMER AFFAIRS • CALIFORNIA VETERINARY MEDICAL BOARD
1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2987
P (916) 515-5520 | Toll-Free (866) 229-0170 | www.vmb.ca.gov



#### VIA ELECTRONIC MAIL, CERTIFIED MAIL AND REGULAR MAIL

September 5, 2025

Dr. Kim L. Kuhlmann San Francisco Equine 15 Augusta Ct. Alamo, CA 94507-2301

Drew Couto Klinedinst Law 755 West A Street, Ste. 100 San Diego, CA 92101

RE: HEARING NOTICE OAH Case No. TBD

Petition for Reinstatement or Modification of Penalty - Dr. Kim L. Kuhlmann

Dear Dr. Kim L. Kuhlmann:

You are hereby notified that a hearing will be held before the California Veterinary Medical Board, Department of Consumer Affairs:

Date: Thursday, October 16, 2025

Time: 9:00 AM Pacific Time

**Location: Department of Consumer Affairs** 

Hearing Room 1625 N. Market Blvd Sacramento, CA 95834

Alternatively, in lieu of attending in-person at this hearing in the Sacramento office, you may attend and participate virtually via Webex:

#### Event address:

https://dca-meetings.webex.com/dca-meetings/j.php?MTID=m7ddadf7a4a8a1147878bd4349ec28e79

Event number: 2492 180 1395 Event password: CVMB1016

Phone audio conference: (415) 655-0001 Access code: 2492 180 0395 Passcode: 28621016 The hearing will be conducted before the California Veterinary Medical Board, Department of Consumer Affairs and an administrative law judge of the Office of Administrative Hearings, who will preside over the Petition for Reinstatement or Modification of Penalty.

You may be present at the hearing. You have the right to be represented by an attorney at your own expense. You are not entitled to the appointment of an attorney to represent you at public expense. You are entitled to represent yourself without legal counsel. You may present any relevant evidence and will be given full opportunity to cross-examine all witnesses testifying against you. You are entitled to the issuance of subpoenas to compel the attendance of witnesses and the production of books, documents, or other things by applying to:

Office of Administrative Hearings Attn: General Jurisdiction 2349 Gateway Oaks, Suite 200 Sacramento CA 95833

**INTREPRETER:** Pursuant to section 11435.20 of the Government Code, the hearing shall be conducted in English language. If a party or party's witness does not proficiently speak or understand the English language and before commencement of the hearing requests language assistance, an agency subject to the language assistance requirement in section 11435.15 of the Government Code shall provide a certified interpreter or an interpreter approved by the administrative law judge conducting the proceedings. The cost of providing the interpreter shall be paid by the agency having jurisdiction over the matter if the administrative law judge or hearing officer so directs, otherwise by the party for whom the interpreter is provided. If you or a witness requires the assistance of an interpreter, ample advance notice of this fact should be given to the Office of Administrative Hearings so that appropriate arrangements can be made.

**CONTINUANCES:** Under section 11524 of the Government Code, the agency may grant a continuance, but when an administrative law judge of the Office of Administrative Hearings has been assigned to the hearing, no continuance may be granted except by him or her or by the presiding judge for good cause. When seeking a continuance, a party shall apply for the continuance within 10 working days following the time the party discovered or reasonably should have discovered the event or occurrence which establishes good cause for the continuance. A continuance may be granted for good cause after the 10 working days have lapsed only if the party seeking the continuance is not responsible for and has made a good faith effort to prevent the condition or even establishing the good cause.

Please visit the Board's website at <a href="www.vmb.ca.gov">www.vmb.ca.gov</a> to view a copy of the agenda or you may contact me at (279) 895-6043 or via email at <a href="mailto:Rachel.McKowen@dca.ca.gov">Rachel.McKowen@dca.ca.gov</a>.

Sincerely,

Rachel McKowen
Probation Monitor
California Veterinary Medical Board

cc: Neva Tassan, Deputy Attorney General Drew Couto, Petitioner's Counsel



## BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY · GAVIN NEWSOM, GOVERNOR DEPARTMENT OF CONSUMER AFFAIRS · CALIFORNIA VETERINARY MEDICAL BOARD 1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2987 P (916) 515-5520 | Toll-Free (866) 229-0170 | www.vmb.ca.gov



#### VIA ELECTRONIC MAIL, CERTIFIED MAIL AND REGULAR MAIL

September 5, 2025

Drew Couto Klinedinst Law 755 West A Street, Ste. 100 San Diego, CA 92101

Dr. Kim L. Kuhlmann San Francisco Equine 15 Augusta Ct. Alamo, CA 94507-2301

RE: HEARING NOTICE OAH Case No. TBD

Petition for Reinstatement or Modification of Penalty – Dr. Kim L. Kuhlmann

Dear Dr. Kim L. Kuhlmann:

You are hereby notified that a hearing will be held before the California Veterinary Medical Board, Department of Consumer Affairs:

Date: Thursday, October 16, 2025

Time: 9:00 AM Pacific Time

**Location: Department of Consumer Affairs** 

Hearing Room 1625 N. Market Blvd Sacramento, CA 95834

Alternatively, in lieu of attending in-person at this hearing in the Sacramento office, you may attend and participate virtually via Webex:

#### **Event address:**

https://dca-meetings.webex.com/dca-meetings/j.php?MTID=m7ddadf7a4a8a1147878bd4349ec28e79

Event number: 2492 180 1395 Event password: CVMB1016

Phone audio conference: (415) 655-0001
Access code: 2492 180 0395
Passcode: 28621016

The hearing will be conducted before the California Veterinary Medical Board, Department of Consumer Affairs and an administrative law judge of the Office of Administrative Hearings, who will preside over the Petition for Reinstatement or Modification of Penalty.

You may be present at the hearing. You have the right to be represented by an attorney at your own expense. You are not entitled to the appointment of an attorney to represent you at public expense. You are entitled to represent yourself without legal counsel. You may present any relevant evidence and will be given full opportunity to cross-examine all witnesses testifying against you. You are entitled to the issuance of subpoenas to compel the attendance of witnesses and the production of books, documents, or other things by applying to:

Office of Administrative Hearings Attn: General Jurisdiction 2349 Gateway Oaks, Suite 200 Sacramento CA 95833

**INTREPRETER:** Pursuant to section 11435.20 of the Government Code, the hearing shall be conducted in English language. If a party or party's witness does not proficiently speak or understand the English language and before commencement of the hearing requests language assistance, an agency subject to the language assistance requirement in section 11435.15 of the Government Code shall provide a certified interpreter or an interpreter approved by the administrative law judge conducting the proceedings. The cost of providing the interpreter shall be paid by the agency having jurisdiction over the matter if the administrative law judge or hearing officer so directs, otherwise by the party for whom the interpreter is provided. If you or a witness requires the assistance of an interpreter, ample advance notice of this fact should be given to the Office of Administrative Hearings so that appropriate arrangements can be made.

**CONTINUANCES:** Under section 11524 of the Government Code, the agency may grant a continuance, but when an administrative law judge of the Office of Administrative Hearings has been assigned to the hearing, no continuance may be granted except by him or her or by the presiding judge for good cause. When seeking a continuance, a party shall apply for the continuance within 10 working days following the time the party discovered or reasonably should have discovered the event or occurrence which establishes good cause for the continuance. A continuance may be granted for good cause after the 10 working days have lapsed only if the party seeking the continuance is not responsible for and has made a good faith effort to prevent the condition or even establishing the good cause.

Please visit the Board's website at <a href="www.vmb.ca.gov">www.vmb.ca.gov</a> to view a copy of the agenda or you may contact me at (279) 895-6043 or via email at <a href="Rachel.McKowen@dca.ca.gov">Rachel.McKowen@dca.ca.gov</a>.

Sincerely,

Rachel McKowen
Probation Monitor
California Veterinary Medical Board

cc: Neva Tassan, Deputy Attorney General Drew Couto, Petitioner's Counsel



## BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY • GAVIN NEWSOM, GOVERNOR DEPARTMENT OF CONSUMER AFFAIRS • CALIFORNIA VETERINARY MEDICAL BOARD 1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2987 P (916) 515-5520 | Toll-Free (866) 229-0170 | www.vmb.ca.gov



### DECLARATION OF SERVICE BY CERTIFIED, REGULAR, & ELECTRONIC MAIL

**RE: Notice of Hearing** 

I, the undersigned declare that I am over 18 years of age; my business address is 1747 N. Market Boulevard, Suite 230, Sacramento, CA 95834. I served a true copy of the attached letter by Certified Mail on the following, by placing same in an envelope addressed as follows:

## **NAME AND ADDRESS**

Dr. Kim L. Kuhlmann San Francisco Equine 15 Augusta Ct. Alamo, CA 94507-2301

Drew Couto Klinedinst Law 755 West A Street, Ste. 100 San Diego, CA 92101

Neva Tassan, DAG Neva.Tassan@doj.ca.gov **CERTIFIED NUMBER:** 

**LICENSE NO: VET 8208** 

9589 0710 5270 2856 5943 72

9589 0710 5270 2856 5943 89

Email

Said envelope was then, on **September 5, 2025**, sealed and deposited in the United States Mail at 1747 N. Market Boulevard, Suite 230, Sacramento, CA 95834, the county in which I am employed, as certified mail with postage thereon fully prepaid, return receipt requested.

Executed on **September 5, 2025** at Sacramento, California.

I DECLARE UNDER PENALTY OF PERJURY UNDER THE LAWS OF THE STATE OF CALIFORNIA THAT THE FOREGOING IS TRUE AND CORRECT.

## **DECLARANT:**

SIGNATURE ON FILE **Emilia Gutierrez** 

Office Technician

**California Veterinary Medical Board** 

1 72	U.S. Postal Service <sup>™</sup> CERTIFIED MAIL <sup>®</sup> Domestic Mail Only	
943	For delivery information, visit our	r website at www.usps.com®.
LU.	and Jan Tea Trans US	AL USE
0710 5270 2856	Certified Mail Fee  \$ Extra Services & Fees (check box, add fee as ap) Return Receipt (hardcopy) Return Receipt (electronic) Certified Mail Restricted Delivery Adult Signature Required Adult Signature Restricted Delivery \$ Postage  \$ Total Postage and Fees	NOM Postmark Here
589	Sent To Street and Apt. No., or PO Box No.	of delivery (ed.) on the recipient's algorithm of the country of t
0	City, State, ZIP446 physical straum visits and the Visits PS Form 3800, January 2023 PSN 7530-0	9-02-000-9047 See Reverse for Instructions

7 <del>0</del> 7	U.S. Postal Service™ CERTIFIED MAIL®  Domestic Mail Only	REC	EIPT
_	For delivery information, visit out	website	at www.usps.com®.
5.1		AT	San Dange a vol.
56	Certified Mail Fee \$ 1000   10	e with Service <sup>0</sup> ,	Kuhlmann
u	Extra Services & Fees (check box, add fee as a) Return Receipt (hardcopy) Return Receipt (electronic)	opropriate)	NOH-Couto
25 70	Certified Mail Restricted Delivery \$	e outrines	of oldelisys for Here myo controls of
J U	Adult Signature Restricted Delivery \$	erb no	of Certified Miss service does not other thousands service automatically incl
7	\$ Total Postage and Fees		cetain Printly Mail Rums. For an additional teer and with a prope
ロイアロ	so theurstood a bean their trouble quippension	y request	andorsement on the mailplens, you do the following services:  List of the first service whet product
ro	Street and Apt. No., or PO Box No.	na m telan	of delivery flectrong the cooplent's a Course occosed a boroscopic strong on conditional of a charactery rel
7	City, State, ZIP+4® 200 200 4 10 10 10 10 10 10 10 10 10 10 10 10 10	mujai	Richtering 1785 mol 29 and according upy of 1186 mol 29 to all according

## Exhibit 2



BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY · GAVIN NEWSOM, GOVERNOR

DEPARTMENT OF CONSUMER AFFAIRS · CALIFORNIA VETERINARY MEDICAL BOARD

1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2987

P (916) 515-5520 | Toll-Free (866) 229-0170 | www.vmb.ca.gov



#### CERTIFICATION OF LICENSE HISTORY

This is to certify that I, Ashley Sanchez, Enforcement Manager of the California Veterinary Medical Board (Board), Department of Consumer Affairs, State of California, share the responsibility of maintaining control and custody of the official records of the Board. I made or caused to be made a diligent search of the files and records concerning the license history of Dr. Kim Kuhlmann. I have determined that the official records prepared by Board employees, acting within the scope of their duties, show the dates and time periods listed herein for the issuance, expiration, periods of invalidity, and renewals of the license, as well as citations issued and periods of formal Board discipline:

#### **VET No. 8208**:

Kim Lewis Kuhlmann San Francisco Equine Inc. 15 Augusta Ct. Alamo, CA 94507-2301

First Issued: March 7, 1983 Expiration: January 31, 2026

Status: Current Secondary Status: Probation

#### **HSP No. 6179**:

San Francisco Equine Inc. 15 Augusta Ct. Alamo, CA 94507-2301

First Issued: May 30, 2006
Expiration: May 31, 2026
Status: Current
Secondary Status: Probation

#### Discipline:

On or about April 7, 2022, the Board filed a First Amended Accusation (Case No. 4602018000299) against Respondent. On October 14, 2022, Respondent agreed to a Stipulated Settlement, placing his license on probation for four years with terms and conditions, effective December 30, 2022.

Dated at Sacramento, California, this 20th day of August 2025

SIGNATURE ON FILE

Ashley Sanchez, Enforcement Manager

Exhibit 3

# BEFORE THE VETERINARY MEDICAL BOARD DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the First Amended Accusation Against:

Kim Lewis Kuhlmann, DVM,

Veterinarian License No. VET 8208,

and

San Francisco Equine, Inc.

**Premises Registration No. HSP 6179** 

Respondents

Case No. 4602018000299

OAH No. 2021040361

## **DECISION AND ORDER**

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Veterinary Medical Board, Department of Consumer Affairs, State of California, as its Decision in this matter.

This Decision shall become effective on <u>December 30, 2022</u>.

It is so ORDERED November 30, 2022.

SIGNATURE ON FILE

Kathy Bowler, President
VETERINARY MEDICAL BOARD
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

1	Rob Bonta	
2	Attorney General of California KIM KASRELIOVICH	
3	Supervising Deputy Attorney General MICHAEL YI	
	Deputy Attorney General	
4	State Bar No. 217174 ELAINE YAN	
5	Deputy Attorney General State Bar No. 277961	
6	300 So. Spring Street, Suite 1702	
7	Los Angeles, CA 90013 Telephone: (213) 269-6483	
8	Facsimile: (916) 731-2126 E-mail: Michael.Yi@doj.ca.gov	
9	Attorneys for Complainant	
2012/03/15		
10	BEFOR VETERINARY MI	
11	DEPARTMENT OF CO	ONSUMER AFFAIRS
12	STATE OF CA	ALIFORNIA
13		
14	In the Matter of the Accusation Against:	Case No. 4602018000299
15	KIM LEWIS KUHLMANN SAN FRANCISCO EOUINE, INC.	OAH No. 2021040361
16		STIPULATED SETTLEMENT AND DISCIPLINARY ORDER
17	Veterinarian License No. VET 8208,	COLLABORAT MARGARITA SAARGARIGOTTONIANA VIOLETINA SAARGARIA
18	and	
19	SAN FRANCISCO EQUINE, INC.,	
20	KIM LEWIS KUHLMANN, DVM  Managing Licensee	
21	Wallastiis Dicelisee	
22		
23	Premises Registration No. HSP 6179,	
24	Respondents.	
14.700 92.400		
25		
26		
27		
28		

IT IS HEREBY STIPULATED AND AGREED by and between the parties to the aboveentitled proceedings that the following matters are true:

### **PARTIES**

- 1. Jessica Sieferman (Complainant) is the Executive Officer of the Veterinary Medical Board (Board). She brought this action solely in her official capacity and is represented in this matter by Rob Bonta, Attorney General of the State of California, by Michael Yi and Elaine Yan, Deputy Attorneys General.
- 2. Respondents Kim Lewis Kuhlmann (Respondent Kuhlmann) and San Francisco Equine, Inc. (Respondent SFE) are represented in this proceeding by attorney George M. Wallace of Wallace, Brown & Schwartz, whose address is: 215 North Marengo Ave, 3rd Floor, Pasadena, CA 91101-1504.
- 3. On March 3, 1983, the Board issued Veterinarian License Number VET 8208 to Respondent Kuhlmann. The Veterinarian License was in full force and effect at all times relevant to the charges brought in First Amended Accusation number 4602018000299, and will expire on January 31, 2024, unless renewed.
- 4. On May 30, 2006, the Board issued Premises Registration Number HSP 6179 to Respondent Kuhlmann, as managing licensee of the premises, San Francisco Equine, Inc. The Premises Registration was in full force and effect at all times relevant to the charges brought in First Amended Accusation number 4602018000299, and will expire on May 31, 2023, unless renewed.

#### **JURISDICTION**

- 5. First Amended Accusation number 4602018000299 was filed before the Board, and is currently pending against Respondents. The First Amended Accusation and all other statutorily required documents were properly served on Respondents on April 11, 2022. Respondents timely filed their Notice of Defense contesting the First Amended Accusation.
- A copy of First Amended Accusation number 4602018000299 is attached as Exhibit
   A and incorporated herein by reference.

## 

## 

## 

## 

## 

## 

## 

## ADVISEMENT AND WAIVERS

- 7. Respondents have carefully read, fully discussed with counsel, and understand the charges and allegations in First Amended Accusation number 4602018000299. Respondents have also carefully read, fully discussed with counsel, and understand the effects of this Stipulated Settlement and Disciplinary Order.
- 8. Respondents are fully aware of their legal rights in this matter, including the right to a hearing on the charges and allegations in the First Amended Accusation; the right to confront and cross-examine the witnesses against them; the right to present evidence and to testify on their own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision; and all other rights accorded by the California Administrative Procedure Act and other applicable laws.
- 9. Respondents voluntarily, knowingly, and intelligently waive and give up each and every right set forth above.

## **CULPABILITY**

- 10. Respondents understand and agree that the charges and allegations in First Amended Accusation number 4602018000299, if proven at a hearing, constitute cause for imposing discipline upon their Veterinarian License and Premises Registration.
- 11. For the purpose of resolving the First Amended Accusation without the expense and uncertainty of further proceedings, Respondents agree that, at a hearing, Complainant could establish a factual basis for the charges in the First Amended Accusation, and that Respondents hereby gives up their right to contest those charges.
- 12. Respondents agree that their Veterinarian License and Premises Registration are subject to discipline and they agree to be bound by the Board's probationary terms as set forth in the Disciplinary Order below.

////

////

////

2

3 4

5 6

7 8

9

10 11

12

13 14

15 16

17

18

19 20

21

22 23

24

25

26

27

28

#### **CONTINGENCY**

- 13. This stipulation shall be subject to approval by the Veterinary Medical Board. Respondents understand and agree that counsel for Complainant and the staff of the Veterinary Medical Board may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondents or their counsel. By signing the stipulation, Respondents understand and agree that they may not withdraw their agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.
- 14. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals.
- 15. This Stipulated Settlement and Disciplinary Order is intended by the parties to be an integrated writing representing the complete, final, and exclusive embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements, understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order may not be altered, amended, modified, supplemented, or otherwise changed except by a writing executed by an authorized representative of each of the parties.
- 16. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Disciplinary Order:

////

//// ////

////

////

#### **DISCIPLINARY ORDER**

IT IS HEREBY ORDERED that Veterinarian License Number VET 8208 and Premises Registration Number HSP 6179 issued to Respondent Kuhlmann are revoked. However, the revocation is stayed and Respondents are placed on probation for four (4) years on the following terms and conditions:

### 1. Obey All Laws

Respondent Kuhlmann shall obey all federal and state laws and regulations substantially related to the practice of veterinary medicine. Within thirty (30) days of any arrest, Respondent Kuhlmann shall notify the Board. Within thirty (30) days of any conviction, Respondent Kuhlmann shall report to the Board and provide proof of compliance with the terms and conditions of the court order including, but not limited to, probation and restitution requirements. Obey all laws shall not be tolled.

### 2. Quarterly Reports

Respondent Kuhlmann shall report quarterly to the Board or its designee, under penalty of perjury, on forms provided by the Board, stating whether there has been compliance with all terms and conditions of probation. Omission or falsification in any manner of any information on these reports shall constitute a violation of probation and shall result in the filing of an accusation and/or a petition to revoke probation against Respondents' license registration or permit. If the final written quarterly report is not made as directed, the period of probation shall be extended until the final report is received by the Board. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation.

### 3. Interview with the Board

Within 30 days off the effective date of the Decision, Respondent Kuhlmann shall appear in person for an interview with the Board or its designee to review the terms and conditions of probation. Thereafter, Respondent Kuhlmann shall, upon reasonable request, report or appear in person as directed. Interview with the Board shall not be tolled.

////

////

#### 4. Cooperation with Board Staff

Respondents shall cooperate with the Board's inspection program and with the Board's monitoring and investigation of Respondents' compliance with the terms and conditions of Respondents' probation. Respondents may receive the assistance of private counsel, but Respondents shall communicate directly with the Board or its designee, and written communications from the Board will only be sent to the Respondents. Respondents shall make available all patient records, hospital records, books, logs, and other documents relating to the practice of veterinary medicine to the Board, upon request.

Respondents shall claim all certified mail issued by the Board, respond in a timely manner to all notices and requests for information, and submit Reports, Identification Update reports or other reports similar in nature, as requested and directed by the Board or its designee.

Respondents are encouraged to contact the Board's probation monitoring program representative at any time Respondents have a question or concern regarding the terms and conditions of Respondents' probation.

## 5. **Probation Monitoring Costs**

Probation monitoring costs are set at a rate of \$100 per month for the duration of the probation. These costs shall be payable to the Board on a schedule as directed by the Board or its designee.

## 6. Changes of Employment or Address

Respondents shall notify the Board, and appointed probation monitor in writing, of any and all changes of employment, location, and address within fourteen (14) calendar days of such change. This includes, but is not limited to, termination or resignation from employment, change in employment status, and change in supervisors, administrators or directors. Respondents shall also notify Respondents' probation monitor AND the Board IN WRITING of any changes of residence or mailing address within fourteen (14) calendar days. P.O. Boxes are accepted for mailing purposes; however, Respondents must also provide Respondents' physical residence address as well.

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

#### 

## 

## 7. No Supervision of Students, Interns, or Residents

Respondent Kuhlmann shall not supervise students, interns, or residents.

### 8. **Notice to Employers**

During the period of probation, Respondent Kuhlmann shall notify all present and prospective employers of this Decision and the terms, conditions, and restrictions imposed on Respondents by this Decision, as follows:

Within thirty (30) days of the effective date of this Decision and within fifteen (15) days of Respondent Kuhlmann undertaking any new employment, Respondent Kuhlmann shall cause Respondent Kuhlmann's supervisor and/or managing licensee (licensee manager) to report to the Board in writing, acknowledging that the listed individual(s) has/have read this Decision, including the terms conditions, and restrictions imposed. It shall be Respondent Kuhlmann's responsibility to ensure that Respondent Kuhlmann's supervisor and/or licensee manager submit timely acknowledgment(s) to the Board.

If Respondent Kuhlmann provides veterinary services as a relief veterinarian, Respondent Kuhlmann shall notify each individual or entity with whom Respondent Kuhlmann is employed or contracted and require the supervisor and/or licensee manager to submit to the Board timely acknowledgment of receipt of the notice.

## 9. **Notice to Employees**

Throughout the probationary period, and in a manner that is visible to all licensed, registered, or permitted veterinary employees at the veterinary premises, Respondents shall post a notice provided or approved by the Board, that recites the violations for which Respondents have been disciplined and the terms and conditions of probation.

## 10. **Tolling of Probation**

Respondent Kuhlmann shall notify the Board or its designee in writing within fifteen (15) calendar days of any periods of non-practice lasting more than thirty (30) calendar days and shall notify the Board or its designee within fifteen (15) calendar days of Respondent Kuhlmann's return to practice. Any period of non-practice will result in the Respondent Kuhlmann's probation being tolled.

Non-practice is defined as any period of time exceeding thirty (30) calendar days in which Respondent Kuhlmann is not engaging in the practice of veterinary medicine in California.

It shall be considered a violation of probation if Respondent Kuhlmann's periods of temporary or permanent residence or practice outside California total two years. However, it shall not be considered a violation of probation if Respondent Kuhlmann is residing and practicing in another state of the United States and is on active probation with the licensing authority of that state, in which case the two-year tolling limitation period shall begin on the date probation is completed or terminated in that state.

The following terms and conditions, if required, shall not be tolled:

Obey All Laws
Interview with the Board
Tolling of Probation
Maintain a Current and Active License
Cost Recovery

Non-practice is also defined as any period that Respondent Kuhlmann fails to engage in the practice of veterinary medicine in California for a minimum of 24 hours per week for the duration of probation (except reasonable time away from work for vacations, illnesses, etc.) or as determined by the Board. While tolled for not meeting the hourly requirement, Respondent Kuhlmann shall comply with all terms and conditions of this Decision.

Any period of tolling will not apply to the reduction of the probationary term.

#### 11. Maintain a Current and Active License

At all times while on probation, Respondent Kuhlmann shall maintain a current and active license with the Board. Maintain a current and active license shall not be tolled.

## 12. **Violation of Probation**

If Respondents violate probation in any respect, the Board, after giving Respondents notice and the opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed. If an accusation or petition to revoke probation is filed against Respondents during probation, or if the Attorney General's office has been requested to prepare any disciplinary action against Respondents' license, the Board shall have continuing jurisdiction until the matter

10 11

12

13 14

15

16 17

18

19 20

21 22

23

24

25

26 27

28

is final, and the period of probation shall be extended until the matter is final. No petition for modification or termination of probation shall be considered while there is an accusation or petition to revoke probation pending against Respondents.

#### 13. **License Surrender While on Probation/Suspension**

Following the effective date of this Decision, should Respondent Kuhlmann cease to practice veterinary medicine due to retirement or health issues, or be otherwise unable to satisfy the terms and conditions of probation, Respondent Kuhlmann may tender his license to practice veterinary medicine to the Board for surrender. The Board or its designee has the discretion to grant the request for surrender or to take any other action it deems appropriate and reasonable. Upon formal acceptance of the license surrender, Respondent Kuhlmann will no longer be subject to the terms and conditions of probation. The surrender constitutes a record of discipline and shall become a part of the Respondent Kuhlmann's license history with the Board.

Respondent Kuhlmann must relinquish his license to the Board within ten (10) days of receiving notification from the Board that the surrender has been accepted.

#### 14. **Completion of Probation**

All costs for probation monitoring and/or mandatory premises inspections shall be borne by Respondents. Failure to pay all costs due shall result in an extension of probation until the matter is resolved and costs paid or a petition to revoke probation is filed. Upon successful completion of probation and all payment of fees due, Respondents' license or permit will be fully restored.

#### 15. **Cost Recovery**

Pursuant to Section 125.3 of the California Business and Professions Code, within thirty (30) days of the effective date of this Decision, Respondents shall pay to the Board its enforcement costs including investigation and prosecution, in the amount of \$71,001.01, which may be paid over time in accordance with a Board approved payment plan, within six (6) months before the end of the probation term. Cost recovery shall not be tolled.

#### **Inspections** 16.

If Respondent Kuhlmann is the owner or managing licensee of a veterinary premises, the following probationary conditions apply:

- (A) The location or mobile veterinary practice shall hold a current premises registration issued by the Board, and Respondent Kuhlmann shall make the practice or location available for inspections by a Board representative to determine whether the location or veterinary practice meets minimum standards for a veterinary premises. The inspections will be conducted on an announced or unannounced basis and shall be held during normal business hours. The Board reserves the right to conduct these inspections on at least a quarterly basis during probation. Respondent Kuhlmann shall pay the Board for the cost of each inspection, which is \$500.
- (B) As a condition precedent to any premises registration issued to Respondent Kuhlmann as Owner or managing licensee, the location or mobile veterinary practice for which application is made shall be inspected by a Board representative to determine whether the location or mobile veterinary practice meets minimum standards for a veterinary premises. Respondent Kuhlmann shall submit to the Board, along with any premises registration application, a \$500 inspection fee.

#### 17. Medical Records Review

Within 30 calendar days of the effective date of this Decision, Respondent Kuhlmann shall provide to the Board or its designee the name and qualifications of one or more proposed reviewer of the medical records of animal patients created and maintained by Respondents. If Respondent Kuhlmann's terms of probation include Supervised Practice, that supervisor also may serve as the medical records reviewer. Each reviewer shall be a licensed veterinarian in California, have held a valid California license for at least five (5) years, and have never been subject to any disciplinary action by the Board.

The Board or its designee shall provide the approved reviewer with copies of this Decision. Within fifteen (15) calendar days of the reviewer's receipt of this Decision, the reviewer shall sign an affirmation that they have reviewed the terms and conditions of this Decision and fully understands the role of the reviewer.

If Respondent Kuhlmann fails to obtain the Board's or its designee's approval of a reviewer within sixty (60) calendar days of the effective date of this Decision, Respondent Kuhlmann shall receive a notification from the Board or its designee to cease practicing veterinary medicine within three (3) calendar days after being notified. Respondent Kuhlmann shall cease practice

until a reviewer is approved to provide medical records review services.

The reviewer shall review a minimum of ten percent (10%) of Respondents' animal patient medical records or fifteen (15) records (whichever is greater), a minimum of twelve (12) times per year. The reviewer shall determine the method of random selection of medical records to review and shall access the medical records directly from where the medical records are being kept. Review of Respondents' medical records shall not be delegated to Respondents or Respondents' staff. The reviewer's random selection of medical records shall include medical records that correlate to the animal patient care issues or other issues identified in the disciplinary action that resulted in this Decision. Respondents are required to make all animal patient medical records available for immediate inspection and copying by the reviewer at all times during business hours. The reviewer shall immediately notify the Board's Probation Monitor if Respondents fail or refuse to make the medical records available for inspection and/or copying.

Any potential costs associated with conducting the medical records review shall be borne by Respondents.

The reviewer shall evaluate the medical records to assess 1) The medical necessity and appropriateness of Respondents' treatment; 2) Respondents' compliance with minimum standards of practice in the diagnosis and treatment of animal patients; 3) Respondents' maintenance of necessary and appropriate treatment; 4) Respondents' maintenance of necessary and appropriate records and chart entries; and 5) Respondents' compliance with existing statutes and regulations governing the practice of veterinary medicine.

The reviewer shall submit quarterly reports to the Board on a form designated by the Board. The reports shall be submitted by the reviewer directly to the Board's Probation Monitor within seven (7) calendar days after the end of the preceding quarter. The quarterly reporting periods and due dates are as follows:

Reporting Time Period	Due No Later Than
January 1 to March 31 (Quarter I)	April 7
April 1 to June 30 (Quarter II)	July 7
July 1 to September 30 (Quarter III)	October 7
October 1 to December 31 (Quarter IV)	January 7

2

3 4

5 6 7

9 10

8

12 13

11

18 19

20 21

22 23

24 25

26

27 28

#### 18. **Continuing Education**

Within sixty (60) days of the effective date of this Decision, and on an annual basis thereafter, Respondent Kuhlmann shall submit to the Board for its prior approval, an educational program or course related to recordkeeping which shall not be less than 8 hours per year, for each year of probation. Upon successful completion of the course, Respondent Kuhlmann shall provide proof to the Board. This program shall be in addition to the Continuing Education required of all licensees for licensure renewal. All costs shall be borne by Respondent Kuhlmann.

#### 19. Fine

Respondent Kuhlmann shall pay to the Board a fine in the amount of \$5,000 pursuant to Business and Professions Code sections 4875 and 4883, which may be paid over time in accordance with a Board approved payment plan, within six (6) months before the end of the probation term.

## ACCEPTANCE

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney George M. Wallace. I understand the stipulation and the effect it will have on my Veterinarian License and Premises Registration. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Veterinary Medical Board.

Respondent

I have read and fully discussed with Respondent Kim Lewis Kuhlmann the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.

DATED: October 15, 2022

George M. Wallace GEORGE M. WALLACE Attorney for Respondents

12

STIPULATED SETTLEMENT (4602018000299)

**ENDORSEMENT** The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Veterinary Medical Board. DATED: October 16, 2022 Respectfully submitted, ROB BONTA Attorney General of California KIM KASRELIOVICH Supervising Deputy Attorney General ELAINE YAN Deputy Attorney General Michael Gi MICHAEL YI Deputy Attorney General Attorneys for Complainant LA2021600024 

## Exhibit A

First Amended Accusation number 4602018000299

Î		
1	Rob Bonta	
2	Attorney General of California KIM KASRELIOVICH	
3	Supervising Deputy Attorney General MICHAEL YI	
	Deputy Attorney General	
4	State Bar No. 217174 ELAINE YAN	
5	Deputy Attorney General State Bar No. 277961	
6	300 So. Spring Street, Suite 1702 Los Angeles, CA 90013	
7	Telephone: (213) 269-6483 Facsimile: (916) 731-2126	
8	E-mail: Michael.Yi@doj.ca.gov  Attorneys for Complainant	
9		
10	BEFOR VETERINARY MI	
11	DEPARTMENT OF CO	ONSUMER AFFAIRS
12	STATE OF CA	ALIFORNIA
13		
14	In the Matter of the Accusation Against:	Case No. 4602018000299
15	KIM LEWIS KUHLMANN SAN FRANCISCO EOUINE, INC.	FIRST AMENDED ACCUSATION
16		
17	Veterinarian License No. VET 8208,	
18	and	
19	SAN FRANCISCO EQUINE, INC.,	
20	KIM LEWIS KUHLMANN, DVM  Managing Licensee	
21	Wallaging Licensee	
22	Describes Designation No. 110D (170	
23	Premises Registration No. HSP 6179,	
24	Respondents.	
25		
26		
27		
28		

**PARTIES** 

- Jessica Sieferman (Complainant) brings this First Amended Accusation (Accusation) solely in her official capacity as the Executive Officer of the Veterinary Medical Board (Board),
   Department of Consumer Affairs, State of California.
- 2. On or about March 7, 1983, the Board issued Veterinarian License Number VET 8208 to Kim Lewis Kuhlmann (Respondent Kuhlmann). The Veterinarian License was in full force and effect at all times relevant to the charges brought in this Accusation and will expire on January 31, 2024, unless renewed.
- 3. On or about May 30, 2006, the Board issued Premises Registration Number HSP 6179 to Respondent Kuhlmann, as managing licensee of the premises, San Francisco Equine, Inc. (Respondent SFE or SFE). Respondent Kuhlmann is the Chief Executive Officer of San Francisco Equine, Inc. The Premises Registration was in full force and effect at all times relevant to the charges brought in this Accusation and will expire on May 31, 2022, unless renewed.

## **JURISDICTION**

- 4. This Accusation is brought before the Board under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.
- 5. Section 118, subdivision (b), provides that suspension, expiration, surrender, or cancellation of a license shall not deprive the Board of jurisdiction to proceed with a disciplinary action during the period within which the license may be renewed, restored, reissued, or reinstated.
- 6. Section 4853.6 provides, in relevant part, that the Board shall withhold, suspend, or revoke registration of a veterinary premises when the license of the managing licensee to practice veterinary medicine is revoked or suspended.
- 7. Section 4875 provides, in relevant part, that the Board may revoke or suspend the license of any person to practice veterinary medicine, or any branch thereof, in this state for any causes provided in the Veterinary Medicine Practice Act (Bus. & Prof. Code § 4800, et seq.). In addition, the Board has the authority to assess a fine not in excess of \$5,000 against a licensee for

(KIM LEWIS KUHLMANN; SAN FRANCISCO EQUINE, INC.) FIRST AMENDED ACCUSATION

1		(2) The dangerous drugs or dangerous devices are necessary in the treatment of the
2		condition for which the prescriber is attending the patient.
3	13.	Section 4854 requires all premises where veterinary medicine, veterinary dentistry, or
4	veterinary	surgery is being practiced, and all instruments, apparatus and apparel used in
5	connection	n with those practices, to be kept clean and sanitary at all times, and conform to those
6	minimum	standards established by the Board.
7	14.	Section 4855 requires a veterinarian, as required by regulation of the Board, to keep a
8	written rec	cord of all animals receiving veterinary services, and provide a summary of that record
9	to the own	er of animals receiving veterinary services, when requested.
10	15.	Section 4883 states, in relevant part:
11		The board may deny, revoke, or suspend a license or registration or assess a fine as
12		
13		
14		(g) Unprofessional conduct, that includes, but is not limited to, the following:
15		••••
16		(3) A violation of any federal statute, rule, or regulation or any of the statutes, rules, or regulations of this state regulating dangerous drugs or controlled substances.
17		••••
18		(i) Fraud, deception, negligence, or incompetence in the practice of veterinary medicine.
19		••••
20		(o) Violation, or the assisting or abetting violation, of any regulations adopted by the
21		board pursuant to this chapter [the Veterinary Medicine Practice Act].
22	16.	Health and Safety Code section 11190 states, in relevant part:
23		
24		(c)(1) For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance that is dispensed by a prescriber pursuant to Section 4170 of the Business
25		and Professions Code, the prescriber shall record and maintain the following information:
26		(A) Full name, address, and the telephone number of the ultimate user or research
27		subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the
28		patient.
		4

1	(B) The prescriber's category of licensure and license number; federal controlled substance registration number; and the state medical license number of any prescriber
2	using the federal controlled substance registration number of a government-exempt facility.
3	(C) NDC (National Drug Code) number of the controlled substance dispensed.
4	(D) Quantity of the controlled substance dispensed.
5	(E) ICD-9 (diagnosis code), if available.
6	(F) Number of refills ordered.
7 8	(G) Whether the drug was dispensed as a refill of a prescription or as a first-time request.
9	(H) Date of origin of the prescription.
10	(2) (A) Each prescriber that dispenses controlled substances shall provide the
11	Department of Justice the information required by this subdivision on a weekly basis in a format set by the Department of Justice pursuant to regulation.
12	(B) The reporting requirement in this section shall not apply to the direct administration of a controlled substance to the body of an ultimate user.
13	(d) This section shall become operative on January 1, 2005.
14	(e) The reporting requirement in this section for Schedule IV controlled substances shall not apply to any of the following:
15 16	(1) The dispensing of a controlled substance in a quantity limited to an amount adequate to treat the ultimate user involved for 48 hours or less.
17 18	(2) The administration or dispensing of a controlled substance in accordance with any other exclusion identified by the United States Health and Human Service Secretary for the National All Schedules Prescription Electronic Reporting Act of 2005.
19	(f) Notwithstanding paragraph (2) of subdivision (c), the reporting requirement of the
20	information required by this section for a Schedule II or Schedule III controlled substance, in a format set by the Department of Justice pursuant to regulation, shall
21	be on a monthly basis for all of the following:
22	(1) The dispensing of a controlled substance in a quantity limited to an amount adequate to treat the ultimate user involved for 48 hours or less.
23	(2) The administration or dispensing of a controlled substance in accordance with any
24	other exclusion identified by the United States Health and Human Service Secretary for the National All Schedules Prescription Electronic Reporting Act of 2005.
25	17. Health and Safety Code section 111345 states: "Any drug or device is misbranded if
26	any word, statement, or other information required by or under this part to appear on the label or
27	labeling is not prominently placed on the label or labeling with conspicuousness, as compared

1	to be read and understood by the ordinary individual under customary conditions of purchase and
2	use."
3	18. Health and Safety Code section 111395, subdivision (a), provides that any drug is
4	misbranded if it is an imitation of another drug.
5	19. Health and Safety Code section 111440 states: "It is unlawful for any person to
6	manufacture, sell, deliver, hold, or offer for sale any drug or device that is misbranded."
7	20. Health and Safety Code section 111500 states, in relevant part, that a veterinarian
8	may personally furnish his or her own patient with drugs as are necessary in the treatment of the
9	condition for which he or she attends the patient provided that the drug is properly labeled to
10	show all the information required in Section 111480 except the prescription number.
11	The following information is required under Section 111480:
12	(a) Except where the prescriber orders otherwise, either the manufacturer's trade
13	name of the drug, or the generic name and the name of the manufacturer. Commonly used abbreviations may be used. Preparations containing two or more active
14	ingredients may be identified by the manufacturer's trade name or the commonly used name or the principal active ingredients.
15	(b) The directions for the use of the drug or device.
16	(c) The name of the patient(s).
17	(d) The name of the prescriber.
18	(e) The date of issue.
19	(f) The name, address of the furnisher, and prescription number or other means of identifying the prescription.
20	(g) The strength of the drug or drugs dispensed.
21	(h) The quantity of the drug or drugs dispensed.
22	
23	(i) The expiration date of the effectiveness of the drug or device if the information is included on the original label of the manufacturer of the drug or device.
24	REGULATORY PROVISIONS
25	21. Code of Federal Regulations, title 21, section 1304.22, provides, in relevant part:
26	Each person registered or authorized (by §§ 1301.13(e), 1307.11, 1307.13, or part
27	1317 of this chapter) to manufacture, distribute, dispense, import, export, reverse distribute, destroy, conduct research with controlled substances, or collect controlled substances from ultimate users, shall maintain records with the information listed in
28	substances from ultimate users, shall maintain records with the information listed in paragraphs (a) through (f) of this section.

1		(a) <i>Records for manufacturers</i> . Each person registered or authorized to manufacture controlled substances shall maintain records with the following information:
2		· · · ·
3		(2) For each controlled substance in finished form,
4		(i) The name of the substance;
5		(ii) Each finished form (e.g., 10-milligram tablet or 10-milligram concentration per
6		fluid ounce or milliliter) and the number of units or volume of finished form in each commercial container (e.g., 100-tablet bottle or 3-milliliter vial);
7		
8		(iv) The number of units of finished forms and/or commercial containers acquired
9		from other persons, including the date of and number of units and/or commercial containers in each acquisition to inventory and the name, address, and registration
10		number of the person from whom the units were acquired;
12 13		(vii) The number of commercial containers distributed to other persons, including the date of and number of containers in each reduction from inventory, and the name, address, and registration number of the person to whom the containers were
14		distributed; (viii) The number of commercial containers exported directly by the registrant (under a registration as an exporter), including the date, number of
15		containers and export permit or declaration number for each exportation; and
16		(ix) The number of units of finished forms and/or commercial containers distributed or disposed of in any other manner by the registrant (e.g., by distribution of
17		complimentary samples or by destruction), including the date and manner of distribution or disposal, the name, address, and registration number of the person to whom distributed, and the quantity in finished form distributed or disposed.
18		• • • •
19		
20		(c) Records for dispensers and researchers. Each person registered or authorized to dispense or conduct research with controlled substances shall maintain records with
21		the same information required of manufacturers pursuant to paragraph (a)(2)(i), (ii), (iv), (vii), and (ix) of this section. In addition, records shall be maintained of the
22		number of units or volume of such finished form dispensed, including the name and address of the person to whom it was dispensed, the date of dispensing, the number of
<ul><li>23</li><li>24</li></ul>		units or volume dispensed, and the written or typewritten name or initials of the individual who dispensed or administered the substance on behalf of the dispenser. In addition to the requirements of this paragraph, practitioners dispensing gamma
25		addition to the requirements of this paragraph, practitioners dispensing gammahydroxybutyric acid under a prescription must also comply with § 1304.26.
26	////	
27	////	
28	////	
20	1111	

- 22. California Code of Regulations (CCR), title 4, section 1867, subdivision (b), prohibits the possession and/or use on the premises of a facility under the jurisdiction of the California Horse Racing Board (CHRB) of any drug, substance, or medication by a veterinarian that has not been approved by the United States Food and Drug Administration for use in the United States.
  - 23. CCR, title 16, section 2030 states, in relevant part:

All fixed premises where veterinary medicine and its various branches are being practiced, and all instruments, apparatus and apparel used in connection with those the following minimum standards:

. . . .

(f) The veterinary premises shall meet the following standards:

. . . .

- (6) All drugs and biologicals shall be maintained, administered, dispensed and
- 24. CCR, title 16, section 2030.05, subdivision (b), states that the Licensee Manager is responsible for ensuring that the premises for which he/she is manager complies with the requirements in Code sections 4853, 4854, 4855 and 4856. The Licensee Manager is responsible for ensuring that the physical and operational components of a premises meet the minimum standards of practice as set forth in CCR, title 16, sections 2030 through 2032.5.
  - 25. CCR, title 16, section 2032.1 provides, in relevant part:
    - (a) It is unprofessional conduct for a veterinarian to administer, prescribe, dispense or furnish a drug, medicine, appliance, or treatment of whatever nature for the prevention, cure, or relief of a wound, fracture or bodily injury or disease of an animal without having first established a veterinarian-client-patient relationship with the animal patient or patients and the client, except where the patient is a wild animal or the owner is unknown.
    - (b) A veterinarian-client-patient relationship shall be established by the following:
    - (1) The client has authorized the veterinarian to assume responsibility for making medical judgments regarding the health of the animal, including the need for medical treatment,
    - (2) The veterinarian has sufficient knowledge of the animal(s) to initiate at least a general or preliminary diagnosis of the medical condition of the animal(s). This means that the veterinarian is personally acquainted with the care of the animal(s) by virtue of an examination of the animal or by medically appropriate and timely visits to the premises where the animals are kept, and

1 2		(3) The veterinarian has assumed responsibility for making medical judgments regarding the health of the animal and has communicated with the client a course of treatment appropriate to the circumstance.
3		(c) A drug shall not be prescribed for a duration inconsistent with the medical
4		condition of the animal(s) or type of drug prescribed. The veterinarian shall not prescribe a drug for a duration longer than one year from the date the veterinarian
5		examined the animal(s) and prescribed the drug.
6		(d) As used herein, "drug" shall mean any controlled substance, as defined by Section 4021 of the code, and any dangerous drug, as defined by Section 4022 of the code.
7		(e) No person may practice veterinary medicine in this state except within the context
8		of a veterinarian-client-patient relationship or as otherwise permitted by law. A veterinarian-client-patient relationship cannot be established solely by telephonic or electronic means.
9		
10	26.	CCR, title 16, section 2032.3 provides, in relevant part:
11		(a) Every veterinarian performing any act requiring a license pursuant to the
12		provisions of Chapter 11, Division 2, of the code, upon any animal or group of animals shall prepare a legible, written or computer generated record concerning the
13		animal or animals which shall contain the following information:
14		••••
15		(4) Except for herds or flocks, age, sex, breed, species, and color of the animal.
16		
17		(6) A history or pertinent information as it pertains to each animal, herd, or flock's medical status.
18		(7) Data, including that obtained by instrumentation, from the physical examination.
19		(8) Treatment and intended treatment plan, including medications, dosages, route of
20		administration, and frequency of use.
21		••••
22		(10) Diagnosis or assessment prior to performing a treatment or procedure.
23		(11) If relevant, a prognosis of the animal's condition.
24		(12) All medications and treatments prescribed and dispensed, including strength,
25		dosage, route of administration, quantity, and frequency of use.
26		(13) Daily progress, if relevant, and disposition of the case.
27	////	
28	////	
20	////	
		9

#### COST RECOVERY

27. Section 125.3 provides that a board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

## **DRUG CLASSIFICATIONS**

- 28. Acepromazine, commonly known as Ace, is a tranquilizer used in horses.

  Acepromazine is restricted for use by or on the order of a licensed veterinarian and is a dangerous drug pursuant to section 4022.
- 29. *Acetylcysteine*, sold as Acetyl-L-Cysteine, is an injectable used for a number of clinical uses in horses. Acetylcysteine is a dangerous drug pursuant to section 4022.
- 30. Adrenocorticotropic hormone, sold under the brand name ACTH, is an injectable polypeptide tropic hormone used in the treatment of adrenal cortex suppression and severe stress in horses. Adrenocorticotropic hormone is a dangerous drug pursuant to section 4022.
- 31. *Aminocaproic acid* is used to treat various bleeding disorders in horses. Aminocaproic acid is a dangerous drug pursuant to section 4022.
- 32. *Branched chain amino acids*, commonly known as BC2A paste, is marketed to support horse health and performance, including joints, muscles, hooves, skin and coat, mane and tail, and digestion.
- 33. *Bupivacaine hydrochloride*, sold as Marcaine, is a local anesthetic used to treat pain. Bupivacaine hydrochloride is a dangerous drug pursuant to section 4022.
- 34. *Butorphanol tartrate* is a narcotic, Schedule IV controlled substance pursuant to Health and Safety Code section 11057, subdivision (c)(3), and a dangerous drug pursuant to section 4022.
- 35. *Calcium gluconate* in an injectable in the treatment of hypocalcemic conditions. Calcium gluconate is a dangerous drug pursuant to section 4022.
- 36. *Carisprodol* is a depressant used as a muscle relaxant in horses. Meprobamate is the primary active metabolite in carisprodol. Meprobamate is a Schedule IV controlled substance

47. Flumethasone, sold under the brand name Flucort, is an injectable corticosteroid used
in horses for musculoskeletal conditions due to inflammation, where permanent structural
changes do not exist, such as bursitis, carpitis, osselets, and myositis. Flumethasone is a
dangerous drug pursuant to section 4022.

- 48. *Flunixin meglumine*, sold under the brand name Banamine, is an injectable non-steroidal anti-inflammatory drug (NSAID) approved for use in cattle and horses in the United States. Flunixin meglumine is a dangerous drug pursuant to section 4022.
- 49. *Glycopyrrolate* is a quaternary ammonium salt and synthetic anti-cholinergic drug that exerts peripheral anti-muscarinic effects on the respiratory tract. Glycopyrrolate is a dangerous drug pursuant to section 4022
- 50. *Guaifenesin* is a centrally acting skeletal muscle relaxant used in horses. Guaifenesin is a dangerous drug pursuant to section 4022.
- 51. *Heparin* is an anticoagulant drug used to treat a variety of medical conditions where there is excessive clotting or increased risk of clot formation. Heparin is a dangerous drug pursuant to section 4022
- 52. *Iodine in almond oil* is a compounded sterile drug prescribed for horses to treat tendon, ligament, and muscle strains. Iodine in almond oil is a dangerous drug pursuant to section 4022.
- 53. *Ketamine* is a Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (g), and a dangerous drug pursuant to section 4022.
- 54. *Ketoprofen*, sold under the brand name Ketofen, is an injectable NSAID used for the alleviation of inflammation and pain associated with musculoskeletal disorders in horses. Ketoprofen is a dangerous drug pursuant to section 4022.
- 55. *L-arginine* is an injectable prescribed for use in horses. L-arginine is a dangerous drug pursuant to section 4022.
- 56. *N-butyl alcohol*, commonly known as Clotol, is a pre-race bleeding medication. N-butyl alcohol is a dangerous drug pursuant to section 4022.

- 57. *Normosol-R* is a sterile, nonpyrogenic isotonic solution of electrolytes in water administered by intravenous infusion to treat dehydration, as fluid replacement during surgery, and in treating diseases, such as colic in horses. Normosol-R is a dangerous drug pursuant to section 4022.
- 58. *Omeprazole paste*, sold under the brand name Gastrogard, is used to treat equine gastric ulcers. Omeprazole paste is a dangerous drug pursuant to section 4022.
- 59. *Parapox ovis virus immunomodulator*, sold under the brand name Zylexis, is a vaccine used in the treatment of equine herpes virus or in periods of stress. Parapox ovis virus immunomodulator is a dangerous drug pursuant to section 4022.
- 60. Pentosan polysulfate sodium, sold under the brand name Pentosan, is approved for use as a post-surgical joint lavage, but is used off-label via intramuscular injection as a general joint supplement and anti-inflammatory. Pentosan is a dangerous drug pursuant to section 4022.
- 61. *Phenylbutazone*, commonly known as Bute and sold as Butazolidin, is an NSAID used to treat lameness in horses. Phenylbutazone is a dangerous drug pursuant to section 4022.
- 62. *Platinum Performance Equine* is a nutritional supplement marketed to support horse health and performance.
- 63. Polysulfated glycosaminoglycan, sold under the brand name Adequan, is used for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. Polysulfated glycosaminoglycan is a dangerous drug pursuant to section 4022.
- 64. *Magnesium sulfate*, commonly referred to as Magsul or Magsulfate, is used for muscle function. Magnesium sulfate is a dangerous drug pursuant to section 4022.
- 65. *Medroxyprogesterone* is a synthetic progestin hormone administered to mares off-label to suppress behavioral estrus and may be prescribed for behavior control.

  Medroxyprogesterone is a dangerous drug pursuant to section 4022.
- 66. *Methocarbamol*, sold under the brand name Robaxin-V, is a potent skeletal muscle relaxant, and federal law restricts this drug to use by or on the order of a licensed veterinarian. Methocarbamol is a dangerous drug pursuant to section 4022.

- 67. *Minocycline* is an antibiotic used in horses to treat susceptible bacterial infections and tick-borne diseases. Minocycline is a dangerous drug pursuant to section 4022.
- 68. *Reserpine* is a long-acting tranquilizer used in horses to sedate excitable or difficult horses. Reserpine is a dangerous drug pursuant to section 4022.
- 69. *Sarapin* is a prescription medication designed to reduce joint pain and inflammation in horses. Sarapin in a dangerous drug pursuant to section 4022.
- 70. Selenium-tocopherol, sold under the brand name E-SE, is an injectable drug and labeled for only veterinary use to control myositis syndrome, rapid respiration, profuse sweating, muscle spasms and stiffness. Selenium-tocopherol is restricted by federal law for use by or on the order of a licensed veterinarian and is a dangerous drug pursuant to section 4022.
- 71. *Seramune* is used for the treatment of failure of passive transfer in neonatal foals and sold for veterinary use. Seramune is a dangerous drug pursuant to section 4022.
- 72. *Sodium hyaluronate* injection, sold as Hylartin-V, is used to treat joint dysfunction in horses. Sodium hyaluronate is restricted for use by or on the order of a licensed veterinarian and is a dangerous drug pursuant to section 4022.
- 73. Sodium pentobarbital and phenytoin sodium solution, commonly referred to as Euthanasia Solution, is used to cause humane, painless, and rapid euthanasia of animals. Sodium pentobarbital and phenytoin sodium solution is restricted by federal law for use by or on the order of a licensed veterinarians, is a Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (c)(1)(C), and is a dangerous drug pursuant to section 4022.
- 74. *Stanozolol*, sold under the brand name Winstrol, is an anabolic steroid, Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (f), and a dangerous drug pursuant to section 4022.
- 75. Stop Two is a homeopathic animal medicine that is not FDA-approved for the treatment or mitigation of any disease. The Stop Two label states an indication "to reduce the incidence and severity of EPIH (bleeding) in performance horses." The label also states it is "RX Only for IV injection." Stop Two is a dangerous drug pursuant to section 4022.

- 76. *Trimethoprim and sulfadiazine*, sold as Uniprim, is an oral antibiotic powder used in horses to treat systemic bacterial infections. Trimethoprim and sulfadiazine is restricted for use by or on the order of a licensed veterinarian and is a dangerous drug pursuant to section 4022.
- 77. *Vitamin C*, an injectable nutritive supplement used in horses, is a dangerous drug pursuant to section 4022.
- 78. *Vitamin/electrolyte*, a substance injected or administered intravenously, is a dangerous drug pursuant to section 4022.
- 79. *Vitamins*, injectable nutritive supplements used in horses, are dangerous drugs pursuant to section 4022.
  - 80. Zylkene is a nutritional supplement marketed for calming horses.

# **FACTUAL ALLEGATIONS**

- 81. On or about September 22, 2017, the Board received a complaint from the California Horse Racing Board (CHRB) alleging that Respondent Kuhlmann and two other veterinarians employed at Respondent SFE, Dr. Kenneth Allison and Dr. Steven Boyer (collectively, "the SFE veterinarians"), prescribed and administered medications to equine patients per the trainer's instructions, without an examination or medical necessity. The complaint alleged the SFE veterinarians prescribed the medications because the equine patients were entered to race not to treat any specific condition diagnosed by the veterinarians. The complaint included CHRB veterinarian reports completed by the SFE veterinarians, dated June 2017 through August 2017. The reports showed that the trainers of SFE's equine patients, rather than the SFE veterinarians, made the decisions to prescribe and administer the medications.
- 82. On or about September 27, 2018, Board Inspector J. H., assisted by investigators J. A. and C. R. from the Department of Consumer Affairs, Division of Investigation, inspected Respondent SFE's premises (Board inspection). No SFE veterinarians were present during the inspection. J. A. requested that SFE's Office Manager, S. K., provide records for the equine patients allegedly treated by the SFE veterinarians. S. K. could not locate records for some of the equine patients. The records produced by S. K. showed that there was no examination, assessment, medical explanation, or quantity for the medication given to the equine patients.

1	d. BC2	A paste; and
2	e. Elec	trolyte paste.
3	86. On or about Ju	ly 2, 2017, without performing an examination and forming a
4	diagnosis of any condition	that required treatment, Respondent Kuhlmann prescribed, dispensed,
5	or administered the followi	ng medications to equine patient Y. T.:
6	a. Keto	profen;
7	b. Flun	nethasone;
8	c. BC2	A paste;
9	d. Elec	trolyte paste;
10	e. Con	ugated equine estrogen; and
11	f. Vita	min C-K injection.
12	87. On or about Ju	ly 2, 2017, without performing an examination and forming a
13	diagnosis of any condition	that required treatment, Respondent Kuhlmann prescribed, dispensed,
14	or administered the followi	ng medications to equine patient M. B.:
15	a. Flun	ixin meglumine injection;
16	b. Calc	ium gluconate injection;
17	c. Vita	min C injection;
18	d. BC2	A paste;
19	e. Elec	trolyte paste; and
20	f. Flun	nethasone.
21	88. On or about Ju	ly 2, 2017, without performing an examination and forming a
22	diagnosis of any condition	that required treatment, Respondent Kuhlmann prescribed, dispensed,
23	or administered the followi	ng medications to equine patient Mi. B.:
24	a. Flun	nethasone;
25	b. Flun	ixin meglumine injection;
26	c. Calc	ium gluconate injection;
27	d. Vita	min C injection;
28	e. BC2	A paste; and
		17
	ÎÎ	Ex. 3 - 032

1	f.	Electrolyte paste.
2		
3	89. On or a	bout July 2, 2017, without performing an examination and forming a
4	diagnosis of any cor	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
5	or administered the	following medications to equine patient Q. S.:
6	a.	Flumethasone;
7	b.	Flunixin meglumine injection;
8	c.	Calcium gluconate injection;
9	d.	Vitamin C injection;
10	e.	BC2A paste; and
11	f.	Electrolyte paste.
12	90. On or al	bout July 2, 2017, without performing an examination and forming a
13	diagnosis of any cor	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
14	or administered the	following medications to equine patient A. P.:
15	a.	Ketoprofen;
16	b.	Flumethasone;
17	c.	Pentosan polysulfate sodium;
18	d.	BC2A paste;
19	e.	Electrolyte paste;
20	f.	Methocarbamol injection;
21	g.	Estrone; and
22	h.	Adrenocorticotropic hormone.
23	91. On or al	bout August 1, 2017, without performing an examination and forming a
24	diagnosis of any cor	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
25	or administered the	following medications to equine patient S.:
26	a.	Ketoprofen;
27	b.	Flumethasone;
28	c.	Pentosan polysulfate sodium;
		18

d. Methocarbamol injection;  e. BC2A paste;  f. Electrolyte paste; and  g. Estrone.  92. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient M. M.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;			
f. Electrolyte paste; and g. Estrone.  92. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient M. M.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	1	d.	Methocarbamol injection;
g. Estrone.  92. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient M. M.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  2. f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	2	e.	BC2A paste;
92. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient M. M.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	3	f.	Electrolyte paste; and
diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient M. M.:  a. Ketoprofen; b. Flumethasone; c. Pentosan polysulfate sodium; d. Methocarbamol injection; e. BC2A paste; and f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen; b. Flumethasone; c. Pentosan polysulfate sodium; d. Methocarbamol injection; e. BC2A paste; and f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection; b. Flumethasone; c. Calcium gluconate injection;	4	g.	Estrone.
or administered the following medications to equine patient M. M.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	5	92. On or al	oout August 1, 2017, without performing an examination and forming a
a. Ketoprofen; b. Flumethasone; c. Pentosan polysulfate sodium; d. Methocarbamol injection; e. BC2A paste; and f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen; b. Flumethasone; c. Pentosan polysulfate sodium; d. Methocarbamol injection; e. BC2A paste; and f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection; b. Flumethasone; c. Calcium gluconate injection;	6	diagnosis of any cor	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	7	or administered the	following medications to equine patient M. M.:
c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	8	a.	Ketoprofen;
d. Methocarbamol injection; e. BC2A paste; and f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen; b. Flumethasone; c. Pentosan polysulfate sodium; d. Methocarbamol injection; e. BC2A paste; and f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone; c. Calcium gluconate injection;	9	b.	Flumethasone;
e. BC2A paste; and f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	10	c.	Pentosan polysulfate sodium;
f. Electrolyte paste.  93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	11	d.	Methocarbamol injection;
93. On or about August 1, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	12	e.	BC2A paste; and
diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient S. F.:  a. Ketoprofen;  b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	13	f.	Electrolyte paste.
or administered the following medications to equine patient S. F.:  a. Ketoprofen; b. Flumethasone; c. Pentosan polysulfate sodium; d. Methocarbamol injection; e. BC2A paste; and f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection; b. Flumethasone; c. Calcium gluconate injection;	14	93. On or al	pout August 1, 2017, without performing an examination and forming a
a. Ketoprofen; b. Flumethasone; c. Pentosan polysulfate sodium; d. Methocarbamol injection; e. BC2A paste; and f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection; b. Flumethasone; c. Calcium gluconate injection;	15	diagnosis of any cor	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
b. Flumethasone;  c. Pentosan polysulfate sodium;  d. Methocarbamol injection;  e. BC2A paste; and  f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	16	or administered the	following medications to equine patient S. F.:
c. Pentosan polysulfate sodium; d. Methocarbamol injection; e. BC2A paste; and f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection; b. Flumethasone; c. Calcium gluconate injection;	17	a.	Ketoprofen;
d. Methocarbamol injection; e. BC2A paste; and f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection; b. Flumethasone; c. Calcium gluconate injection;	18	b.	Flumethasone;
e. BC2A paste; and f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection; b. Flumethasone; c. Calcium gluconate injection;	19	c.	Pentosan polysulfate sodium;
f. Electrolyte paste.  94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	20	d.	Methocarbamol injection;
94. On or about August 3, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection; b. Flumethasone; c. Calcium gluconate injection;	21	e.	BC2A paste; and
diagnosis of any condition that required treatment, Respondent Kuhlmann prescribed, dispensed, or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection; b. Flumethasone; c. Calcium gluconate injection;	22	f.	Electrolyte paste.
or administered the following medications to equine patient L. T.:  a. Flunixin meglumine injection;  b. Flumethasone;  c. Calcium gluconate injection;	23	94. On or al	pout August 3, 2017, without performing an examination and forming a
26 a. Flunixin meglumine injection; 27 b. Flumethasone; 28 c. Calcium gluconate injection; 19	24	diagnosis of any cor	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
<ul> <li>b. Flumethasone;</li> <li>c. Calcium gluconate injection;</li> <li>19</li> </ul>	25	or administered the	following medications to equine patient L. T.:
c. Calcium gluconate injection;  19	26	a.	Flunixin meglumine injection;
19	27	b.	Flumethasone;
	28	c.	Calcium gluconate injection;
			19 Ex. 3 - 034

1	d.	Vitamin C injection;
2	e.	BC2A paste;
3	f.	Electrolyte paste; and
4	g.	Vitamin/electrolyte.
5	95. On or a	about August 3, 2017, without performing an examination and forming a
6	diagnosis of any co	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
7	or administered the	following medications to equine patient E. B.:
8	a.	Flunixin meglumine injection;
9	b.	Flumethasone;
10	c.	Calcium gluconate injection;
11	d.	Vitamin C injection;
12	e.	BC2A paste;
13	f.	Electrolyte paste; and
14	g.	Vitamin/electrolyte.
15	96. On or a	about August 3, 2017, without performing an examination and forming a
16	diagnosis of any co	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
17	or administered the	following medications to equine patient R. A.:
18	a.	Flunixin meglumine injection;
19	b.	Flumethasone;
20	c.	Calcium gluconate injection;
21	d.	Vitamin C injection;
22	e.	BC2A paste; and
23	f.	Electrolyte paste.
24	97. On or a	about August 3, 2017, without performing an examination and forming a
25	diagnosis of any co	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
26	or administered the	following medications to equine patient M.:
27	a.	Ketoprofen;
28	b.	Flumethasone;
		20 Ex. 3 - 035

1	c.	Pentosan polysulfate sodium;
2	d.	BC2A paste; and
3	e.	Electrolyte paste.
4	98. On or a	bout August 3, 2017, without performing an examination and forming a
5	diagnosis of any cor	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
6	or administered the	following medications to equine patient R. H.:
7	a.	Ketoprofen;
8	b.	Flumethasone;
9	c.	Pentosan polysulfate sodium;
10	d.	BC2A paste;
11	e.	Electrolyte paste; and
12	f.	Calcium gluconate injection.
13	99. On or a	bout August 4, 2017, without performing an examination and forming a
14	diagnosis of any cor	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
15	or administered the	following medications to equine patient O.:
16	a.	Flunixin meglumine injection;
17	b.	Methocarbamol injection;
18	c.	Flumethasone;
19	d.	Dimethyl sulfoxide IV;
20	e.	Polysulfated glycosaminoglycan injection; and
21	f.	Vitamin/electrolyte.
22	100. On or	about August 4, 2017, without performing an examination and forming a
23	diagnosis of any cor	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
24	or administered the	following medications to equine patient G. S.:
25	a.	Flunixin meglumine injection;
26	b.	Methocarbamol injection;
27	c.	Flumethasone;
28	d.	Dimethyl sulfoxide IV;
		21

1	e.	Vitamin/electrolyte;
2	f.	Stop Two; and
3	g.	Gastrogard paste.
4	101. On	or about August 4, 2017, without performing an examination and forming a
5	diagnosis of any	condition that required treatment, Respondent Kuhlmann prescribed, dispensed,
6	or administered the	he following medications to equine patient C. S.:
7	a.	Flunixin meglumine injection;
8	b.	Flumethasone;
9	c.	Calcium gluconate injection;
10	d.	Vitamin C injection;
11	e.	BC2A paste; and
12	f.	Electrolyte paste.
13	102. On	or about August 4, 2017, without performing an examination and forming a
14	diagnosis of any	condition that required treatment, Respondent Kuhlmann prescribed, dispensed,
15	or administered the	he following medications to equine patient A. M.:
16	a.	Flunixin meglumine injection;
17	b.	Flumethasone;
18	c.	Calcium gluconate injection;
19	d.	Vitamin C injection;
20	e.	BC2A paste; and
21	f.	Electrolyte paste.
22	103. On	or about August 4, 2017, without performing an examination and forming a
23	diagnosis of any	condition that required treatment, Respondent Kuhlmann prescribed, dispensed,
24	or administered the	he following medications to equine patient E.:
25	a.	Flunixin meglumine injection;
26	b.	Flumethasone;
27	c.	Calcium gluconate injection;
28	d.	Vitamin C injection;
		22 Ex. 3 - 037

1		e.	BC2A paste; and
2		f.	Electrolyte paste.
3	104.	On or a	about August 4, 2017, without performing an examination and forming a
4	diagnosis of a	ny cor	dition that required treatment, Respondent Kuhlmann prescribed, dispensed,
5	or administer	ed the	following medications to equine patient S.P.:
6		a.	Flunixin meglumine injection;
7		b.	Flumethasone;
8		c.	Calcium gluconate injection;
9		d.	Vitamin C injection;
10		e.	BC2A paste; and
11		f.	Electrolyte paste.
12	105.	On or	about August 16, 2017, without performing an examination and forming a
13	diagnosis of a	ny con	adition that required treatment, Respondent Kuhlmann prescribed, dispensed,
14	or administer	ed the	following medications to equine patient J. L.:
15		a.	Vitamin/Electrolyte;
16		b.	Ketoprofen injection;
17		c.	BC2A paste;
18		d.	Electrolyte paste; and
19		e.	Entrolyte packet.
20	106.	On or a	about August 16, 2017, without performing an examination and forming a
21	diagnosis of a	ny con	adition that required treatment, Respondent Kuhlmann prescribed, dispensed,
22	or administer	ed the	following medications to equine patient L. A.:
23		a.	Ketoprofen;
24		b.	Flumethasone;
25		c.	Calcium gluconate injection;
26		d.	Vitamin C injection;
27		e.	BC2A paste;
28		f.	Electrolyte paste; and
			23 Ex. 3 - 038

1	g.	Entrolyte packet.
2	107. On or	about August 16, 2017, without performing an examination and forming a
3	diagnosis of any con	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
4	or administered the	following medications to equine patient E. G.:
5	a.	Flunixin meglumine injection;
6	b.	Methocarbamol injection;
7	c.	Electrolytes D;
8	d.	Cyanocobalamin (2); and
9	e.	Calcium gluconate injection (2).
10	108. On or	about August 16, 2017, without performing an examination and forming a
11	diagnosis of any con	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
12	or administered the	following medications to equine patient S.:
13	a.	Ketoprofen;
14	b.	Flumethasone;
15	c.	Pentosan polysulfate sodium;
16	d.	BC2A paste;
17	e.	Electrolyte paste; and
18	f.	Methocarbamol injection.
19	109. On or	about August 16, 2017, without performing an examination and forming a
20	diagnosis of any con	ndition that required treatment, Respondent Kuhlmann prescribed, dispensed,
21	or administered the	following medications to equine patient D. E.:
22	a.	Polysulfated glycosaminoglycan injection;
23	b.	Ketoprofen;
24	c.	Flumethasone;
25	d.	BC2A paste;
26	e.	Entrolyte packet; and
27	f.	Adrenocorticotropic hormone.
28		

1	SECOND CAUSE FOR DISCIPLINE		
2	(Unprofessio	onal Conduct – Dispensing Dangerous Drugs Without Medical Necessity)	
3	115. Res	pondent Kuhlmann is subject to disciplinary action for unprofessional conduct	
4	under section 488	33, subdivision (g)(3), for violating section 4170, subdivision (a)(2). Respondent	
5	Kuhlmann disper	sed dangerous drugs to equine patients that were unnecessary for the treatment	
6	of any condition,	as follows:	
7	116. On o	or about July 2, 2017, without performing an examination and forming a	
8	diagnosis of any	condition that required treatment, Respondent Kuhlmann dispensed the	
9	following unnece	ssary dangerous drugs to equine patient W.:	
10	a.	Ketoprofen;	
11	b.	Flumethasone;	
12	c.	Vitamin C injection;	
13	d.	Pentosan polysulfate sodium;	
14	e.	Conjugated equine estrogen; and	
15	f.	Methocarbamol injection.	
16	117. On o	r about July 2, 2017, without performing an examination and forming a	
17	diagnosis of any	condition that required treatment, Respondent Kuhlmann dispensed the	
18	following unnece	ssary dangerous drugs to equine patient T. I.:	
19	a.	Ketoprofen;	
20	b.	Flumethasone; and	
21	c.	Pentosan polysulfate sodium.	
22	118. On o	r about July 2, 2017, without performing an examination and forming a	
23	diagnosis of any	condition that required treatment, Respondent Kuhlmann dispensed the	
24	following unnece	ssary dangerous drugs to equine patient Y. T.:	
25	a.	Ketoprofen;	
26	b.	Flumethasone;	
27	c.	Conjugated equine estrogen; and	
28	d.	Vitamin C injection.	

1	119.	On or	about July 2, 2017, without performing an examination and forming a
2	diagnosis of	any co	ndition that required treatment, Respondent Kuhlmann dispensed the
3	following u	nnecess	ary dangerous drugs to equine patient M. B.:
4		a.	Flunixin meglumine injection;
5		b.	Calcium gluconate injection;
6		c.	Vitamin C injection; and
7		d.	Flumethasone.
8	120.	On or	about July 2, 2017, without performing an examination and forming a
9	diagnosis of	any co	ndition that required treatment, Respondent Kuhlmann dispensed the
10	following u	nnecess	ary dangerous drugs to equine patient Mi. B.:
11		a.	Flumethasone;
12		b.	Flunixin meglumine injection;
13		c.	Calcium gluconate injection; and
14		d.	Vitamin C injection.
15	121.	On or	about July 2, 2017, without performing an examination and forming a
16	diagnosis of	any co	ndition that required treatment, Respondent Kuhlmann dispensed the
17	following u	nnecess	ary dangerous drugs to equine patient Q. S.:
18		a.	Flumethasone;
19		b.	Flunixin meglumine injection;
20		c.	Calcium gluconate injection; and
21		d.	Vitamin C injection.
22	122.	On or	about July 2, 2017, without performing an examination and forming a
23	diagnosis of	any co	ndition that required treatment, Respondent Kuhlmann dispensed the
24	following u	nnecess	ary dangerous drugs to equine patient A. P.:
25		a.	Ketoprofen;
26		b.	Flumethasone;
27		c.	Pentosan polysulfate sodium;
28		d.	Methocarbamol injection;

1	e. Estrone; and	
2	f. Adrenocorticotropic hormone.	
3	123. On or about August 1, 2017, without performing an examination and forming	a
4	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the	
5	following unnecessary dangerous drugs to equine patient S.:	
6	a. Ketoprofen;	
7	b. Flumethasone;	
8	c. Pentosan polysulfate sodium;	
9	d. Methocarbamol injection; and	
10	e. Estrone.	
11	124. On or about August 1, 2017, without performing an examination and forming	a
12	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the	
13	following unnecessary dangerous drugs to equine patient M. M.:	
14	a. Ketoprofen;	
15	b. Flumethasone;	
16	c. Pentosan polysulfate sodium; and	
17	d. Methocarbamol injection.	
18	125. On or about August 1, 2017, without performing an examination and forming	a
19	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the	
20	following unnecessary dangerous drugs to equine patient S. F.:	
21	a. Ketoprofen;	
22	b. Flumethasone;	
23	c. Pentosan polysulfate sodium; and	
24	d. Methocarbamol injection.	
25		
26		
27		
28		

1	126. On or about August 3, 2017, without performing an examination and forming a
2	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the
3	following unnecessary dangerous drugs to equine patient L. T.:
4	a. Flunixin meglumine injection;
5	b. Flumethasone;
6	c. Calcium gluconate injection;
7	d. Vitamin C injection; and
8	e. Vitamin/electrolyte.
9	127. On or about August 3, 2017, without performing an examination and forming a
10	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the
11	following unnecessary dangerous drugs to equine patient E. B.:
12	a. Flunixin meglumine injection;
13	b. Flumethasone;
14	c. Calcium gluconate injection;
15	d. Vitamin C injection; and
16	e. Vitamin/electrolyte.
17	128. On or about August 3, 2017, without performing an examination and forming a
18	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the
19	following unnecessary dangerous drugs to equine patient R. A.:
20	a. Flunixin meglumine injection;
21	b. Flumethasone;
22	c. Calcium gluconate injection; and
23	d. Vitamin C injection.
24	129. On or about August 3, 2017, without performing an examination and forming a
25	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the
26	following unnecessary dangerous drugs to equine patient M.:
27	a. Ketoprofen;
28	b. Flumethasone; and

1		c.	Pentosan polysulfate sodium.
2	130.	On or a	about August 3, 2017, without performing an examination and forming a
3	diagnosis of	any con	dition that required treatment, Respondent Kuhlmann dispensed the
4	following un	necessa	ry dangerous drugs to equine patient R. H.:
5		a.	Ketoprofen;
6		b.	Flumethasone;
7		c.	Pentosan polysulfate sodium; and
8		d.	Calcium gluconate injection.
9	131.	On or a	about August 4, 2017, without performing an examination and forming a
10	diagnosis of	any con	dition that required treatment, Respondent Kuhlmann dispensed the
11	following un	necessa	ry dangerous drugs to equine patient O.:
12		a.	Flunixin meglumine injection;
13		b.	Methocarbamol injection;
14		c.	Flumethasone;
15		d.	Polysulfated glycosaminoglycan injection; and
16		e.	Vitamin/electrolyte.
17	132.	On or a	about August 4, 2017, without performing an examination and forming a
18	diagnosis of	any con	dition that required treatment, Respondent Kuhlmann dispensed the
19	following un	necessa	ry dangerous drugs to equine patient G. S.:
20		a.	Flunixin meglumine injection;
21		b.	Methocarbamol injection;
22		c.	Flumethasone;
23		d.	Vitamin/electrolyte;
24		e.	Stop Two; and
25		f.	Gastrogard paste.
26	////		
27	////		
28	////		

	III	
1	133. On or about Augu	ast 4, 2017, without performing an examination and forming a
2	diagnosis of any condition that	required treatment, Respondent Kuhlmann dispensed the
3	following unnecessary dangero	us drugs to equine patient C. S.:
4	a. Flunixin	meglumine injection;
5	b. Flumeth	asone;
6	c. Calcium	gluconate injection; and
7	d. Vitamin	C injection.
8	134. On or about Augu	ast 4, 2017, without performing an examination and forming a
9	diagnosis of any condition that	required treatment, Respondent Kuhlmann dispensed the
10	following unnecessary dangero	us drugs to equine patient A. M.:
11	a. Flunixin	meglumine injection;
12	b. Flumeth	asone;
13	c. Calcium	gluconate injection; and
14	d. Vitamin	C injection.
15	135. On or about Augu	ast 4, 2017, without performing an examination and forming a
16	diagnosis of any condition that	required treatment, Respondent Kuhlmann dispensed the
17	following unnecessary dangero	us drugs to equine patient E.:
18	a. Flunixin	meglumine injection;
19	b. Flumeth	asone;
20	c. Calcium	gluconate injection; and
21	d. Vitamin	C injection.
22	136. On or about Augu	ast 4, 2017, without performing an examination and forming a
23	diagnosis of any condition that	required treatment, Respondent Kuhlmann dispensed the
24	following unnecessary dangero	us drugs to equine patient S.P.:
25	a. Flunixin	meglumine injection;
26	b. Flumeth	asone;
27	c. Calcium	gluconate injection; and
28	d. Vitamin	C injection.

1	137.	On or a	about August 16, 2017, without performing an examination and forming a
2	diagnosis of a	ny con	dition that required treatment, Respondent Kuhlmann dispensed the
3	following unn	ecessa	ry dangerous drugs to equine patient J. L.:
4		a.	Vitamin/electrolyte; and
5		b.	Ketoprofen injection.
6	138.	On or a	about August 16, 2017, without performing an examination and forming a
7	diagnosis of a	ny con	dition that required treatment, Respondent Kuhlmann dispensed the
8	following unn	ecessa	ary dangerous drugs to equine patient L. A.:
9		a.	Ketoprofen;
10		b.	Flumethasone;
11		c.	Calcium gluconate injection; and
12		d.	Vitamin C injection.
13	139.	On or a	about August 16, 2017, without performing an examination and forming a
14	diagnosis of a	ny con	dition that required treatment, Respondent Kuhlmann dispensed the
15	following unn	ecessa	ary dangerous drugs to equine patient E. G.:
16		a.	Flunixin meglumine injection;
17		b.	Methocarbamol injection;
18		c.	Cyanocobalamin (2); and
19		d.	Calcium gluconate injection (2).
20	140.	On or a	about August 16, 2017, without performing an examination and forming a
21	diagnosis of a	ny con	dition that required treatment, Respondent Kuhlmann dispensed the
22	following unn	ecessa	ary dangerous drugs to equine patient S.:
23		a.	Ketoprofen;
24		b.	Flumethasone;
25		c.	Pentosan polysulfate sodium; and
26		d.	Methocarbamol injection.
27	////		
28	////		

1	141. On or about August 16, 2017, without performing an examination and forming a
2	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the
3	following unnecessary dangerous drugs to equine patient D. E.:
4	a. Polysulfated glycosaminoglycan injection;
5	b. Ketoprofen;
6	c. Flumethasone; and
7	d. Adrenocorticotropic hormone.
8	142. On or about August 16, 2017, without performing an examination and forming a
9	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the
10	following unnecessary dangerous drugs to equine patient I. J.:
11	a. Polysulfated glycosaminoglycan injection;
12	b. Ketoprofen;
13	c. Flumethasone; and
14	d. Adrenocorticotropic hormone.
15	143. On or about August 16, 2017, without performing an examination and forming a
16	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the
17	following unnecessary dangerous drugs to equine patient N. J.:
18	a. Polysulfated glycosaminoglycan injection;
19	b. Ketoprofen;
20	c. Flumethasone; and
21	d. Adrenocorticotropic hormone.
22	144. On or about August 17, 2017, without performing an examination and forming a
23	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the
24	following unnecessary dangerous drug to equine patient W. N.: N-butyl alcohol.
25	145. On or about August 17, 2017, without performing an examination and forming a
26	diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the
27	following unnecessary dangerous drug to equine patient A.: N-butyl alcohol.

146. On or about August 17, 2017, without performing an examination and forming a diagnosis of any condition that required treatment, Respondent Kuhlmann dispensed the following unnecessary dangerous drug to equine patient U. G.: N-butyl alcohol.

### THIRD CAUSE FOR DISCIPLINE

# (Unprofessional Conduct – Failure to Establish a Veterinarian-Client-Patient Relationship)

- 147. Respondent Kuhlmann is subject to disciplinary action for unprofessional conduct under section 4883, subdivisions (g) and (o), and CCR, title 16, section 2032.1, subdivision (a). Respondent did not establish a veterinarian-client-patient relationship before administering, prescribing, dispensing, or furnishing a drug, medicine, application, or treatment, as follows:
- 148. As set forth in paragraphs 81 through 146 above, incorporated here by reference, Respondent Kuhlmann prescribed, dispensed, or administered drugs to equine patients, without establishing a veterinarian-client-patient relationship with the patients. Respondent Kuhlmann did not: (1) perform and/or document an examination of the patients; (2) form and/or document a diagnoses of any condition that required treatment; or (3) communicate and/or document the appropriate course of treatment with the client.
- 149. On August 16, 2017, Respondent Kuhlmann also provided pharynx treatment to equine patient M. G. Before providing treatment, Respondent did not: (1) perform and/or document an examination of M. G.; (2) form and/or document a diagnoses of any condition that required treatment; or (3) communicate and/or document the appropriate course of treatment with the client. Accordingly, Respondent Kuhlmann failed to establish the required veterinarian-client-patient relationship before treating M. G.

## **FOURTH CAUSE FOR DISCIPLINE**

## (Record keeping)

150. Respondent Kuhlmann is subject to disciplinary action under sections 4855 and 4883, subdivision (o), for failing to keep written records containing the information required under CCR, title 16, section 2032.3, for equine patients receiving veterinary services, as follows:

////

8 | ////

1	151.	The Pat	tient History Report for equine patient W., dated July 2, 2017, failed to
2	include the	following	g information:
3		a.	Age, sex, breed, and color of the equine patient as required under CCR,
4			title 16, section 2032.3, subdivision (a)(4);
5		b.	A history or pertinent information as it pertains to the equine patient's
6			medical statutes as required under CCR, title 16, section 2032.3,
7			subdivision (a)(6);
8		c.	Data, including that obtained by instrumentation, from the physical
9			examination of the equine patient as required under CCR, title 16, section
10			2032.3, subdivision (a)(7);
11		d.	Treatment and intended treatment plan, including medication dosages as
12			required under CCR, title 16, section 2032.3, subdivision (a)(8);
13		e.	Diagnosis or assessment prior to performing a treatment or procedure as
14			required under CCR, title 16, section 2032.3, subdivision (a)(10);
15		f.	A prognosis of the animal's condition as required under CCR, title 16,
16			section 2032.3, subdivision (a)(11);
17		g.	For each medication prescribed and dispensed, the strength, dosage, route
18			of administration, quantity, and frequency of use as required under CCR,
19			title 16, section 2032.3, subdivision (a)(12); and
20		h.	Daily progress and disposition of the case as required under CCR title 16,
21			section 2032.3, subdivision (a)(13).
22	152.	The Pat	tient History Report for equine patient T. I., dated July 2, 2017, failed to
23	include the	following	g information:
24		a.	A history or pertinent information as it pertains to the equine patient's
25			medical statutes as required under CCR, title 16, section 2032.3,
26			subdivision (a)(6);
27	////		
28	////		

1	b.	Data, including that obtained by instrumentation, from the physical
2		examination of the equine patient as required under CCR, title 16, section
3		2032.3, subdivision (a)(7);
4	c.	Treatment and intended treatment plan, including medication dosages as
5		required under CCR, title 16, section 2032.3, subdivision (a)(8);
6	d.	Diagnosis or assessment prior to performing a treatment or procedure as
7		required under CCR, title 16, section 2032.3, subdivision (a)(10);
8	e.	A prognosis of the animal's condition as required under CCR, title 16,
9		section 2032.3, subdivision (a)(11);
10	f.	For each medication prescribed and dispensed, the strength, dosage, route
11		of administration, quantity, and frequency of use as required under CCR,
12		title 16, section 2032.3, subdivision (a)(12); and
13	g.	Daily progress and disposition of the case as required under CCR title 16,
14		section 2032.3, subdivision (a)(13).
15	153. The Pa	tient History Report for equine patient Y. T., dated July 2, 2017, failed to
16	include the following	g information:
17	a.	Age, sex, breed, and color of the equine patient as required under CCR,
18		title 16, section 2032.3, subdivision (a)(4);
19	b.	A history or pertinent information as it pertains to the equine patient's
20		medical statutes as required under CCR, title 16, section 2032.3,
21		subdivision (a)(6);
22	c.	Data, including that obtained by instrumentation, from the physical
23		examination of the equine patient as required under CCR, title 16, section
24		2032.3, subdivision (a)(7);
25	d.	Treatment and intended treatment plan, including medication dosages as
26		required under CCR, title 16, section 2032.3, subdivision (a)(8);
27	e.	Diagnosis or assessment prior to performing a treatment or procedure as
28		required under CCR, title 16, section 2032.3, subdivision (a)(10);

1	f.	A prognosis of the animal's condition as required under CCR, title 16,
2		section 2032.3, subdivision (a)(11);
3	g.	For each medication prescribed and dispensed, the strength, dosage, route
4		of administration, quantity, and frequency of use as required under CCR,
5		title 16, section 2032.3, subdivision (a)(12); and
6	h.	Daily progress and disposition of the case as required under CCR title 16,
7		section 2032.3, subdivision (a)(13).
8	154. The Pa	atient History Report for equine patient M. B., dated July 2, 2017, failed to
9	include the followin	g information:
10	a.	Age, sex, breed, and color of the equine patient as required under CCR,
11		title 16, section 2032.3, subdivision (a)(4);
12	b.	A history or pertinent information as it pertains to the equine patient's
13		medical statutes as required under CCR, title 16, section 2032.3,
14		subdivision (a)(6);
15	c.	Data, including that obtained by instrumentation, from the physical
16		examination of the equine patient as required under CCR, title 16, section
17		2032.3, subdivision (a)(7);
18	d.	Treatment and intended treatment plan, including medication dosages as
19		required under CCR, title 16, section 2032.3, subdivision (a)(8);
20	e.	Diagnosis or assessment prior to performing a treatment or procedure as
21		required under CCR, title 16, section 2032.3, subdivision (a)(10);
22	f.	A prognosis of the animal's condition as required under CCR, title 16,
23		section 2032.3, subdivision (a)(11);
24	g.	For each medication prescribed and dispensed, the strength, dosage, route
25		of administration, quantity, and frequency of use as required under CCR,
26		title 16, section 2032.3, subdivision (a)(12); and
27	h.	Daily progress and disposition of the case as required under CCR title 16,
28		section 2032.3, subdivision (a)(13).

1	155.	The Pat	cient History Report for equine patient Mi. B., dated July 2, 2017, failed to
2	include the	following	g information:
3		a.	Age, sex, breed, and color of the equine patient as required under CCR,
4			title 16, section 2032.3, subdivision (a)(4);
5		b.	A history or pertinent information as it pertains to the equine patient's
6			medical statutes as required under CCR, title 16, section 2032.3,
7			subdivision (a)(6);
8		c.	Data, including that obtained by instrumentation, from the physical
9			examination of the equine patient as required under CCR, title 16, section
10			2032.3, subdivision (a)(7);
11		d.	Treatment and intended treatment plan, including medication dosages as
12			required under CCR, title 16, section 2032.3, subdivision (a)(8);
13		e.	Diagnosis or assessment prior to performing a treatment or procedure as
14			required under CCR, title 16, section 2032.3, subdivision (a)(10);
15		f.	A prognosis of the animal's condition as required under CCR, title 16,
16			section 2032.3, subdivision (a)(11);
17		g.	For each medication prescribed and dispensed, the strength, dosage, route
18			of administration, quantity, and frequency of use as required under CCR,
19			title 16, section 2032.3, subdivision (a)(12); and
20		h.	Daily progress and disposition of the case as required under CCR title 16,
21			section 2032.3, subdivision (a)(13).
22	156.	The Pat	tient History Report for equine patient Q. S., dated July 2, 2017, failed to
23	include the	following	g information:
24		a.	Age, sex, breed, and color of the equine patient as required under CCR,
25			title 16, section 2032.3, subdivision (a)(4);
26	////		
27	////		
28			

1	b.	A history or pertinent information as it pertains to the equine patient's
2		medical statutes as required under CCR, title 16, section 2032.3,
3		subdivision (a)(6);
4	c.	Data, including that obtained by instrumentation, from the physical
5		examination of the equine patient as required under CCR, title 16, section
6		2032.3, subdivision (a)(7);
7	d.	Treatment and intended treatment plan, including medication dosages as
8		required under CCR, title 16, section 2032.3, subdivision (a)(8);
9	e.	Diagnosis or assessment prior to performing a treatment or procedure as
10		required under CCR, title 16, section 2032.3, subdivision (a)(10);
11	f.	A prognosis of the animal's condition as required under CCR, title 16,
12		section 2032.3, subdivision (a)(11);
13	g.	For each medication prescribed and dispensed, the strength, dosage, route
14		of administration, quantity, and frequency of use as required under CCR,
15		title 16, section 2032.3, subdivision (a)(12); and
16	h.	Daily progress and disposition of the case as required under CCR title 16,
17		section 2032.3, subdivision (a)(13).
18	157. The Pa	tient History Report for equine patient A. P., dated July 2, 2017, failed to
19	include the following	g information:
20	a.	Age, sex, breed, and color of the equine patient as required under CCR,
21		title 16, section 2032.3, subdivision (a)(4);
22	b.	A history or pertinent information as it pertains to the equine patient's
23		medical statutes as required under CCR, title 16, section 2032.3,
24		subdivision (a)(6);
25	c.	Data, including that obtained by instrumentation, from the physical
26		examination of the equine patient as required under CCR, title 16, section
27		2032.3, subdivision (a)(7);
28		

1	d.	Treatment and intended treatment plan, including medication dosages as	
2		required under CCR, title 16, section 2032.3, subdivision (a)(8);	
3	e.	Diagnosis or assessment prior to performing a treatment or procedure as	
4		required under CCR, title 16, section 2032.3, subdivision (a)(10);	
5	f.	A prognosis of the animal's condition as required under CCR, title 16,	
6		section 2032.3, subdivision (a)(11);	
7	g.	For each medication prescribed and dispensed, the strength, dosage, route	
8		of administration, quantity, and frequency of use as required under CCR,	
9		title 16, section 2032.3, subdivision (a)(12); and	
10	h.	Daily progress and disposition of the case as required under CCR title 16,	
11		section 2032.3, subdivision (a)(13).	
12	158. The Pa	tient History Report for equine patient S., dated August 1, 2017, failed to	
13	include the following information:		
14	a.	Age, sex, and color of the equine patient as required under CCR, title 16,	
15		section 2032.3, subdivision (a)(4);	
16	b.	A history or pertinent information as it pertains to the equine patient's	
17		medical statutes as required under CCR, title 16, section 2032.3,	
18		subdivision (a)(6);	
19	c.	Data, including that obtained by instrumentation, from the physical	
20		examination of the equine patient as required under CCR, title 16, section	
21		2032.3, subdivision (a)(7);	
22	d.	Treatment and intended treatment plan, including medication dosages as	
23		required under CCR, title 16, section 2032.3, subdivision (a)(8);	
24	e.	Diagnosis or assessment prior to performing a treatment or procedure as	
25		required under CCR, title 16, section 2032.3, subdivision (a)(10);	
26	f.	A prognosis of the animal's condition as required under CCR, title 16,	
27		section 2032.3, subdivision (a)(11);	
28			

1		g.	For each medication prescribed and dispensed, the strength, dosage, route
2			of administration, quantity, and frequency of use as required under CCR,
3			title 16, section 2032.3, subdivision (a)(12); and
4	]	h.	Daily progress and disposition of the case as required under CCR title 16,
5			section 2032.3, subdivision (a)(13).
6	159. T	he Pat	ient History Report for equine patient M. M., dated August 1, 2017, failed to
7	include the following information:		
8	:	a.	A history or pertinent information as it pertains to the equine patient's
9			medical statutes as required under CCR, title 16, section 2032.3,
10			subdivision (a)(6);
11	1	b.	Data, including that obtained by instrumentation, from the physical
12			examination of the equine patient as required under CCR, title 16, section
13			2032.3, subdivision (a)(7);
14		c.	Treatment and intended treatment plan, including medication dosages as
15			required under CCR, title 16, section 2032.3, subdivision (a)(8);
16		d.	Diagnosis or assessment prior to performing a treatment or procedure as
17			required under CCR, title 16, section 2032.3, subdivision (a)(10);
18		e.	A prognosis of the animal's condition as required under CCR, title 16,
19			section 2032.3, subdivision (a)(11);
20	į	f.	For each medication prescribed and dispensed, the strength, dosage, route
21			of administration, quantity, and frequency of use as required under CCR,
22			title 16, section 2032.3, subdivision (a)(12); and
23		g.	Daily progress and disposition of the case as required under CCR title 16,
24			section 2032.3, subdivision (a)(13).
25	////		
26	////		
27	////		
28	////		

1	160.	The Pat	cient History Report for equine patient S. F., dated August 1, 2017, failed to
2	include the following information:		
3		a.	A history or pertinent information as it pertains to the equine patient's
4			medical statutes as required under CCR, title 16, section 2032.3,
5			subdivision (a)(6);
6		b.	Data, including that obtained by instrumentation, from the physical
7			examination of the equine patient as required under CCR, title 16, section
8			2032.3, subdivision (a)(7);
9		c.	Treatment and intended treatment plan, including medication dosages as
10			required under CCR, title 16, section 2032.3, subdivision (a)(8);
11		d.	Diagnosis or assessment prior to performing a treatment or procedure as
12			required under CCR, title 16, section 2032.3, subdivision (a)(10);
13		e.	A prognosis of the animal's condition as required under CCR, title 16,
14			section 2032.3, subdivision (a)(11);
15		f.	For each medication prescribed and dispensed, the strength, dosage, route
16			of administration, quantity, and frequency of use as required under CCR,
17			title 16, section 2032.3, subdivision (a)(12); and
18		g.	Daily progress and disposition of the case as required under CCR title 16,
19			section 2032.3, subdivision (a)(13).
20	161. The Patient History Report for equine patient L. T., dated August 3, 2017, failed to		
21	include the following information:		
22		a.	A history or pertinent information as it pertains to the equine patient's
23			medical statutes as required under CCR, title 16, section 2032.3,
24			subdivision (a)(6);
25		b.	Data, including that obtained by instrumentation, from the physical
26			examination of the equine patient as required under CCR, title 16, section
27			2032.3, subdivision (a)(7);
28			

1	c.	Treatment and intended treatment plan, including medication dosages as
2		required under CCR, title 16, section 2032.3, subdivision (a)(8);
3	d.	Diagnosis or assessment prior to performing a treatment or procedure as
4		required under CCR, title 16, section 2032.3, subdivision (a)(10);
5	e.	A prognosis of the animal's condition as required under CCR, title 16,
6		section 2032.3, subdivision (a)(11);
7	f.	For each medication prescribed and dispensed, the strength, dosage, route
8		of administration, quantity, and frequency of use as required under CCR,
9		title 16, section 2032.3, subdivision (a)(12); and
10	g.	Daily progress and disposition of the case as required under CCR title 16,
11		section 2032.3, subdivision (a)(13).
12	162. The Pa	atient History Report for equine patient M., dated August 3, 2017, failed to
13	include the followin	g information:
14	a.	Age, sex, breed, and color of the equine patient as required under CCR,
15		title 16, section 2032.3, subdivision (a)(4);
16	b.	A history or pertinent information as it pertains to the equine patient's
17		medical statutes as required under CCR, title 16, section 2032.3,
18		subdivision (a)(6);
19	c.	Data, including that obtained by instrumentation, from the physical
20		examination of the equine patient as required under CCR, title 16, section
21		2032.3, subdivision (a)(7);
22	d.	Treatment and intended treatment plan, including medication dosages as
23		required under CCR, title 16, section 2032.3, subdivision (a)(8);
24	e.	Diagnosis or assessment prior to performing a treatment or procedure as
25		required under CCR, title 16, section 2032.3, subdivision (a)(10);
26	f.	A prognosis of the animal's condition as required under CCR, title 16,
27		section 2032.3, subdivision (a)(11);
28		

1	g. For each medication prescribed and dispensed, the strength, dosage, route
2	of administration, quantity, and frequency of use as required under CCR,
3	title 16, section 2032.3, subdivision (a)(12); and
4	h. Daily progress and disposition of the case as required under CCR title 16,
5	section 2032.3, subdivision (a)(13).
6	163. The Patient History Report for equine patient R. H., dated August 3, 2017, failed to
7	include the following information:
8	a. A history or pertinent information as it pertains to the equine patient's
9	medical statutes as required under CCR, title 16, section 2032.3,
10	subdivision (a)(6);
11	b. Data, including that obtained by instrumentation, from the physical
12	examination of the equine patient as required under CCR, title 16, section
13	2032.3, subdivision (a)(7);
14	c. Treatment and intended treatment plan, including medication dosages as
15	required under CCR, title 16, section 2032.3, subdivision (a)(8);
16	d. Diagnosis or assessment prior to performing a treatment or procedure as
17	required under CCR, title 16, section 2032.3, subdivision (a)(10);
18	e. A prognosis of the animal's condition as required under CCR, title 16,
19	section 2032.3, subdivision (a)(11);
20	f. For each medication prescribed and dispensed, the strength, dosage, route
21	of administration, quantity, and frequency of use as required under CCR,
22	title 16, section 2032.3, subdivision (a)(12); and
23	g. Daily progress and disposition of the case as required under CCR title 16,
24	section 2032.3, subdivision (a)(13).
25	164. The Patient History Report for equine patient E. B., dated August 3, 2017, failed to
26	include the following information:
27	a. Age, sex, breed, and color of the equine patient as required under CCR,
28	title 16, section 2032.3, subdivision (a)(4);

1	b.	A history or pertinent information as it pertains to the equine patient's
2		medical statutes as required under CCR, title 16, section 2032.3,
3		subdivision (a)(6);
4	c.	Data, including that obtained by instrumentation, from the physical
5		examination of the equine patient as required under CCR, title 16, section
6		2032.3, subdivision (a)(7);
7	d.	Treatment and intended treatment plan, including medication dosages as
8		required under CCR, title 16, section 2032.3, subdivision (a)(8);
9	e.	Diagnosis or assessment prior to performing a treatment or procedure as
10		required under CCR, title 16, section 2032.3, subdivision (a)(10);
11	f.	A prognosis of the animal's condition as required under CCR, title 16,
12		section 2032.3, subdivision (a)(11);
13	g.	For each medication prescribed and dispensed, the strength, dosage, route
14		of administration, quantity, and frequency of use as required under CCR,
15		title 16, section 2032.3, subdivision (a)(12); and
16	h.	Daily progress and disposition of the case as required under CCR title 16,
17		section 2032.3, subdivision (a)(13).
18	165. The Pa	tient History Report for equine patient R. A., dated August 3, 2017, failed to
19	include the following	g information:
20	a.	Age, sex, and color of the equine patient as required under CCR, title 16,
21		section 2032.3, subdivision (a)(4);
22	b.	A history or pertinent information as it pertains to the equine patient's
23		medical statutes as required under CCR, title 16, section 2032.3,
24		subdivision (a)(6);
25	c.	Data, including that obtained by instrumentation, from the physical
26		examination of the equine patient as required under CCR, title 16, section
27		2032.3, subdivision (a)(7);
28		

1	d.	Treatment and intended treatment plan, including medication dosages as
2		required under CCR, title 16, section 2032.3, subdivision (a)(8);
3	e.	Diagnosis or assessment prior to performing a treatment or procedure as
4		required under CCR, title 16, section 2032.3, subdivision (a)(10);
5	f.	A prognosis of the animal's condition as required under CCR, title 16,
6		section 2032.3, subdivision (a)(11);
7	g.	For each medication prescribed and dispensed, the strength, dosage, route
8		of administration, quantity, and frequency of use as required under CCR,
9		title 16, section 2032.3, subdivision (a)(12); and
10	h.	Daily progress and disposition of the case as required under CCR title 16,
11		section 2032.3, subdivision (a)(13).
12	166. The Pat	ient History Report for equine patient O., dated August 4, 2017, failed to
13	include the following	information:
14	a.	A history or pertinent information as it pertains to the equine patient's
15		medical statutes as required under CCR, title 16, section 2032.3,
16		subdivision (a)(6);
17	b.	Data, including that obtained by instrumentation, from the physical
18		examination of the equine patient as required under CCR, title 16, section
19		2032.3, subdivision (a)(7);
20	c.	Treatment and intended treatment plan, including medication dosages as
21		required under CCR, title 16, section 2032.3, subdivision (a)(8);
22	d.	Diagnosis or assessment prior to performing a treatment or procedure as
23		required under CCR, title 16, section 2032.3, subdivision (a)(10);
24	e.	A prognosis of the animal's condition as required under CCR, title 16,
25		section 2032.3, subdivision (a)(11);
26	f.	For each medication prescribed and dispensed, the strength, dosage, route
27		of administration, quantity, and frequency of use as required under CCR,
28		title 16, section 2032.3, subdivision (a)(12); and

1		g.	Daily progress and disposition of the case as required under CCR title 16,
2			section 2032.3, subdivision (a)(13).
3	167.	The Pa	atient History Report for equine patient G. S., dated August 4, 2017, failed to
4	include the	followin	ng information:
5		a.	Age, sex, breed, and color of the equine patient as required under CCR,
6			title 16, section 2032.3, subdivision (a)(4);
7		b.	A history or pertinent information as it pertains to the equine patient's
8			medical statutes as required under CCR, title 16, section 2032.3,
9			subdivision (a)(6);
10		c.	Data, including that obtained by instrumentation, from the physical
11			examination of the equine patient as required under CCR, title 16, section
12			2032.3, subdivision (a)(7);
13		d.	Treatment and intended treatment plan, including medication dosages as
14			required under CCR, title 16, section 2032.3, subdivision (a)(8);
15		e.	Diagnosis or assessment prior to performing a treatment or procedure as
16			required under CCR, title 16, section 2032.3, subdivision (a)(10);
17		f.	A prognosis of the animal's condition as required under CCR, title 16,
18			section 2032.3, subdivision (a)(11);
19		g.	For each medication prescribed and dispensed, the strength, dosage, route
20			of administration, quantity, and frequency of use as required under CCR,
21			title 16, section 2032.3, subdivision (a)(12); and
22		h.	Daily progress and disposition of the case as required under CCR title 16,
23			section 2032.3, subdivision (a)(13).
24	168.	The Pa	atient History Report for equine patient C. S., dated August 4, 2017, failed to
25	include the	followin	g information:
26		a.	A history or pertinent information as it pertains to the equine patient's
27			medical statutes as required under CCR, title 16, section 2032.3,
28			subdivision (a)(6);
	i		

1		b.	Data, including that obtained by instrumentation, from the physical
2			examination of the equine patient as required under CCR, title 16, section
3			2032.3, subdivision (a)(7);
4		c.	Treatment and intended treatment plan, including medication dosages as
5			required under CCR, title 16, section 2032.3, subdivision (a)(8);
6		d.	Diagnosis or assessment prior to performing a treatment or procedure as
7			required under CCR, title 16, section 2032.3, subdivision (a)(10);
8		e.	A prognosis of the animal's condition as required under CCR, title 16,
9			section 2032.3, subdivision (a)(11);
10		f.	For each medication prescribed and dispensed, the strength, dosage, route
11			of administration, quantity, and frequency of use as required under CCR,
12			title 16, section 2032.3, subdivision (a)(12); and
13		g.	Daily progress and disposition of the case as required under CCR title 16,
14			section 2032.3, subdivision (a)(13).
15	169.	The Par	tient History Report for equine patient A. M., dated August 4, 2017, failed to
16	include the f	following	g information:
17		a.	A history or pertinent information as it pertains to the equine patient's
18			medical statutes as required under CCR, title 16, section 2032.3,
19			subdivision (a)(6);
20		b.	Data, including that obtained by instrumentation, from the physical
21			examination of the equine patient as required under CCR, title 16, section
22			2032.3, subdivision (a)(7);
23		c.	Treatment and intended treatment plan, including medication dosages as
24			required under CCR, title 16, section 2032.3, subdivision (a)(8);
25		d.	Diagnosis or assessment prior to performing a treatment or procedure as
26			required under CCR, title 16, section 2032.3, subdivision (a)(10);
27		e.	A prognosis of the animal's condition as required under CCR, title 16,
28			section 2032.3, subdivision (a)(11);

1	f.	For each medication prescribed and dispensed, the strength, dosage, route
2		of administration, quantity, and frequency of use as required under CCR,
3		title 16, section 2032.3, subdivision (a)(12); and
4	g.	Daily progress and disposition of the case as required under CCR title 16,
5		section 2032.3, subdivision (a)(13).
6	170. The Pat	ient History Report for equine patient E., dated August 4, 2017, failed to
7	include the following	g information:
8	a.	A history or pertinent information as it pertains to the equine patient's
9		medical statutes as required under CCR, title 16, section 2032.3,
10		subdivision (a)(6);
11	b.	Data, including that obtained by instrumentation, from the physical
12		examination of the equine patient as required under CCR, title 16, section
13		2032.3, subdivision (a)(7);
14	c.	Treatment and intended treatment plan, including medication dosages as
15		required under CCR, title 16, section 2032.3, subdivision (a)(8);
16	d.	Diagnosis or assessment prior to performing a treatment or procedure as
17		required under CCR, title 16, section 2032.3, subdivision (a)(10);
18	e.	A prognosis of the animal's condition as required under CCR, title 16,
19		section 2032.3, subdivision (a)(11);
20	f.	For each medication prescribed and dispensed, the strength, dosage, route
21		of administration, quantity, and frequency of use as required under CCR,
22		title 16, section 2032.3, subdivision (a)(12); and
23	g.	Daily progress and disposition of the case as required under CCR title 16,
24		section 2032.3, subdivision (a)(13).
25	////	
26	////	
27	////	
28	////	

1	171. The Pa	atient History Report for equine patient S.P., dated August 4, 2017, failed to
2	include the followin	g information:
3	a.	A history or pertinent information as it pertains to the equine patient's
4		medical statutes as required under CCR, title 16, section 2032.3,
5		subdivision (a)(6);
6	b.	Data, including that obtained by instrumentation, from the physical
7		examination of the equine patient as required under CCR, title 16, section
8		2032.3, subdivision (a)(7);
9	c.	Treatment and intended treatment plan, including medication dosages as
10		required under CCR, title 16, section 2032.3, subdivision (a)(8);
11	d.	Diagnosis or assessment prior to performing a treatment or procedure as
12		required under CCR, title 16, section 2032.3, subdivision (a)(10);
13	e.	A prognosis of the animal's condition as required under CCR, title 16,
14		section 2032.3, subdivision (a)(11);
15	f.	For each medication prescribed and dispensed, the strength, dosage, route
16		of administration, quantity, and frequency of use as required under CCR,
17		title 16, section 2032.3, subdivision (a)(12); and
18	g.	Daily progress and disposition of the case as required under CCR title 16,
19		section 2032.3, subdivision (a)(13).
20	172. The Pa	atient History Report for equine patient D. E., dated August 16, 2017, failed to
21	include the followin	g information:
22	a.	A history or pertinent information as it pertains to the equine patient's
23		medical statutes as required under CCR, title 16, section 2032.3,
24		subdivision (a)(6);
25	b.	Data, including that obtained by instrumentation, from the physical
26		examination of the equine patient as required under CCR, title 16, section
27		2032.3, subdivision (a)(7);
28		

1	c.	Treatment and intended treatment plan, including medication dosages as
2		required under CCR, title 16, section 2032.3, subdivision (a)(8);
3	d.	Diagnosis or assessment prior to performing a treatment or procedure as
4		required under CCR, title 16, section 2032.3, subdivision (a)(10);
5	e.	A prognosis of the animal's condition as required under CCR, title 16,
6		section 2032.3, subdivision (a)(11);
7	f.	For each medication prescribed and dispensed, the strength, dosage, route
8		of administration, quantity, and frequency of use as required under CCR,
9		title 16, section 2032.3, subdivision (a)(12); and
10	g.	Daily progress and disposition of the case as required under CCR title 16,
11		section 2032.3, subdivision (a)(13).
12	173. The Pat	ient History Report for equine patient I. J., dated August 16, 2017, failed to
13	include the following	g information:
14	a.	A history or pertinent information as it pertains to the equine patient's
15		medical statutes as required under CCR, title 16, section 2032.3,
16		subdivision (a)(6);
17	b.	Data, including that obtained by instrumentation, from the physical
18		examination of the equine patient as required under CCR, title 16, section
19		2032.3, subdivision (a)(7);
20	c.	Treatment and intended treatment plan, including medication dosages as
21		required under CCR, title 16, section 2032.3, subdivision (a)(8);
22	d.	Diagnosis or assessment prior to performing a treatment or procedure as
23		required under CCR, title 16, section 2032.3, subdivision (a)(10);
24	e.	A prognosis of the animal's condition as required under CCR, title 16,
25		section 2032.3, subdivision (a)(11);
26	f.	For each medication prescribed and dispensed, the strength, dosage, route
27		of administration, quantity, and frequency of use as required under CCR,
28		title 16, section 2032.3, subdivision (a)(12); and
	i	

1	g. Daily progress and disposition of the case as required under CCR title 16,
2	section 2032.3, subdivision (a)(13).
3	174. The Patient History Report for equine patient N. J., dated August 16, 2017, failed to
4	include the following information:
5	a. A history or pertinent information as it pertains to the equine patient's
6	medical statutes as required under CCR, title 16, section 2032.3,
7	subdivision (a)(6);
8	b. Data, including that obtained by instrumentation, from the physical
9	examination of the equine patient as required under CCR, title 16, section
10	2032.3, subdivision (a)(7);
11	c. Treatment and intended treatment plan, including medication dosages as
12	required under CCR, title 16, section 2032.3, subdivision (a)(8);
13	d. Diagnosis or assessment prior to performing a treatment or procedure as
14	required under CCR, title 16, section 2032.3, subdivision (a)(10);
15	e. A prognosis of the animal's condition as required under CCR, title 16,
16	section 2032.3, subdivision (a)(11);
17	f. For each medication prescribed and dispensed, the strength, dosage, route
18	of administration, quantity, and frequency of use as required under CCR,
19	title 16, section 2032.3, subdivision (a)(12); and
20	g. Daily progress and disposition of the case as required under CCR title 16,
21	section 2032.3, subdivision (a)(13).
22	175. The Patient History Report for equine patient J. L., dated August 16, 2017, failed to
23	include the following information:
24	a. A history or pertinent information as it pertains to the equine patient's
25	medical statutes as required under CCR, title 16, section 2032.3,
26	subdivision (a)(6);
27	
28	

1	b.	Data, including that obtained by instrumentation, from the physical
2		examination of the equine patient as required under CCR, title 16, section
3		2032.3, subdivision (a)(7);
4	c.	Treatment and intended treatment plan, including medication dosages as
5		required under CCR, title 16, section 2032.3, subdivision (a)(8);
6	d.	Diagnosis or assessment prior to performing a treatment or procedure as
7		required under CCR, title 16, section 2032.3, subdivision (a)(10);
8	e.	A prognosis of the animal's condition as required under CCR, title 16,
9		section 2032.3, subdivision (a)(11);
10	f.	For each medication prescribed and dispensed, the strength, dosage, route
11		of administration, quantity, and frequency of use as required under CCR,
12		title 16, section 2032.3, subdivision (a)(12); and
13	g.	Daily progress and disposition of the case as required under CCR title 16,
14		section 2032.3, subdivision (a)(13).
15	176. The P	ratient History Report for equine patient L. A., dated August 16, 2017, failed to
16	include the following	ng information:
17	a.	A history or pertinent information as it pertains to the equine patient's
18		medical statutes as required under CCR, title 16, section 2032.3,
19		subdivision (a)(6);
20	b.	Data, including that obtained by instrumentation, from the physical
21		examination of the equine patient as required under CCR, title 16, section
22		2032.3, subdivision (a)(7);
23	c.	Treatment and intended treatment plan, including medication dosages as
24		required under CCR, title 16, section 2032.3, subdivision (a)(8);
25	d.	Diagnosis or assessment prior to performing a treatment or procedure as
26		required under CCR, title 16, section 2032.3, subdivision (a)(10);
27	e.	A prognosis of the animal's condition as required under CCR, title 16,
28		section 2032.3, subdivision (a)(11);

1	f. For each medication prescribed and dispensed, the strength, dosage, route
2	of administration, quantity, and frequency of use as required under CCR,
3	title 16, section 2032.3, subdivision (a)(12); and
4	g. Daily progress and disposition of the case as required under CCR title 16,
5	section 2032.3, subdivision (a)(13).
6	177. The Patient History Report for equine patient E. G., dated August 16, 2017, failed to
7	include the following information:
8	a. A history or pertinent information as it pertains to the equine patient's
9	medical statutes as required under CCR, title 16, section 2032.3,
10	subdivision (a)(6);
11	b. Data, including that obtained by instrumentation, from the physical
12	examination of the equine patient as required under CCR, title 16, section
13	2032.3, subdivision (a)(7);
14	c. Treatment and intended treatment plan, including medication dosages as
15	required under CCR, title 16, section 2032.3, subdivision (a)(8);
16	d. Diagnosis or assessment prior to performing a treatment or procedure as
17	required under CCR, title 16, section 2032.3, subdivision (a)(10);
18	e. A prognosis of the animal's condition as required under CCR, title 16,
19	section 2032.3, subdivision (a)(11);
20	f. For each medication prescribed and dispensed, the strength, dosage, route
21	of administration, quantity, and frequency of use as required under CCR,
22	title 16, section 2032.3, subdivision (a)(12); and
23	g. Daily progress and disposition of the case as required under CCR title 16,
24	section 2032.3, subdivision (a)(13).
25	178. The Patient History Report for equine patient S., dated August 16, 2017, failed to
26	include the following information:
27	a. Age, sex, and color of the equine patient as required under CCR, title 16,
28	section 2032.3, subdivision (a)(4);

1	b.	A history or pertinent information as it pertains to the equine patient's
2		medical statutes as required under CCR, title 16, section 2032.3,
3		subdivision (a)(6);
4	c.	Data, including that obtained by instrumentation, from the physical
5		examination of the equine patient as required under CCR, title 16, section
6		2032.3, subdivision (a)(7);
7	d.	Treatment and intended treatment plan, including medication dosages as
8		required under CCR, title 16, section 2032.3, subdivision (a)(8);
9	e.	Diagnosis or assessment prior to performing a treatment or procedure as
10		required under CCR, title 16, section 2032.3, subdivision (a)(10);
11	f.	A prognosis of the animal's condition as required under CCR, title 16,
12		section 2032.3, subdivision (a)(11);
13	g.	For each medication prescribed and dispensed, the strength, dosage, route
14		of administration, quantity, and frequency of use as required under CCR,
15		title 16, section 2032.3, subdivision (a)(12); and
16	h.	Daily progress and disposition of the case as required under CCR title 16,
17		section 2032.3, subdivision (a)(13).
18	179. The Pat	ient History Report for equine patient A., dated August 16, 2017, failed to
19	include the following	g information:
20	a.	A history or pertinent information as it pertains to the equine patient's
21		medical statutes as required under CCR, title 16, section 2032.3,
22		subdivision (a)(6);
23	b.	Data, including that obtained by instrumentation, from the physical
24		examination of the equine patient as required under CCR, title 16, section
25		2032.3, subdivision (a)(7);
26	c.	Treatment and intended treatment plan, including medication dosages as
27		required under CCR, title 16, section 2032.3, subdivision (a)(8);
28		

I		
1	d.	Diagnosis or assessment prior to performing a treatment or procedure as
2		required under CCR, title 16, section 2032.3, subdivision (a)(10);
3	e.	A prognosis of the animal's condition as required under CCR, title 16,
4		section 2032.3, subdivision (a)(11);
5	f.	For each medication prescribed and dispensed, the strength, dosage, route
6		of administration, quantity, and frequency of use as required under CCR,
7		title 16, section 2032.3, subdivision (a)(12); and
8	g.	Daily progress and disposition of the case as required under CCR title 16,
9		section 2032.3, subdivision (a)(13).
10	180. The Pa	tient History Report for equine patient W. N., dated August 17, 2017, failed
11	to include the follow	ving information:
12	a.	Age, sex, breed, and color of the equine patient as required under CCR,
13		title 16, section 2032.3, subdivision (a)(4);
14	b.	A history or pertinent information as it pertains to the equine patient's
15		medical statutes as required under CCR, title 16, section 2032.3,
16		subdivision (a)(6);
17	c.	Data, including that obtained by instrumentation, from the physical
18		examination of the equine patient as required under CCR, title 16, section
19		2032.3, subdivision (a)(7);
20	d.	Treatment and intended treatment plan, including medication dosages as
21		required under CCR, title 16, section 2032.3, subdivision (a)(8);
22	e.	Diagnosis or assessment prior to performing a treatment or procedure as
23		required under CCR, title 16, section 2032.3, subdivision (a)(10);
24	f.	A prognosis of the animal's condition as required under CCR, title 16,
25		section 2032.3, subdivision (a)(11);
26	g.	For each medication prescribed and dispensed, the strength, dosage, route
27		of administration, quantity, and frequency of use as required under CCR,
28		title 16, section 2032.3, subdivision (a)(12); and

		h.	Daily progress and disposition of the case as required under CCR title 16,
			section 2032.3, subdivision (a)(13).
	181.	The Pa	atient History Report for equine patient U. G., dated August 17, 2017, failed
			ving information:
		a.	A history or pertinent information as it pertains to the equine patient's
			medical statutes as required under CCR, title 16, section 2032.3,
			subdivision (a)(6);
		b.	Data, including that obtained by instrumentation, from the physical
			examination of the equine patient as required under CCR, title 16, section
			2032.3, subdivision (a)(7);
		c.	Treatment and intended treatment plan, including medication dosages as
.			required under CCR, title 16, section 2032.3, subdivision (a)(8);
		d.	Diagnosis or assessment prior to performing a treatment or procedure as
			required under CCR, title 16, section 2032.3, subdivision (a)(10);
		e.	A prognosis of the animal's condition as required under CCR, title 16,
			section 2032.3, subdivision (a)(11);
		f.	For each medication prescribed and dispensed, the strength, dosage, route
			of administration, quantity, and frequency of use as required under CCR,
			title 16, section 2032.3, subdivision (a)(12); and
		g.	Daily progress and disposition of the case as required under CCR title 16,
			section 2032.3, subdivision (a)(13).
	////		
	////		
	////		
	////		
	////		
	////		
	////		
			57

1	FIFTH CAUSE FOR DISCIPLINE
2	(Unprofessional Conduct – Prohibited Veterinary Practices)
3	182. Respondent Kuhlmann is subject to disciplinary action for unprofessional conduct
4	under section 4883, subdivision (g)(3), for violating CCR, title 4, section 1867, subdivision (b).
5	Respondent Kuhlmann possessed a drug, substance, or medication that has not been approved by
6	the United States Food and Drug Administration (FDA) for use in the United States, as follows:
7	183. On or about July 2, 2017, Respondent Kuhlmann used the following medications
8	not approved by the FDA to treat equine patient W.:
9	a. Vitamin C-K, compounded injection; and
10	b. Pentosan polysulfate sodium, compounded.
11	184. On or about July 2, 2017, Respondent Kuhlmann used the following medications
12	not approved by the FDA to treat equine patient T. I.:
13	a. Pentosan polysulfate sodium, compounded.
14	185. On or about July 2, 2017, Respondent Kuhlmann used the following medications
15	not approved by the FDA to treat equine patient Y. T.:
16	a. Vitamin C-K, compounded injection.
17	186. On or about July 2, 2017, Respondent Kuhlmann used the following medications
18	not approved by the FDA to treat equine patient A. P.:
19	a. Pentosan polysulfate sodium, compounded; and
20	b. Estrone, compounded.
21	187. On or about August 1, 2017, Respondent Kuhlmann used the following medication
22	not approved by the FDA to treat equine patient S.:
23	a. Pentosan polysulfate sodium, compounded; and
24	b. Estrone, compounded.
25	188. On or about August 1, 2017, Respondent Kuhlmann used the following medication
26	not approved by the FDA to treat equine patient M. M.:
27	a. Pentosan polysulfate sodium, compounded.
10	

1	189. On or about August 1, 2017, Respondent Kuhlmann used the following medications
2	not approved by the FDA to treat equine patient S. F.:
3	a. Pentosan polysulfate sodium, compounded.
4	190. On or about August 3, 2017, Respondent Kuhlmann used the following medications
5	not approved by the FDA to treat equine patient M.:
6	a. Pentosan polysulfate sodium, compounded.
7	191. On or about August 3, 2017, Respondent Kuhlmann used the following medications
8	not approved by the FDA to treat equine patient R. H.:
9	a. Pentosan polysulfate sodium, compounded.
10	192. On or about August 3, 2017, Respondent Kuhlmann used the following medications
11	not approved by the FDA to treat four (4) equine patients:
12	a. N-butyl alcohol, compounded.
13	193. On or about August 4, 2017, Respondent Kuhlmann used the following medications
14	not approved by the FDA to treat equine patient O.:
15	a. Dimethyl sulfoxide IV, industrial solvent.
16	194. On or about August 4, 2017, Respondent Kuhlmann used the following medications
17	not approved by the FDA to treat equine patient G. S.:
18	a. Dimethyl sulfoxide IV, industrial solvent; and
19	b. Stop Two, homeopathic, misbranded.
20	195. On or about August 4, 2017, Respondent Kuhlmann used the following medications
21	not approved by the FDA to treat six (6) equine patients:
22	a. N-butyl alcohol, compounded.
23	196. On or about August 4, 2017, Respondent Kuhlmann used the following medications
24	not approved by the FDA to treat two (2) equine patients:
25	a. Dimethyl sulfoxide, compounded.
26	197. On or about August 16, 2017, Respondent Kuhlmann used the following
27	medications not approved by the FDA to treat equine patient S.:
28	a. Pentosan polysulfate sodium, compounded.

1	198. On or about August 17, 2017, Respondent Kuhlmann used N-butyl alcohol,
2	compounded, which is not approved by the FDA, to treat equine patient W. N.
3	199. On or about August 17, 2017, Respondent Kuhlmann used N-butyl alcohol,
4	compounded, which is not approved by the FDA, to treat equine patient A.
5	200. On or about August 17, 2017, Respondent Kuhlmann used N-butyl alcohol,
6	compounded, which is not approved by the FDA, to treat equine patient U. G.
7	SIXTH CAUSE FOR DISCIPLINE
8	(Unprofessional Conduct – Misbranded Drugs; Compounded Imitation Drugs)
9	201. Respondent Kuhlmann is subject to disciplinary action for unprofessional conduct
10	under section 4883, subdivision (g)(3), for violations of section 4169, subdivision (a)(3), and
11	Health and Safety Code sections 111395, subdivision (a), and 111440. Respondent Kuhlmann
12	manufactured, sold, delivered, held, or offered for sale, drugs that were imitations of
13	commercially available drugs, and therefore misbranded, as follows:
14	202. An extremely large number of compounded drugs were found during the Board
15	inspection. Many of the compounded drugs were commercially obtainable at the same
16	concentrations as ketoprofen, glycopyrrolate, and others.
17	203. Respondent Kuhlmann compounded the drugs to circumvent the cost of
18	commercially obtainable drugs. The compounded drugs imitated commercially available drugs.
19	Accordingly, Respondent Kuhlmann misbranded the compounded drugs.
20	SEVENTH CAUSE FOR DISCIPLINE
21	(Unprofessional Conduct – Misbranded Drugs; Labeling Requirements)
22	204. Respondent Kuhlmann is subject to disciplinary action for unprofessional conduct
23	under section 4883, subdivision (g)(3), for violations of section 4169, subdivision (a)(3), and
24	Health and Safety Code sections 111345, subdivision (a), 111440, and 111500. Respondent
25	Kuhlmann manufactured, sold, delivered, held, or offered for sale, drugs that were improperly
26	labeled, and therefore misbranded, as follows:
27	
•	uu

1	205. Inspectors found a bottle labeled as "Laryngeal Lavage" during the Board
2	inspection. The label on the bottle failed to include the following required information:
3	(a) Except where the prescriber orders otherwise, either the manufacturer's trade name of the drug, or the generic name and the name of the manufacturer.
4 5	Commonly used abbreviations may be used. Preparations containing two or more active ingredients may be identified by the manufacturer's trade name or the commonly used name or the principal active ingredients.
6	(b) The directions for the use of the drug or device.
7	(c) The name of the patient(s).
8	(d) The name of the prescriber.
9	(e) The date of issue.
10	(f) The name, address of the furnisher, and prescription number or other means of identifying the prescription.
11	(g) The strength of the drug or drugs dispensed.
12	(h) The quantity of the drug or drugs dispensed.
13 14	(i) The expiration date of the effectiveness of the drug or device if the information is included on the original label of the manufacturer of the drug or device.
15	By maintaining an improperly labeled drug at Respondent SFE's premises, Respondent
16	Kuhlmann manufactured, sold, delivered, held, or offered for sale a misbranded drug.
17	EIGHTH CAUSE FOR DISCIPLINE
18	(Unprofessional Conduct – Expired Drugs)
19	206. Respondent Kuhlmann is subject to disciplinary action for unprofessional conduct
20	under section 4883, subdivision (g)(3), for violations of section 4169, subdivision (a)(4), for
21	purchasing, trading, selling, or transferring dangerous drugs after the beyond use date on the
22	label, as follows:
23	207. A large number of expired <sup>2</sup> dangerous drugs were found during the Board
24	inspection. The expired drugs were not separated from non-expired drugs, which suggested that
25	the SFE veterinarians used expired drugs to treat animal patients.
<ul><li>26</li><li>27</li></ul>	<sup>2</sup> An expiration date (EXP) reflects the stability of the product as prepared by the manufacturer; the beyond-use date (BUD) is the last date that a product can be safely used after it has been altered for patient use. Expiration dates are found on drugs from manufacturers that make FDA approved drugs. Beyond-use dates are found on compounded drugs that are not
28	make 1 D11 approved drugs. Deyond-use dates are round on compounded drugs that are not

1	208.	The fo	ollowing expired dangerous drugs were found on Respondent SFE's premises:
2		a.	Aminocaproic acid, Buy-Rite Drugs, Inc., compounded, BUD 9/11/18;
3		b.	Acepromazine injectable, EXP 09/17;
4		c.	Acetyl-L-Cysteine, Wedgewood Pharmacy, compounded, BUD 08/24/18;
5		d.	Enroflox 100, EXP 04/2018;
6		e.	Glycopyrrolate, Buy-Rite Drugs, Inc., compounded BUD 09/12/18;
7		f.	Heparin, EXP 02/2018;
8		g.	Iodine in Almond Oil, Pharmacy Resources, Inc., compounded, BUD
9			01/31/2018;
10		h.	Medroxyprogesterone, 300 mg/ml, Wedgewood Pharmacy, compounded,
11			BUD 03/04/2018;
12		i.	Medroxyprogesterone, 200 mg/ml, Wedgewood Pharmacy, compounded,
13			BUD 03/20/2018;
14		j.	Marcaine, EXP SEP 2016;
15		k.	Reserpine, Buy-Rite Drugs, Inc., compounded, BUD 09/07/2018;
16		1.	Vitamin B 15 / DMG, Buy-Rite Drugs, Inc., compounded, BUD 06/12/18;
17		m.	Guaifenesin in D5W, Precision Compounding, compounded, BUD
18			5/9/2017;
19		n.	Sarapin Repack, US Compounding, compounded, BUD 9/3/2018;
20		0.	Minocycline, UC Davis VMTH Pharmacy, EXP 10/16;
21		p.	Uniprim, marked "exp 1/18 use first," EXP 01/26/2018;
22		q.	Parapox Ovis Virus; EXP 07/MAY/13;
23		r.	Hylartin-V, EXP 09/2009;
24		s.	Normosol-R IV fluids, EXP Jan 2012;
25		t.	L-arginine, Buy-Rite Drugs, Inc., compounded, BUD 09/10/18; and
26		u.	Stanozolol (C-V), Pharmacy Resources, Inc., compounded, BUD 2/13/18.
27			
28			OA. Expiration dates and beyond-use dates are furnished to define the dates large are considered unsafe for patient use.

#### 

## 

### 

# 

## 

## 

## 

#### 

#### 

## 

#### **NINTH CAUSE FOR DISCIPLINE**

#### (Unprofessional Conduct – Minimum Standards for Drugs and Biologics)

209. Respondent Kuhlmann is subject to disciplinary action for unprofessional conduct under sections 4854 and 4883, subdivision (o), for violations of CCR, title 16, sections 2030, subdivision (f)(6), and 2030.05, subdivision (b). Respondent Kuhlmann failed to ensure that all drugs and biologics at SFE's premises were maintained, administered, dispensed, and prescribed in compliance with state and federal laws, as follows: no protocols regarding the disposal of expired drugs or monitoring of expired drugs, were provided to inspectors during the Board inspection.

#### TENTH CAUSE FOR DISCIPLINE

#### (Unprofessional Conduct - Minimum Standards for Medical Waste)

210. Respondent Kuhlmann is subject to disciplinary action for unprofessional conduct under sections 4854 and 4883, subdivision (o), for violations of CCR, title 16, sections 2030, subdivision (f)(3), and 2030.05, subdivision (b). Respondent Kuhlmann failed to ensure that Respondent SFE complied with regulations regarding the disposal of waste material, as follows: Respondent SFE was not registered in Contra Costa County as a medical waste generator, as of September 17, 2018.

#### **ELEVENTH CAUSE FOR DISCIPLINE**

#### (Unprofessional Conduct – Schedule IV Drug Record)

- 211. Respondent Kuhlmann is subject to disciplinary action for unprofessional conduct under sections 4854 and 4883, subdivisions (g)(3) and (o), and CCR, title 16, sections 2030, subdivision (f)(6), and 2030.05, subdivision (b), for violations of Health and Safety Code section 11190, subdivision (c)(1). Respondent Kuhlmann, as the managing licensee of Respondent SFE, failed to ensure that Schedule IV drugs dispensed by SFE veterinarians were properly recorded and maintained, as follows:
- 212. The CHRB Veterinarian Report completed by Dr. Boyer, dated August 18, 2017, showed that Dr. Boyer dispensed 500 tablets of carisprodol to equine patient L. C. Respondent SFE's drug logs, as of September 17, 2018, did not include a record of the dispensed carisoprodol

1	tablets. Respondent	Kuhlmann also failed to ensure the drug logs included the following required
2	information:	
3	a.	Full name, address, and the telephone number of the ultimate user or
4		research subject, or contact information as determined by the Secretary of
5		the United States Department of Health and Human Services, and the
6		gender, and date of birth of the patient.
7	b.	The prescriber's category of licensure and license number; federal
8		controlled substance registration number; and the state medical license
9		number of any prescriber using the federal controlled substance registration
10		number of a government-exempt facility.
11	c.	NDC (National Drug Code) number of the controlled substance dispensed.
12	d.	ICD-9 (diagnosis code), if available.
13	e.	Number of refills ordered.
14	f.	Whether the drug was dispensed as a refill of a prescription or as a first-
15		time request.
16	g.	Date of origin of the prescription.
17		TWELFTH CAUSE FOR DISCIPLINE
18		(Unprofessional Conduct – CURES Reporting)
19	213. Respon	ndent Kuhlmann is subject to disciplinary action for unprofessional conduct
20	under sections 4854	and 4883, subdivision (g)(3), for violating Health and Safety Code section
21	11190, subdivision (	(c)(2)(A). Respondent Kuhlmann failed to report the dispensing of a
22	controlled substance	to the Department of Justice, as follows:
23	214. Respoi	ndent Kuhlmann holds the only Drug Enforcement Agency (DEA)
24	registration at Respo	ondent SFE's premises. The Board inspection revealed that Dr. Boyer and
25	Dr. Allison prescrib	bed, distributed and administered controlled substances as agents under
26	Respondent Kuhlma	nn's DEA registration.
27	////	
28	////	

- 215. The CHRB Veterinarian Report completed by Dr. Boyer, dated August 18, 2017, showed that Dr. Boyer dispensed 500 tablets of carisprodol, a Schedule IV controlled substance, to equine patient L. C. No record of dispensation of this Schedule IV controlled substance was found in the Controlled Substance Utilization Review and Evaluation System (CURES) database on or about May 21, 2019.
- 216. Respondent Kuhlmann failed to report the dispensing of carisoprodol to the Department of Justice, along with the following information:
  - a. Full name, address, and the telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the patient.
  - b. The prescriber's category of licensure and license number; federal controlled substance registration number; and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
  - c. NDC (National Drug Code) number of the controlled substance dispensed.
  - d. Quantity of the controlled substance dispensed.
  - e. ICD-9 (diagnosis code), if available.
  - f. Number of refills ordered.
  - g. Whether the drug was dispensed as a refill of a prescription or as a first-time request.
  - h. Date of origin of the prescription.

#### THIRTEENTH CAUSE FOR DISCIPLINE

#### (Unprofessional Conduct – Minimum Standards for Drug Logs)

217. Respondent Kuhlmann is subject to disciplinary action for unprofessional conduct under sections 4854, 4855, and 4883, subdivisions (g)(3) and (o), and CCR, title 16, sections 2030, subdivision (f)(6), and 2030.05, subdivision (b), for violations of Code of Federal Regulations, title 21, section 1304.22, subdivision (c), as follows: Respondent SFE's drug

dispensing logs obtained during the Board inspection failed to include the name and address of the person to whom the drugs were dispensed. The logs were also incomplete, as continuation marks were used.

#### **FOURTEENTH CAUSE FOR DISCIPLINE**

#### (Recordkeeping – Licensee Manager)

- 218. Respondent Kuhlmann is subject to disciplinary action for unprofessional conduct under sections 4854, 4855, and 4883, subdivision (o), and CCR, title 16, sections 2032.3, and 2030.05, subdivision (b). Respondent Kuhlmann failed to ensure the medical records maintained at Respondent SFE complied with minimum standards for recordkeeping, as follows:
- 219. The Patient History Report for equine patient E. R., dated June 21, 2017, failed to include the following information:
  - a. A history or pertinent information as it pertains to the equine patient's medical statutes as required under CCR, title 16, section 2032.3, subdivision (a)(6);
  - b. Data, including that obtained by instrumentation, from the physical examination of the equine patient as required under CCR, title 16, section 2032.3, subdivision (a)(7);
  - c. Treatment and intended treatment plan, including medication dosages as required under CCR, title 16, section 2032.3, subdivision (a)(8);
  - d. Diagnosis or assessment prior to performing a treatment or procedure as required under CCR, title 16, section 2032.3, subdivision (a)(10);
  - e. A prognosis of the animal's condition as required under CCR, title 16, section 2032.3, subdivision (a)(11);
  - f. For each medication prescribed and dispensed, the strength, dosage, route of administration, quantity, and frequency of use as required under CCR, title 16, section 2032.3, subdivision (a)(12); and
  - g. Daily progress and disposition of the case as required under CCR title 16, section 2032.3, subdivision (a)(13).

1	220. The Pa	atient History Report for equine patient S.Y., dated June 21, 2017, failed to
2	include the following	g information:
3	a.	A history or pertinent information as it pertains to the equine patient's
4		medical statutes as required under CCR, title 16, section 2032.3,
5		subdivision (a)(6);
6	b.	Data, including that obtained by instrumentation, from the physical
7		examination of the equine patient as required under CCR, title 16, section
8		2032.3, subdivision (a)(7);
9	c.	Treatment and intended treatment plan, including medication dosages as
10		required under CCR, title 16, section 2032.3, subdivision (a)(8);
11	d.	Diagnosis or assessment prior to performing a treatment or procedure as
12		required under CCR, title 16, section 2032.3, subdivision (a)(10);
13	e.	A prognosis of the animal's condition as required under CCR, title 16,
14		section 2032.3, subdivision (a)(11);
15	f.	For each medication prescribed and dispensed, the strength, dosage, route
16		of administration, quantity, and frequency of use as required under CCR,
17		title 16, section 2032.3, subdivision (a)(12); and
18	g.	Daily progress and disposition of the case as required under CCR title 16,
19		section 2032.3, subdivision (a)(13).
20	221. The Pa	atient History Report for equine patient O. M., dated June 22, 2017, failed to
21	include the following	g information:
22	a.	A history or pertinent information as it pertains to the equine patient's
23		medical statutes as required under CCR, title 16, section 2032.3,
24		subdivision (a)(6);
25	b.	Data, including that obtained by instrumentation, from the physical
26		examination of the equine patient as required under CCR, title 16, section
27		2032.3, subdivision (a)(7);
28		

1	c.	Treatment and intended treatment plan, including medication dosages as
2		required under CCR, title 16, section 2032.3, subdivision (a)(8);
3	d.	Diagnosis or assessment prior to performing a treatment or procedure as
4		required under CCR, title 16, section 2032.3, subdivision (a)(10);
5	e.	A prognosis of the animal's condition as required under CCR, title 16,
6		section 2032.3, subdivision (a)(11);
7	f.	For each medication prescribed and dispensed, the strength, dosage, route
8		of administration, quantity, and frequency of use as required under CCR,
9		title 16, section 2032.3, subdivision (a)(12); and
10	g.	Daily progress and disposition of the case as required under CCR title 16,
11		section 2032.3, subdivision (a)(13).
12	222. The Pa	tient History Report, dated June 22, 2017, and CHRB Veterinarian Report
13	completed by Respo	ndent Kuhlmann, dated August 18, 2017, for equine patient L. C., failed to
14	include the following	g information:
15	a.	Age, sex, breed, species, and color of the equine patient as required under
16		CCR, title 16, section 2032.3, subdivision (a)(4);
17	b.	A history or pertinent information as it pertains to the equine patient's
18		medical statutes as required under CCR, title 16, section 2032.3,
19		subdivision (a)(6);
20	c.	Data, including that obtained by instrumentation, from the physical
21		examination of the equine patient as required under CCR, title 16, section
22		2032.3, subdivision (a)(7);
23	d.	Treatment and intended treatment plan, including medication dosages as
24		required under CCR, title 16, section 2032.3, subdivision (a)(8);
25	e.	Diagnosis or assessment prior to performing a treatment or procedure as
26		required under CCR, title 16, section 2032.3, subdivision (a)(10);
27	f.	A prognosis of the animal's condition as required under CCR, title 16,
28		section 2032.3, subdivision (a)(11);

1	g.	For each medication prescribed and dispensed, the strength, dosage, route
2		of administration, quantity, and frequency of use as required under CCR,
3		title 16, section 2032.3, subdivision (a)(12); and
4	h.	Daily progress and disposition of the case as required under CCR title 16,
5		section 2032.3, subdivision (a)(13).
6	223. The Pat	ient History Report for equine patient N. N., dated June 23, 2017, failed to
7	include the following	information:
8	a.	A history or pertinent information as it pertains to the equine patient's
9		medical statutes as required under CCR, title 16, section 2032.3,
10		subdivision (a)(6);
11	b.	Data, including that obtained by instrumentation, from the physical
12		examination of the equine patient as required under CCR, title 16, section
13		2032.3, subdivision (a)(7);
14	c.	Treatment and intended treatment plan, including medication dosages as
15		required under CCR, title 16, section 2032.3, subdivision (a)(8);
16	d.	Diagnosis or assessment prior to performing a treatment or procedure as
17		required under CCR, title 16, section 2032.3, subdivision (a)(10);
18	e.	A prognosis of the animal's condition as required under CCR, title 16,
19		section 2032.3, subdivision (a)(11);
20	f.	For each medication prescribed and dispensed, the strength, dosage, route
21		of administration, quantity, and frequency of use as required under CCR,
22		title 16, section 2032.3, subdivision (a)(12); and
23	g.	Daily progress and disposition of the case as required under CCR title 16,
24		section 2032.3, subdivision (a)(13).
25	224. The Pat	ient History Report for equine patient E. S., dated June 23, 2017, failed to
26	include the following	information:
27	a.	Age, sex, breed, species, and color of the equine patient as required under
28		CCR, title 16, section 2032.3, subdivision (a)(4);

1	b.	A history or pertinent information as it pertains to the equine patient's
2		medical statutes as required under CCR, title 16, section 2032.3,
3		subdivision (a)(6);
4	c.	Data, including that obtained by instrumentation, from the physical
5		examination of the equine patient as required under CCR, title 16, section
6		2032.3, subdivision (a)(7);
7	d.	Treatment and intended treatment plan, including medication dosages as
8		required under CCR, title 16, section 2032.3, subdivision (a)(8);
9	e.	Diagnosis or assessment prior to performing a treatment or procedure as
10		required under CCR, title 16, section 2032.3, subdivision (a)(10);
11	f.	A prognosis of the animal's condition as required under CCR, title 16,
12		section 2032.3, subdivision (a)(11);
13	g.	For each medication prescribed and dispensed, the strength, dosage, route
14		of administration, quantity, and frequency of use as required under CCR,
15		title 16, section 2032.3, subdivision (a)(12); and
16	h.	Daily progress and disposition of the case as required under CCR title 16,
17		section 2032.3, subdivision (a)(13).
18	225. The Pa	atient History Report for equine patient V., dated June 29, 2017, failed to
19	include the following	g information:
20	a.	A history or pertinent information as it pertains to the equine patient's
21		medical statutes as required under CCR, title 16, section 2032.3,
22		subdivision (a)(6);
23	b.	Data, including that obtained by instrumentation, from the physical
24		examination of the equine patient as required under CCR, title 16, section
25		2032.3, subdivision (a)(7);
26	c.	Treatment and intended treatment plan, including medication dosages as
27		required under CCR, title 16, section 2032.3, subdivision (a)(8);
28		

1	d	l.	Diagnosis or assessment prior to performing a treatment or procedure as
2			required under CCR, title 16, section 2032.3, subdivision (a)(10);
3	e	<b>.</b>	A prognosis of the animal's condition as required under CCR, title 16,
4			section 2032.3, subdivision (a)(11);
5	f.	•	For each medication prescribed and dispensed, the strength, dosage, route
6			of administration, quantity, and frequency of use as required under CCR,
7			title 16, section 2032.3, subdivision (a)(12); and
8	g	<b>Ţ.</b>	Daily progress and disposition of the case as required under CCR title 16,
9			section 2032.3, subdivision (a)(13).
10	226. Th	ne Pat	ient History Report for equine patient I. C., dated June 29, 2017, failed to
11	include the follo	wing	information:
12	a	l <b>.</b>	A history or pertinent information as it pertains to the equine patient's
13			medical statutes as required under CCR, title 16, section 2032.3,
14			subdivision (a)(6);
15	b	).	Data, including that obtained by instrumentation, from the physical
16			examination of the equine patient as required under CCR, title 16, section
17			2032.3, subdivision (a)(7);
18	c	·.	Treatment and intended treatment plan, including medication dosages as
19			required under CCR, title 16, section 2032.3, subdivision (a)(8);
20	d	l.	Diagnosis or assessment prior to performing a treatment or procedure as
21			required under CCR, title 16, section 2032.3, subdivision (a)(10);
22	e	·.	A prognosis of the animal's condition as required under CCR, title 16,
23			section 2032.3, subdivision (a)(11);
24	f.	•	For each medication prescribed and dispensed, the strength, dosage, route
25			of administration, quantity, and frequency of use as required under CCR,
26			title 16, section 2032.3, subdivision (a)(12); and
27	g	<b>.</b>	Daily progress and disposition of the case as required under CCR title 16,
28			section 2032.3, subdivision (a)(13).

1	227.	The Pa	atient History Report for equine patient T. A., dated June 29, 2017, failed to
2	include the	followin	g information:
3		a.	Age, sex, breed, species, and color of the equine patient as required under
4			CCR, title 16, section 2032.3, subdivision (a)(4);
5		b.	A history or pertinent information as it pertains to the equine patient's
6			medical statutes as required under CCR, title 16, section 2032.3,
7			subdivision (a)(6);
8		c.	Data, including that obtained by instrumentation, from the physical
9			examination of the equine patient as required under CCR, title 16, section
10			2032.3, subdivision (a)(7);
11		d.	Treatment and intended treatment plan, including medication dosages as
12			required under CCR, title 16, section 2032.3, subdivision (a)(8);
13		e.	Diagnosis or assessment prior to performing a treatment or procedure as
14			required under CCR, title 16, section 2032.3, subdivision (a)(10);
15		f.	A prognosis of the animal's condition as required under CCR, title 16,
16			section 2032.3, subdivision (a)(11);
17		g.	For each medication prescribed and dispensed, the strength, dosage, route
18			of administration, quantity, and frequency of use as required under CCR,
19			title 16, section 2032.3, subdivision (a)(12); and
20		h.	Daily progress and disposition of the case as required under CCR title 16,
21			section 2032.3, subdivision (a)(13).
22	228.	The Pa	atient History Report for equine patient S. L., dated June 30, 2017, failed to
23	include the	followin	g information:
24		a.	Age, sex, breed, and color of the equine patient as required under CCR,
25			title 16, section 2032.3, subdivision (a)(4);
26		b.	A history or pertinent information as it pertains to the equine patient's
27			medical statutes as required under CCR, title 16, section 2032.3,
28			subdivision (a)(6);

1	c.	Data, including that obtained by instrumentation, from the physical
2		examination of the equine patient as required under CCR, title 16, section
3		2032.3, subdivision (a)(7);
4	d.	Treatment and intended treatment plan, including medication dosages as
5		required under CCR, title 16, section 2032.3, subdivision (a)(8);
6	e.	Diagnosis or assessment prior to performing a treatment or procedure as
7		required under CCR, title 16, section 2032.3, subdivision (a)(10);
8	f.	A prognosis of the animal's condition as required under CCR, title 16,
9		section 2032.3, subdivision (a)(11);
10	g.	For each medication prescribed and dispensed, the strength, dosage, route
11		of administration, quantity, and frequency of use as required under CCR,
12		title 16, section 2032.3, subdivision (a)(12); and
13	h.	Daily progress and disposition of the case as required under CCR title 16,
14		section 2032.3, subdivision (a)(13).
15	229. The	Patient History Report for equine patient G. S., dated June 30, 2017, failed to
16	include the follow	ving information:
17	a.	Age, sex, breed, and color of the equine patient as required under CCR,
18		title 16, section 2032.3, subdivision (a)(4);
19	b.	A history or pertinent information as it pertains to the equine patient's
20		medical statutes as required under CCR, title 16, section 2032.3,
21		subdivision (a)(6);
22	c.	Data, including that obtained by instrumentation, from the physical
23		examination of the equine patient as required under CCR, title 16, section
24		2032.3, subdivision (a)(7);
25	d.	Treatment and intended treatment plan, including medication dosages as
26		required under CCR, title 16, section 2032.3, subdivision (a)(8);
27	e.	Diagnosis or assessment prior to performing a treatment or procedure as
28		required under CCR, title 16, section 2032.3, subdivision (a)(10);

1		f.	A prognosis of the animal's condition as required under CCR, title 16,
2			section 2032.3, subdivision (a)(11);
3		g.	For each medication prescribed and dispensed, the strength, dosage, route
4			of administration, quantity, and frequency of use as required under CCR,
5			title 16, section 2032.3, subdivision (a)(12); and
6		h.	Daily progress and disposition of the case as required under CCR title 16,
7			section 2032.3, subdivision (a)(13).
8	230.	The Pat	ient History Report for equine patient V., dated July 2, 2017, failed to
9	include the fo	ollowing	g information:
10		a.	A history or pertinent information as it pertains to the equine patient's
11			medical statutes as required under CCR, title 16, section 2032.3,
12			subdivision (a)(6);
13		b.	Data, including that obtained by instrumentation, from the physical
14			examination of the equine patient as required under CCR, title 16, section
15			2032.3, subdivision (a)(7);
16		c.	Treatment and intended treatment plan, including medication dosages as
17			required under CCR, title 16, section 2032.3, subdivision (a)(8);
18		d.	Diagnosis or assessment prior to performing a treatment or procedure as
19			required under CCR, title 16, section 2032.3, subdivision (a)(10);
20		e.	A prognosis of the animal's condition as required under CCR, title 16,
21			section 2032.3, subdivision (a)(11);
22		f.	For each medication prescribed and dispensed, the strength, dosage, route
23			of administration, quantity, and frequency of use as required under CCR,
24			title 16, section 2032.3, subdivision (a)(12); and
25		g.	Daily progress and disposition of the case as required under CCR title 16,
26			section 2032.3, subdivision (a)(13).
27	////		
28	////		

1	231.	The Pat	ient History Report for equine patient R. M., dated July 2, 2017, failed to
2	include the	following	information:
3		a.	Age, sex, breed, and color of the equine patient as required under CCR,
4			title 16, section 2032.3, subdivision (a)(4);
5		b.	A history or pertinent information as it pertains to the equine patient's
6			medical statutes as required under CCR, title 16, section 2032.3,
7			subdivision (a)(6);
8		c.	Data, including that obtained by instrumentation, from the physical
9			examination of the equine patient as required under CCR, title 16, section
10			2032.3, subdivision (a)(7);
11		d.	Treatment and intended treatment plan, including medication dosages as
12			required under CCR, title 16, section 2032.3, subdivision (a)(8);
13		e.	Diagnosis or assessment prior to performing a treatment or procedure as
14			required under CCR, title 16, section 2032.3, subdivision (a)(10);
15		f.	A prognosis of the animal's condition as required under CCR, title 16,
16			section 2032.3, subdivision (a)(11);
17		g.	For each medication prescribed and dispensed, the strength, dosage, route
18			of administration, quantity, and frequency of use as required under CCR,
19			title 16, section 2032.3, subdivision (a)(12); and
20		h.	Daily progress and disposition of the case as required under CCR title 16,
21			section 2032.3, subdivision (a)(13).
22	232.	The Pat	ient History Report for equine patient P. C., dated August 1, 2017, failed to
23	include the	following	information:
24		a.	A history or pertinent information as it pertains to the equine patient's
25			medical statutes as required under CCR, title 16, section 2032.3,
26			subdivision (a)(6);
27	////		
28	////		

1	b.	Data, including that obtained by instrumentation, from the physical
2		examination of the equine patient as required under CCR, title 16, section
3		2032.3, subdivision (a)(7);
4	c.	Treatment and intended treatment plan, including medication dosages as
5		required under CCR, title 16, section 2032.3, subdivision (a)(8);
6	d.	Diagnosis or assessment prior to performing a treatment or procedure as
7		required under CCR, title 16, section 2032.3, subdivision (a)(10);
8	e.	A prognosis of the animal's condition as required under CCR, title 16,
9		section 2032.3, subdivision (a)(11);
10	f.	For each medication prescribed and dispensed, the strength, dosage, route
11		of administration, quantity, and frequency of use as required under CCR,
12		title 16, section 2032.3, subdivision (a)(12); and
13	g.	Daily progress and disposition of the case as required under CCR title 16,
14		section 2032.3, subdivision (a)(13).
15	233. The	Patient History Report for equine patient B. D., dated August 1, 2017, failed to
16	include the follow	ring information:
17	a.	Age, sex, breed, and color of the equine patient as required under CCR,
18		title 16, section 2032.3, subdivision (a)(4);
19	b.	A history or pertinent information as it pertains to the equine patient's
20		medical statutes as required under CCR, title 16, section 2032.3,
21		subdivision (a)(6);
22	c.	Data, including that obtained by instrumentation, from the physical
23		examination of the equine patient as required under CCR, title 16, section
24		2032.3, subdivision (a)(7);
25	d.	Treatment and intended treatment plan, including medication dosages as
26		required under CCR, title 16, section 2032.3, subdivision (a)(8);
27	e.	Diagnosis or assessment prior to performing a treatment or procedure as
28		required under CCR, title 16, section 2032.3, subdivision (a)(10);

1	f.	A prognosis of the animal's condition as required under CCR, title 16,
2		section 2032.3, subdivision (a)(11);
3	g.	For each medication prescribed and dispensed, the strength, dosage, route
4		of administration, quantity, and frequency of use as required under CCR,
5		title 16, section 2032.3, subdivision (a)(12); and
6	h.	Daily progress and disposition of the case as required under CCR title 16,
7		section 2032.3, subdivision (a)(13).
8	234. The	Patient History Report for equine patient N. O., dated August 1, 2017, failed to
9	include the follow	ing information:
10	a.	Age, sex, breed, and color of the equine patient as required under CCR,
11		title 16, section 2032.3, subdivision (a)(4);
12	b.	A history or pertinent information as it pertains to the equine patient's
13		medical statutes as required under CCR, title 16, section 2032.3,
14		subdivision (a)(6);
15	c.	Data, including that obtained by instrumentation, from the physical
16		examination of the equine patient as required under CCR, title 16, section
17		2032.3, subdivision (a)(7);
18	d.	Treatment and intended treatment plan, including medication dosages as
19		required under CCR, title 16, section 2032.3, subdivision (a)(8);
20	e.	Diagnosis or assessment prior to performing a treatment or procedure as
21		required under CCR, title 16, section 2032.3, subdivision (a)(10);
22	f.	A prognosis of the animal's condition as required under CCR, title 16,
23		section 2032.3, subdivision (a)(11);
24	g.	For each medication prescribed and dispensed, the strength, dosage, route
25		of administration, quantity, and frequency of use as required under CCR,
26		title 16, section 2032.3, subdivision (a)(12); and
27	h.	Daily progress and disposition of the case as required under CCR title 16,
28		section 2032.3, subdivision (a)(13).

1	235. Th	e Patient History Report for equine patient N., dated August 1, 2017, failed to
2	include the follo	wing information:
3	a	A history or pertinent information as it pertains to the equine patient's
4		medical statutes as required under CCR, title 16, section 2032.3,
5		subdivision (a)(6);
6	b	Data, including that obtained by instrumentation, from the physical
7		examination of the equine patient as required under CCR, title 16, section
8		2032.3, subdivision (a)(7);
9	c.	Treatment and intended treatment plan, including medication dosages as
10		required under CCR, title 16, section 2032.3, subdivision (a)(8);
11	d	Diagnosis or assessment prior to performing a treatment or procedure as
12		required under CCR, title 16, section 2032.3, subdivision (a)(10);
13	e.	A prognosis of the animal's condition as required under CCR, title 16,
14		section 2032.3, subdivision (a)(11);
15	f.	For each medication prescribed and dispensed, the strength, dosage, route
16		of administration, quantity, and frequency of use as required under CCR,
17		title 16, section 2032.3, subdivision (a)(12); and
18	g	Daily progress and disposition of the case as required under CCR title 16,
19		section 2032.3, subdivision (a)(13).
20	236. Th	e Patient History Report for equine patient A., dated August 1, 2017, failed to
21	include the follo	wing information:
22	a	A history or pertinent information as it pertains to the equine patient's
23		medical statutes as required under CCR, title 16, section 2032.3,
24		subdivision (a)(6);
25	b	Data, including that obtained by instrumentation, from the physical
26		examination of the equine patient as required under CCR, title 16, section
27		2032.3, subdivision (a)(7);
28		

I		
1	c.	Treatment and intended treatment plan, including medication dosages as
2		required under CCR, title 16, section 2032.3, subdivision (a)(8);
3	d.	Diagnosis or assessment prior to performing a treatment or procedure as
4		required under CCR, title 16, section 2032.3, subdivision (a)(10);
5	e.	A prognosis of the animal's condition as required under CCR, title 16,
6		section 2032.3, subdivision (a)(11);
7	f.	For each medication prescribed and dispensed, the strength, dosage, route
8		of administration, quantity, and frequency of use as required under CCR,
9		title 16, section 2032.3, subdivision (a)(12); and
10	g.	Daily progress and disposition of the case as required under CCR title 16,
11		section 2032.3, subdivision (a)(13).
12	237. The Pat	ient History Report for equine patient C., dated August 8, 2017, failed to
13	include the following	g information:
14	a.	A history or pertinent information as it pertains to the equine patient's
15		medical statutes as required under CCR, title 16, section 2032.3,
16		subdivision (a)(6);
17	b.	Data, including that obtained by instrumentation, from the physical
18		examination of the equine patient as required under CCR, title 16, section
19		2032.3, subdivision (a)(7);
20	c.	Treatment and intended treatment plan, including medication dosages as
21		required under CCR, title 16, section 2032.3, subdivision (a)(8);
22	d.	Diagnosis or assessment prior to performing a treatment or procedure as
23		required under CCR, title 16, section 2032.3, subdivision (a)(10);
24	e.	A prognosis of the animal's condition as required under CCR, title 16,
25		section 2032.3, subdivision (a)(11);
26	f.	For each medication prescribed and dispensed, the strength, dosage, route
27		of administration, quantity, and frequency of use as required under CCR,
28		title 16, section 2032.3, subdivision (a)(12); and

1		g.	Daily progress and disposition of the case as required under CCR title 16,
2			section 2032.3, subdivision (a)(13).
3	238.	The Pa	atient History Report for equine patient Y. D., dated August 3, 2017, failed to
4	include the	followin	ng information:
5		a.	Age, sex, breed, and color of the equine patient as required under CCR,
6			title 16, section 2032.3, subdivision (a)(4);
7		b.	A history or pertinent information as it pertains to the equine patient's
8			medical statutes as required under CCR, title 16, section 2032.3,
9			subdivision (a)(6);
10		c.	Data, including that obtained by instrumentation, from the physical
11			examination of the equine patient as required under CCR, title 16, section
12			2032.3, subdivision (a)(7);
13		d.	Treatment and intended treatment plan, including medication dosages as
14			required under CCR, title 16, section 2032.3, subdivision (a)(8);
15		e.	Diagnosis or assessment prior to performing a treatment or procedure as
16			required under CCR, title 16, section 2032.3, subdivision (a)(10);
17		f.	A prognosis of the animal's condition as required under CCR, title 16,
18			section 2032.3, subdivision (a)(11);
19		g.	For each medication prescribed and dispensed, the strength, dosage, route
20			of administration, quantity, and frequency of use as required under CCR,
21			title 16, section 2032.3, subdivision (a)(12); and
22		h.	Daily progress and disposition of the case as required under CCR title 16,
23			section 2032.3, subdivision (a)(13).
24	239.	The Pa	atient History Report for equine patient M. L., dated August 16, 2017, failed
25	to include th	ne follow	ving information:
26		a.	A history or pertinent information as it pertains to the equine patient's
27			medical statutes as required under CCR, title 16, section 2032.3,
28			subdivision (a)(6);

80

1	b.	Data, including that obtained by instrumentation, from the physical
2		examination of the equine patient as required under CCR, title 16, section
3		2032.3, subdivision (a)(7);
4	c.	Treatment and intended treatment plan, including medication dosages as
5		required under CCR, title 16, section 2032.3, subdivision (a)(8);
6	d.	Diagnosis or assessment prior to performing a treatment or procedure as
7		required under CCR, title 16, section 2032.3, subdivision (a)(10);
8	e.	A prognosis of the animal's condition as required under CCR, title 16,
9		section 2032.3, subdivision (a)(11);
10	f.	For each medication prescribed and dispensed, the strength, dosage, route
11		of administration, quantity, and frequency of use as required under CCR,
12		title 16, section 2032.3, subdivision (a)(12); and
13	g.	Daily progress and disposition of the case as required under CCR title 16,
14		section 2032.3, subdivision (a)(13).
15	240. The Pa	tient History Report for equine patient P. S., dated August 16, 2017, failed to
16	include the following	g information:
17	a.	Age, sex, breed, and color of the equine patient as required under CCR,
18		title 16, section 2032.3, subdivision (a)(4);
19	b.	A history or pertinent information as it pertains to the equine patient's
20		medical statutes as required under CCR, title 16, section 2032.3,
21		subdivision (a)(6);
22	c.	Data, including that obtained by instrumentation, from the physical
23		examination of the equine patient as required under CCR, title 16, section
24		2032.3, subdivision (a)(7);
25	d.	Treatment and intended treatment plan, including medication dosages as
26		required under CCR, title 16, section 2032.3, subdivision (a)(8);
27	e.	Diagnosis or assessment prior to performing a treatment or procedure as
28		required under CCR, title 16, section 2032.3, subdivision (a)(10);

1		f.	A prognosis of the animal's condition as required under CCR, title 16,
2			section 2032.3, subdivision (a)(11);
3		g.	For each medication prescribed and dispensed, the strength, dosage, route
4			of administration, quantity, and frequency of use as required under CCR,
5			title 16, section 2032.3, subdivision (a)(12); and
6		h.	Daily progress and disposition of the case as required under CCR title 16,
7			section 2032.3, subdivision (a)(13).
8	241.	The Par	tient History Report for equine patient N., dated August 16, 2017, failed to
9	include the	following	g information:
10		a.	A history or pertinent information as it pertains to the equine patient's
11			medical statutes as required under CCR, title 16, section 2032.3,
12			subdivision (a)(6);
13		b.	Data, including that obtained by instrumentation, from the physical
14			examination of the equine patient as required under CCR, title 16, section
15			2032.3, subdivision (a)(7);
16		c.	Treatment and intended treatment plan, including medication dosages as
17			required under CCR, title 16, section 2032.3, subdivision (a)(8);
18		d.	Diagnosis or assessment prior to performing a treatment or procedure as
19			required under CCR, title 16, section 2032.3, subdivision (a)(10);
20		e.	A prognosis of the animal's condition as required under CCR, title 16,
21			section 2032.3, subdivision (a)(11);
22		f.	For each medication prescribed and dispensed, the strength, dosage, route
23			of administration, quantity, and frequency of use as required under CCR,
24			title 16, section 2032.3, subdivision (a)(12); and
25		g.	Daily progress and disposition of the case as required under CCR title 16,
26			section 2032.3, subdivision (a)(13).
27	////		
28	////		

1	242.	The P	Patient History Report for equine patient M. G., dated August 16, 2017, failed
2	to include the	he follo	wing information:
3		a.	A history or pertinent information as it pertains to the equine patient's
4			medical statutes as required under CCR, title 16, section 2032.3,
5			subdivision (a)(6);
6		b.	Data, including that obtained by instrumentation, from the physical
7			examination of the equine patient as required under CCR, title 16, section
8			2032.3, subdivision (a)(7);
9		c.	Treatment and intended treatment plan, including medication dosages as
10			required under CCR, title 16, section 2032.3, subdivision (a)(8);
11		d.	Diagnosis or assessment prior to performing a treatment or procedure as
12			required under CCR, title 16, section 2032.3, subdivision (a)(10);
13		e.	A prognosis of the animal's condition as required under CCR, title 16,
14			section 2032.3, subdivision (a)(11);
15		f.	For each medication prescribed and dispensed, the strength, dosage, route
16			of administration, quantity, and frequency of use as required under CCR,
17			title 16, section 2032.3, subdivision (a)(12); and
18		g.	Daily progress and disposition of the case as required under CCR title 16,
19			section 2032.3, subdivision (a)(13).
20	243.	The P	Patient History Report for equine patient H. J., dated August 17, 2017, failed to
21	include the	followi	ng information:
22		a.	Age, sex, breed, and color of the equine patient as required under CCR,
23			title 16, section 2032.3, subdivision (a)(4);
24		b.	A history or pertinent information as it pertains to the equine patient's
25			medical statutes as required under CCR, title 16, section 2032.3,
26			subdivision (a)(6);
27	////		
28	////		
	İ		

1	c.	Data, including that obtained by instrumentation, from the physical
2		examination of the equine patient as required under CCR, title 16, section
3		2032.3, subdivision (a)(7);
4	d.	Treatment and intended treatment plan, including medication dosages as
5		required under CCR, title 16, section 2032.3, subdivision (a)(8);
6	e.	Diagnosis or assessment prior to performing a treatment or procedure as
7		required under CCR, title 16, section 2032.3, subdivision (a)(10);
8	f.	A prognosis of the animal's condition as required under CCR, title 16,
9		section 2032.3, subdivision (a)(11);
10	g.	For each medication prescribed and dispensed, the strength, dosage, route
11		of administration, quantity, and frequency of use as required under CCR,
12		title 16, section 2032.3, subdivision (a)(12); and
13	h	Daily progress and disposition of the case as required under CCR title 16,
14		section 2032.3, subdivision (a)(13).
15	244. The	Patient History Report for equine patient T. S., dated August 17, 2017, failed to
16	include the follo	ving information:
17	a.	A history or pertinent information as it pertains to the equine patient's
18		medical statutes as required under CCR, title 16, section 2032.3,
19		subdivision (a)(6);
20	b	Data, including that obtained by instrumentation, from the physical
21		examination of the equine patient as required under CCR, title 16, section
22		2032.3, subdivision (a)(7);
23	c.	Treatment and intended treatment plan, including medication dosages as
24		required under CCR, title 16, section 2032.3, subdivision (a)(8);
25	d	Diagnosis or assessment prior to performing a treatment or procedure as
26		required under CCR, title 16, section 2032.3, subdivision (a)(10);
27	e.	A prognosis of the animal's condition as required under CCR, title 16,
28		section 2032.3, subdivision (a)(11);

1	f. For each medication prescribed and dispensed, the strength, dosage, route
2	of administration, quantity, and frequency of use as required under CCR,
3	title 16, section 2032.3, subdivision (a)(12); and
4	g. Daily progress and disposition of the case as required under CCR title 16,
5	section 2032.3, subdivision (a)(13).
6	245. The Patient History Report for equine patient I. K., dated August 17, 2017, failed to
7	include the following information:
8	a. A history or pertinent information as it pertains to the equine patient's
9	medical statutes as required under CCR, title 16, section 2032.3,
10	subdivision (a)(6);
11	b. Data, including that obtained by instrumentation, from the physical
12	examination of the equine patient as required under CCR, title 16, section
13	2032.3, subdivision (a)(7);
14	c. Treatment and intended treatment plan, including medication dosages as
15	required under CCR, title 16, section 2032.3, subdivision (a)(8);
16	d. Diagnosis or assessment prior to performing a treatment or procedure as
17	required under CCR, title 16, section 2032.3, subdivision (a)(10);
18	e. A prognosis of the animal's condition as required under CCR, title 16,
19	section 2032.3, subdivision (a)(11);
20	f. For each medication prescribed and dispensed, the strength, dosage, route
21	of administration, quantity, and frequency of use as required under CCR,
22	title 16, section 2032.3, subdivision (a)(12); and
23	g. Daily progress and disposition of the case as required under CCR title 16,
24	section 2032.3, subdivision (a)(13).
25	246. The Patient History Report for equine patient B. D., dated August 17, 2017, failed
26	include the following information:
27	a. Age, sex, breed, and color of the equine patient as required under CCR,
28	title 16, section 2032.3, subdivision (a)(4);
	·

1	b.	A history or pertinent information as it pertains to the equine patient's
2		medical statutes as required under CCR, title 16, section 2032.3,
3		subdivision (a)(6);
4	c.	Data, including that obtained by instrumentation, from the physical
5		examination of the equine patient as required under CCR, title 16, section
6		2032.3, subdivision (a)(7);
7	d.	Treatment and intended treatment plan, including medication dosages as
8		required under CCR, title 16, section 2032.3, subdivision (a)(8);
9	e.	Diagnosis or assessment prior to performing a treatment or procedure as
10		required under CCR, title 16, section 2032.3, subdivision (a)(10);
11	f.	A prognosis of the animal's condition as required under CCR, title 16,
12		section 2032.3, subdivision (a)(11);
13	g.	For each medication prescribed and dispensed, the strength, dosage, route
14		of administration, quantity, and frequency of use as required under CCR,
15		title 16, section 2032.3, subdivision (a)(12); and
16	h.	Daily progress and disposition of the case as required under CCR title 16,
17		section 2032.3, subdivision (a)(13).
18	247. The Par	tient History Report for equine patient R. R., dated August 17, 2017, failed to
19	include the following	g information:
20	a.	A history or pertinent information as it pertains to the equine patient's
21		medical statutes as required under CCR, title 16, section 2032.3,
22		subdivision (a)(6);
23	b.	Data, including that obtained by instrumentation, from the physical
24		examination of the equine patient as required under CCR, title 16, section
25		2032.3, subdivision (a)(7);
26	c.	Treatment and intended treatment plan, including medication dosages as
27		required under CCR, title 16, section 2032.3, subdivision (a)(8);
28		

	I .	
1	d.	Diagnosis or assessment prior to performing a treatment or procedure as
2		required under CCR, title 16, section 2032.3, subdivision (a)(10);
3	e.	A prognosis of the animal's condition as required under CCR, title 16,
4		section 2032.3, subdivision (a)(11);
5	f.	For each medication prescribed and dispensed, the strength, dosage, route
6		of administration, quantity, and frequency of use as required under CCR,
7		title 16, section 2032.3, subdivision (a)(12); and
8	g.	Daily progress and disposition of the case as required under CCR title 16,
9		section 2032.3, subdivision (a)(13).
10	248. The P	Patient History Report for equine patient N. O., dated August 17, 2017, failed
11	to include the follo	wing information:
12	a.	Age, sex, breed, and color of the equine patient as required under CCR,
13		title 16, section 2032.3, subdivision (a)(4);
14	b.	A history or pertinent information as it pertains to the equine patient's
15		medical statutes as required under CCR, title 16, section 2032.3,
16		subdivision (a)(6);
17	c.	Data, including that obtained by instrumentation, from the physical
18		examination of the equine patient as required under CCR, title 16, section
19		2032.3, subdivision (a)(7);
20	d.	Treatment and intended treatment plan, including medication dosages as
21		required under CCR, title 16, section 2032.3, subdivision (a)(8);
22	e.	Diagnosis or assessment prior to performing a treatment or procedure as
23		required under CCR, title 16, section 2032.3, subdivision (a)(10);
24	f.	A prognosis of the animal's condition as required under CCR, title 16,
25		section 2032.3, subdivision (a)(11);
26	g.	For each medication prescribed and dispensed, the strength, dosage, route
27		of administration, quantity, and frequency of use as required under CCR,
28		title 16, section 2032.3, subdivision (a)(12); and

1		h.	Daily progress and disposition of the case as required under CCR title 16,
2			section 2032.3, subdivision (a)(13).
3	249.	The P	atient History Report for equine patient P. S., dated August 17, 2017, failed to
4	include the	followir	ng information:
5		a.	Age, sex, breed, and color of the equine patient as required under CCR,
6			title 16, section 2032.3, subdivision (a)(4);
7		b.	A history or pertinent information as it pertains to the equine patient's
8			medical statutes as required under CCR, title 16, section 2032.3,
9			subdivision (a)(6);
10		c.	Data, including that obtained by instrumentation, from the physical
11			examination of the equine patient as required under CCR, title 16, section
12			2032.3, subdivision (a)(7);
13		d.	Treatment and intended treatment plan, including medication dosages as
14			required under CCR, title 16, section 2032.3, subdivision (a)(8);
15		e.	Diagnosis or assessment prior to performing a treatment or procedure as
16			required under CCR, title 16, section 2032.3, subdivision (a)(10);
17		f.	A prognosis of the animal's condition as required under CCR, title 16,
18			section 2032.3, subdivision (a)(11);
19		g.	For each medication prescribed and dispensed, the strength, dosage, route
20			of administration, quantity, and frequency of use as required under CCR,
21			title 16, section 2032.3, subdivision (a)(12); and
22		h.	Daily progress and disposition of the case as required under CCR title 16,
23			section 2032.3, subdivision (a)(13).
24	250.	The P	atient History Report for equine patient A., dated August 17, 2017, failed to
25	include the	followin	ng information:
26		a.	A history or pertinent information as it pertains to the equine patient's
27			medical statutes as required under CCR, title 16, section 2032.3,
28			subdivision (a)(6);

1	b.	Data, including that obtained by instrumentation, from the physical
2		examination of the equine patient as required under CCR, title 16, section
3		2032.3, subdivision (a)(7);
4	c.	Treatment and intended treatment plan, including medication dosages as
5		required under CCR, title 16, section 2032.3, subdivision (a)(8);
6	d.	Diagnosis or assessment prior to performing a treatment or procedure as
7		required under CCR, title 16, section 2032.3, subdivision (a)(10);
8	e.	A prognosis of the animal's condition as required under CCR, title 16,
9		section 2032.3, subdivision (a)(11);
10	f.	For each medication prescribed and dispensed, the strength, dosage, route
11		of administration, quantity, and frequency of use as required under CCR,
12		title 16, section 2032.3, subdivision (a)(12); and
13	g.	Daily progress and disposition of the case as required under CCR title 16,
14		section 2032.3, subdivision (a)(13).
15	251. The	Patient History Report for equine patient M. L., dated August 17, 2017, failed
16	to include the follo	owing information:
17	a.	A history or pertinent information as it pertains to the equine patient's
18		medical statutes as required under CCR, title 16, section 2032.3,
19		subdivision (a)(6);
20	b.	Data, including that obtained by instrumentation, from the physical
21		examination of the equine patient as required under CCR, title 16, section
22		2032.3, subdivision (a)(7);
23	c.	Treatment and intended treatment plan, including medication dosages as
24		required under CCR, title 16, section 2032.3, subdivision (a)(8);
25	d.	Diagnosis or assessment prior to performing a treatment or procedure as
26		required under CCR, title 16, section 2032.3, subdivision (a)(10);
	e.	A prognosis of the animal's condition as required under CCR, title 16,
27	<b>C.</b>	riprognosis of the ainmar s condition as required under every title 10,

1	f.	For each medication prescribed and dispensed, the strength, dosage, route
2		of administration, quantity, and frequency of use as required under CCR,
3		title 16, section 2032.3, subdivision (a)(12); and
4	g.	Daily progress and disposition of the case as required under CCR title 16,
5		section 2032.3, subdivision (a)(13).
6	252. The Par	tient History Report for equine patient M. G., dated August 17, 2017, failed
7	to include the follow	ing information:
8	a.	A history or pertinent information as it pertains to the equine patient's
9		medical statutes as required under CCR, title 16, section 2032.3,
10		subdivision (a)(6);
11	b.	Data, including that obtained by instrumentation, from the physical
12		examination of the equine patient as required under CCR, title 16, section
13		2032.3, subdivision (a)(7);
14	c.	Treatment and intended treatment plan, including medication dosages as
15		required under CCR, title 16, section 2032.3, subdivision (a)(8);
16	d.	Diagnosis or assessment prior to performing a treatment or procedure as
17		required under CCR, title 16, section 2032.3, subdivision (a)(10);
18	e.	A prognosis of the animal's condition as required under CCR, title 16,
19		section 2032.3, subdivision (a)(11);
20	f.	For each medication prescribed and dispensed, the strength, dosage, route
21		of administration, quantity, and frequency of use as required under CCR,
22		title 16, section 2032.3, subdivision (a)(12); and
23	g.	Daily progress and disposition of the case as required under CCR title 16,
24		section 2032.3, subdivision (a)(13).
25	////	
26	////	
27	////	
28	////	

1	253.	The Pa	atient History Report for equine patient N., dated August 17, 2017, failed to
2	include the	followin	g information:
3		a.	A history or pertinent information as it pertains to the equine patient's
4			medical statutes as required under CCR, title 16, section 2032.3,
5			subdivision (a)(6);
6		b.	Data, including that obtained by instrumentation, from the physical
7			examination of the equine patient as required under CCR, title 16, section
8			2032.3, subdivision (a)(7);
9		c.	Treatment and intended treatment plan, including medication dosages as
10			required under CCR, title 16, section 2032.3, subdivision (a)(8);
11		d.	Diagnosis or assessment prior to performing a treatment or procedure as
12			required under CCR, title 16, section 2032.3, subdivision (a)(10);
13		e.	A prognosis of the animal's condition as required under CCR, title 16,
14			section 2032.3, subdivision (a)(11);
15		f.	For each medication prescribed and dispensed, the strength, dosage, route
16			of administration, quantity, and frequency of use as required under CCR,
17			title 16, section 2032.3, subdivision (a)(12); and
18		g.	Daily progress and disposition of the case as required under CCR title 16,
19			section 2032.3, subdivision (a)(13).
20	254.	The Pa	atient History Report for equine patient B. R., dated August 18, 2017, failed to
21	include the	followin	g information:
22		a.	A history or pertinent information as it pertains to the equine patient's
23			medical statutes as required under CCR, title 16, section 2032.3,
24			subdivision (a)(6);
25		b.	Data, including that obtained by instrumentation, from the physical
26			examination of the equine patient as required under CCR, title 16, section
27			2032.3, subdivision (a)(7);
20			

1	c. Treatment and intended treatment plan, including medication dosages as			
2	required under CCR, title 16, section 2032.3, subdivision (a)(8);			
3	d. Diagnosis or assessment prior to performing a treatment or procedure as			
4	required under CCR, title 16, section 2032.3, subdivision (a)(10);			
5	e. A prognosis of the animal's condition as required under CCR, title 16,			
6	section 2032.3, subdivision (a)(11);			
7	f. For each medication prescribed and dispensed, the strength, dosage, route			
8	of administration, quantity, and frequency of use as required under CCR,			
9	title 16, section 2032.3, subdivision (a)(12); and			
10	g. Daily progress and disposition of the case as required under CCR title 16,			
11	section 2032.3, subdivision (a)(13).			
12	<u>VETERINARY PREMISES REGISTRATION</u>			
13	255. Pursuant to section 4853.6, if the Board suspends or revokes Veterinarian License			
14	Number VET 8208 issued to Respondent Kuhlmann, the Board shall suspend or revoke			
15	Veterinary Premises Registration No. HSP 6179 issued to Respondent Kuhlmann, as managing			
16	licensee of Respondent SFE.			
17	<u>PRAYER</u>			
18	WHEREFORE, Complainant requests that a hearing be held on the matters alleged in this			
19	First Amended Accusation, and that following the hearing, the Board issue a decision:			
20	1. Revoking or suspending Veterinarian License Number VET 8208, issued to Kim			
21	Lewis Kuhlmann;			
22	2. Revoking or suspending Premises Registration Number HSP 6179, issued to San			
23	Francisco Equine, Inc., Kim Lewis Kuhlmann, managing licensee;			
24	3. Ordering Kim Lewis Kuhlmann to pay the Veterinary Medical Board the reasonable			
25	costs of the investigation and enforcement of this case, pursuant to Business and Professions			
26	Code section 125.3;			
27	////			
28				

1	4.	Assessing a fine against Kim Lewis Kuhlmann, DVM, not in excess of \$5,000, for
2	each violat	ion of the causes specified in Business and Professions Code section 4883; and
3	5.	Taking such other and further action as deemed necessary and proper.
4		
5		
6	DATED:	JESSICA SIEFERMAN
7		Executive Officer
8		Veterinary Medical Board Department of Consumer Affairs State of California
9		Complainant
10		
11	LA20216000 64987289.do	
12	04707207. <b>u</b> 0	
13		
14		
15		
16		
17		
18 19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
		93

(KIM LEWIS KUHLMANN; SAN FRANCISCO EQUINE, INC.) FIRST AMENDED ACCUSATION 123



BUSINESS CONSUMER SERVICES AND HOUSING AGENCY - GAVEN NEWSOM GOVERNOR DEPARTMENT OF CONSUMER AFFAIRS - VETERINARY MEDICAL BOARD 1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2978 P. (916) 515-5220 | Toll-Free (868) 229-0170 | www.vmb.ca.gov



## PETITION FOR REINSTATEMENT OR MODIFICATION OF PENALTY

INSTRUCTIONS: Please type or print neatly. All blanks must be completed; if not applicable enter N/A. If more space is needed attach additional sheets. Attached to this application should be a "Narrative Statement" and two original verified recommendations from a veterinarian licensed by the Board who has personal knowledge of activities since the disciplinary action was imposed.

TYPE OF PETITION [Reference Business and Professions Code section 4887]							
Reinstatement of Revoked/Surrendered License or Registration Modification of Probation Termination of Probation							
NOTE: A Petition for Modi	fication and/or Termination o	of Probation can be file	d together. If you are	requesting			
	ecify in your "Narrative Stater						
that you want reduced or n	nodified and provide an expl	anation. Please check	all boxes above that	apply.			
PERSONAL INFORMATION	ON			3 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -			
NAME: First	Mid	idle	Last				
Kim	Lewis		Kuhlmann				
Other name(s) licensed under, if	any:						
HOME ADDRESS: Nur	mber & Street	City	State	Zip			
	•						
HOME TELEPHONE NUMBER	WORK TEL	EPHONE NUMBER	CELL NUMB	ER			
( )	(510)	412-3660					
E-mail address:		CA License or Re	gistration Number				
		8208					
Are you licensed by any other state(s) or country(ies) (please include license number(s), issue date(s), and status of license(s)):  NA							
ATTORNEY INFORMATION	N (If Applicable)						
Will you be represented by an at	ttorney? No	✓ Yes (If "Yes," pleas	e provide the followin	g information)			
NAME: Drew Couto							
ADDRESS: 755 West A Street, Suite 100, San Diego, Ca 92101							
PHONE: (858) 354-373	9			N-74-			
DISCIPLINARY INFORMA	TION	i the state of the					
Provide a brief explanation in your "Narrative Statement" as to the cause for the disciplinary action (e.g., negligence or incompetence, self use of drugs or alcohol, extreme departures from sanitary conditions, conviction of a crime, etc.)							
Have you ever had your license revoked, suspended, voluntarily surrendered, denied, or placed on probation in any other state or country?							
(If Yes, give a brief cause for administrative action or license denial in your "Narrative Statement" section, including dates and discipline ordered (e.g., 5 years probation.)							

VETERINARIAN/REGIS	TERED TECHNICIAN BACKGROUND
Total number of years in veter	inary practice:
CONTINUING EDUCAT	ON (List continuing education completed since the date of the disciplinary action)
Lake Tahoe Equine Cor	ference 01/2023, 01/2024 & 01/2025
, ,	g for Veterinarians - DripVet Record Keeping 02/2023
Controlled Substance M	anagement in Veterinary Medicine - Vet Med Team 02/2023
-	ords - Animal & Veterinary Legal Services - 12/2024
Legal Requirements of I	Medical Records - DripVet - 12/2024
	ON OTHER THAN VETERINARIAN OR REGISTERED VET TECHNICIAN practicing as a Veterinarian or Registered Vet Technician)
List employer, address, e-ma	ail address, phone number, job title, and duties:
NIA	
EMPLOYMENT HISTO	RY (list for the past 5 years only)
Provide the employer's name	e, address, phone number, job title and dates of employment:
San Francisco Equine,	Inc. 7026 Koll Center Parkway, Suite 205, Pleasanton, Ca 94566
(510) 412-3660 Veterin	narian 30 years
REHABILITATION	
Describe any rehabiliative or conature of programs or courses,	orrective measures you have taken since your license/registration was disciplined. List dates, and current status. You may include any community service or volunteer work.
Equine related courses Medical Record Keepin Controlled Substance N Veterinary Medical Rec Legal Requirements of	ourses for record keeping and controlled substance management, also g for Veterinarians - DripVet Record Keeping 02/2023 Management in Veterinary Medicine - Vet Med Team 02/2023 ords - Animal & Veterinary Legal Services - 12/2024 Medical Records - DripVet - 12/2024 nference 01/2023, 01/2024 & 01/2025

Ex. 4 002

CURRENT COMPLIANCE						
Since the effective date of your last Veterinary Medical Board disciplinary action have you:						
Been placed on criminal probation or parole?	Yes	<b>V</b>	No			
2. Been charged in any pending criminal action by any state, local or federal agency or court?	Yes	<b>√</b>	No			
3. Been convicted of any criminal offense? (A conviction includes a no contest plea; disregard traffic offenses with a \$100 fine or less.)	Yes	<b>✓</b>	No			
4. Been charged or disciplined by any other veterinary board?	Yes	$\checkmark$	No			
5. Surrendered your license to any other veterinary board?	Yes	<b>√</b>	No			
6. Had your licensee manager's premise permit disciplined?	Yes	$\checkmark$	No			
7. Had any civil malpractice claims filed against you of \$10,000 or more?	Yes	$\checkmark$	No			
Become addicted to the use of narcotics or controlled substances?	Yes	$\checkmark$	No			
9. Become addicted to or received treatment for the use of alcohol?	Yes	$\checkmark$	No			
10. Been hospitalized for alcohol or drug problems or for mental illness?	Yes	$\checkmark$	No			
NOTE: If your answer is "Yes" to <b>any</b> of the above questions, please explain in the "Na	arrative St	ateme	ent."			
COST RECOVERY						
Was cost recovery ordered? Yes ONo If yes, what is the remaining balance? 0						
When is payment anticipated?						
DECLARATION						
Executed on January 23rd 25, at Alamo	(	)	Α			
(City)		(State	e)			
I declare under penalty of perjury under the laws of the State of California that the foregoing is true and correct and that all statements and documents attached in support of this petition are true and correct.						
KIM KUHLMANN						
Petitioner (print name) Signature						
The information in this document is being requested by the Veterinary Medical Board (Board) pursuant to Business and Professions Code section 4887. In carrying out its licensing or disciplinary responsibilities, the Board requires this information to make a determination on your petition for reinstatement or modification of penalty. You have a right to access the Board's records containing your personal information as defined in Civil Code section 1798.3. The Custodian of Records is the Executive Officer at the address shown on the first page.						

## SAN FRANCISCO EQUINE, INC.

KIM L. KUHLMANN, DVM KEN ALLISON, DVM

## 7026 KOLL CENTER PARKWAY, SUITE 205 PLEASANTON, CA 94566 TEL 510-412-3660



January 18, 2025

California Veterinary Medical Board 1747 North Market Blvd. Suite 230 Sacramento, California 95834–2978

To whom it may concern,

I am respectfully requesting the California Veterinary Medical Board (CVMB) consider my petition for early termination and/or modification of my current probation.

By way of background, on July 16, 2019, the CVMB filed Case No. 460-201-8000299. The causes of action included violations of :

- B&P Code, secs. 4883 and 4169 expired drugs;
- B&P Code, secs. 4883 and 4170 CURES reporting;
- B&P Code, sec. BPC4883: medical waste generator;
- B&P Code, sec. 4883 and Cal. Code Regs., Tit. 16, sec. 2030: drug dispensing logs;
- B&P Code, sec. 4883 and Cal. Code Regs., Tit. 16, sec. 2030: compounded drugs;
- B&P Code, sec. 4883 and Cal. Code Regs., Tit. 16, sec. 2032.2: laryngeal lavage, incomplete labeling; and,
- B&P Code, sec. 4883 and Cal. Code Regs., Tit. 16, sec. 2032.3: incomplete medical records, VCPR.

As a result of these charges, a Stipulated Agreement was signed November 30, 2022, with probation beginning on December 30, 2022. Since the date of the Agreement, I have fully adhered to both the terms and spirit of my probation requirements, as conscientiously and meticulously as possible. I have not only filed my quarterly reports in a timely fashion, I have completed my required record keeping and continuing education hours each year. The latter has improved and fortified the understanding and practice of my professional obligations in this regard.

Regarding the specific viblations, these experiences have proved valuable in improving my overall recognition of potential problems and the need to stay vigilant in establishing sound practice procedures. These improvements have been especially helpful as they relate to monitoring regularly expiration dates for medications, which are now done on a monthly basis so as to minimize and avoid the risks of carrying in inventory expired medications. Additionally, I have improved my practice with regard to the disposal of expired medication, ensuring that they are at all times disposed of in the approved and appropriate manner.

In accordance with CURES reporting practices, my practice no longer dispenses controlled substances to patients and has not done so since 2018, following the CVMB's inspection of the practice.

Similarly, in the context of drug dispensing logs, once I learned of my practice's deficiencies in the manner we maintained these logs, I took responsibility and made certain the procedures used to log drug substances was corrected and thus on subsequent inspections have been found to be fully compliant.

As for compounded medications, that was a subject that previously caused me and many of my equine veterinary colleagues' great confusion and frustration. However, in 2022, the Food and Drug Administration (FDA) modified its compounding regulations pertaining to veterinary medicines which provided greater clarification. As implemented, the new guidelines more clearly restrict the number of compounded medications permitted. While certain compounded medications are still permitted to be maintained as equine practice office stock other specified compounded medication is to be considered patient specific and requires a prescription requesting compounding. Since the FDA regulations changes were announced, I and my practice have closely followed these clarified guidelines. My practice maintains a very limited quantity of permitted general compound medications. Patient specific compounded medications are procured only from approved compounders, on an 'as needed basis through specific patient prescriptions based on thorough examinations and/or diagnostic test results warranting such use.

Consistent with the FDA's regulatory changes, in September 2022, the CVMB and the California Horse Racing Board (CHRB) issued written guidance authorizing the use of certain compounded drugs for horses under the same restraints. I and my practice have likewise adhered to the CVMB and CHRB guidelines as well.

As instructed by the CVMB, I and my practice have revised the manner in which we maintain patient (medical) records relating to our examination and/or treatment of horses (Thoroughbreds) regardless of their status as herd animals. Moreover, in January 1, 2021, the CHRB amended CHRB Rule 1842 to require electronic veterinary record keeping for any and all horses, regardless of breed, stabled within a CHRB licensed facility. That particular electronic record system was deemed the official equine treatment and record keeping system, as created and maintained by The Jockey Club.

On January 1, 2023, a new official electronic record keeping system was recognized by the CHRB. That system is known as "EquiTaps." This system was also created by The Jockey Club, and was considered to be an improved system for all users. Like the system before it, EquiTaps required:

- 1. Complete signalment of the patient;
- 2. Identification of any and all medications/substances administered and routes of administration;
- 3. Medication dosages, in milligrams;
- 4. Time of administration; and,
- 5. Specific reason for treatment.

The electronic records submitted are reviewed on a daily basis by qualified and experienced CHRB regulatory veterinarians. The system has enabled practicing veterinarians such as myself to more easily maintain accurate and complete medical records in simple retrievable formats. In addition, our CHRB records are available to and have been reviewed by CVMB approved practitioners on a monthly basis with reports submitted to the CVMB on regular or otherwise appropriate time frames.

As previously admitted, from approximately February 1983 up until late 2018 – when the accusation was first submitted – my record keeping practice was based on what I had been taught by my mentors – longtime CVMB and CHRB licensed veterinarians – and what we all understood to be the authorized and approved methods and standards required by the CHRB, pursuant to their plenary rulemaking authority over all licensees and racing-related

activities. . Once the CVMB determined my records were not in compliance with its standards and the Agreement executed, I immediately revised my practice to comply with the CVMB's requirements.

As I believe my probation records reflect, and based upon my own admission, upon implementation of the CVMB's medical record keeping protocols, I do believe my records are now even more comprehensive and complete than they were previously.

In summary, I believe I have learned from the corrective actions imposed on me by the CVMB and they have improved my methods of practice and made me a better practitioner.

I am hopeful that the CVMB shares in my assessment of these improvements and also believes that my efforts to correct the violations have been sincere, constructive and conscientious. Please be assured that it remains my intent to continue in these efforts to improve as a veterinary medicine practitioner in the future. I also remain hopeful that the CVMB sees my efforts as indicative of one warranting modification as to the length of my probation.

Thank you for your consideration of my request for Petition. Should you have any questions or believe there is any benefit in discussing the request directly in person, please feel free to contact me.

Sincerely yours,

Kim Lewis Kuhlmann, DVM



California Veterinary Medical Board:

Dear Board Members.

I have been asked to provide a letter of assessment for Dr. Kim Kuhlmann, who is a prominent equine practitioner that I have had a positive working relationship since 1995. I understand that under the penalty of perjury, under the laws of the state of California, the foregoing is true and correct.

After graduating from UC Davis School of Veterinary Medicine in 1990, I had spent most of my career at UC Davis. From my residency in equine surgery (1991-95) to my academic career spanning from 1996 to my recent retirement as Professor Emeritus in Equine Surgery in 2024, I feel qualified to provide an assessment of Dr. Kuhlmann's practice standards and ethics. I have recently moved to the New England area, and now I am actively practicing at New England Equine Medical and Surgical Center.

My working relationship with Dr. Kuhlmann has been mainly associated with consulting on challenging orthopedic, respiratory and medical cases. We have also worked together on the Golden Gate Hospital Board for 2 years, and I have assisted him in person him with clinical cases at the Golden Gate Fields Equine Hospital. Dr. Kuhlmann was also instrumental in organizing a sling training session for racetrack practitioners that I hosted at the UC Davis VMTH so that they could use the Anderson Sling for recovery and postoperative management of challenging orthopedic cases. Based on our working relationship for the past 30 years, I believe that I have full knowledge of his skill level, knowledge base, compassion for his patients, integrity and ethics.

I believe that Dr. Kuhlmann has set the standard of care for Northern California racetrack veterinary practice. He continues to strive to meet industry needs, provide exceptional patient care and is always doing his best to improve his knowledge base and clinical skills. I believe he is truly striving hard to provide the greatest health and welfare for the Northern California racing industry.


Please feel free to contact me if you require further information regarding Dr. Kim Kuhlmann.

Respectfully,

Larry D. Galuppo, DVM, Diplomate ACVS

Professor Emeritus, Equine Surgery, School of Veterinary Medicine, UC Davis

### EQUINE SPORTS MEDICINE AND SURGERY, INC.



To Whom It May Concern:

I have been asked to write an assessment of Dr. Kim Kuhlmann for consideration by the California Veterinary Medical Board.

I have been practicing veterinary medicine since 1979. Since 1983 I have been a resident of California and I have specialized in equine surgery and medicine in the San Francisco Bay area. I am president of Equine Sports Medicine and Surgery, Inc. I am currently vice president of the North American Association of Racetrack Veterinarians.

I am confident that Dr. Kuhlmannhas adhered to the requirements of the CVMB for record keeping and inventory management. Since 2021 he has been obligated to follow the revised and more stringent requirements of the California Horse Racing Board, the Horseracing Integrity and Safety Authority and the Horseracing Integrity and Welfare Unit. In 2021 the CHRB initiated the requirement of electronic veterinary record keeping. Since late in 2021, when they were created by Congressional mandate, HISA and HIWU have formulated strict requirements for record keeping and medication management. Since January 1, 2023 the CHRB has utilized the electronic record keeping system known as "EquiTaps" to keep track of medical procedures and medications. As a condition of his CHRB license Dr.Kuhlmannhas been required to adhere to these programs. His record keeping and medication management have been under constant scrutiny by the CHRB as well as HISA/HIWU. Because of this I am confident that Dr. Kuhlmannhas been scrupulous in following appropriate record keeping procedures.

I have practiced in the same venue as Dr. Kuhlmann for the past 42 years. Although we were members of competitive veterinarian practices I have had a high regard for Dr.Kuhlmann's dedication and effectiveness as a veterinarian.

Our region and the country as a whole are facing an increasing demand for veterinarians while at the same time experiencing a shortage of veterinarians to meet that demand, particularly in large animal practice. Dr.Kuhlmann is held in high esteem by his fellow veterinarians and his clients. He devotes an exceptional amount of time to his patients. He is very proficient and professional in his clinical performance. I hope that the actions of the CVMB will facilitate Dr. Kuhlmann's ability to continue to effectively practice veterinary medicine. It would be harmful to our horse population to deny them the attention of a veterinarian as accomplished as Dr. Kuhlmann.

I declare under penalty of perjury, under the laws of the State of California that the foregoing is true and correct.

TOUM

Donald Smith D.V.M.

## **BATTEN EQUINE LLC**

Casille Batten DVM

January 20, 2025

January 20, 2025

To whom it may concern:

I am writing regarding Dr Kim Kuhlmann. I declare under penalty of perjury, under the laws of the State of California, that the foregoing is true and correct.

I have known Dr Kuhlmann since 2020 when I began working as a regulatory practitioner at Golden Gate Fields racetrack in Berkeley. At the beginning of 2024, with the impending closure of Golden Gate Fields, I moved back into private practice and have worked at the same racetrack as Dr Kuhlmann (Pleasanton Race Track). I have also been reviewing the medical records for SF Equine, as required by the Veterinary Medical Board, since 2023.

Dr Kuhlmann has worked diligently over the last few years to improve the discrepancies brought up in the board filing. I review approximately 15% of his medical records every month and he has made every effort to ensure cases are accurately documented and meet the standards required by the California Veterinary Medical Practices Act. SF Equine has also made efforts to ensure veterinary technicians and office staff are following regulations.

On a personal level - Dr Kuhlmann has been servicing the racing community of Northern California for over 40 years and is regarded very highly by all members of that community. While I was working in a regulatory capacity, Dr Kuhlmann would reach out if there were any concerns regarding changes to rules or regulations to ensure he and his patients were in compliance. I always appreciated his openness and willingness to discuss any issues regarding cases.

Please feel free to contact me should you have any questions or concerns

Sincerely,

Casille Batten DVM



# Kim Kuhlmann, DVM

has completed

# Controlled Substance Management in Veterinary Medicine

## on February 28, 2023

This program 769259 is approved by the AAVSB RACE to offer a total of 2.00 CE Credits (2.00 max) being available to any one veterinarian: and/or 2.00 Veterinary Technician CE Credits (2.00 max). This RACE approval is for the subject matter categories of; Medical using the delivery method of Non-interactive Distance, This approval is valid in jurisdictions which recegnize AAVSB RACE; however, participants are responsible for ascertaining each board's CE requirements. RACE does not "accredit" or "endorse" or "certify" any program or person, nor does RACE approval validate the content of the program.

David Tollon, DVM, MBA, Founder

Pat Lynch, Director of Operations

Pat dynch

VetMedTeam, LLC, 2325 SW Dodge Terrace, Port St. Lucie, FL 34953



## drip.vet a part of the VIN Family

## CERTIFICATE OF COMPLETION

6 anytime on-demand CE hours (non-medical) for completing RACE Program 20-981038. This program has been approved for 6 hours of continuing education credit in jurisdictions that recognize RACE approval.

## KIMKUHLMANN

Provided by drip.vet, a part of the VIN Family, RACE Provider 50-26217

Medical Recordkeeping for Veterinarians

Date: 2023-12-28

Serial No.

cert\_gg3hn4yb

State: CA

License Number: *B20B* 



## drip.vet a part of the VIN Family

# CERTIFICATE OF COMPLETION

6 anytime on-demand CE hours (non-medical) for completing RACE Program 20-1042648. This program has been approved for 6 hours of continuing education credit in jurisdictions that recognize RACE approval.

## KIMKUHLMANN

Provided by drip.vet, a part of the VIN Family, RACE Provider 50-26217

Legal Requirements of Medical Records

Date: 2024-11-26

Serial No.

cert\_j66h79dl

State: (A

License 8208 Number:



**Animal & Veterinary Legal Services** 

## **CERTIFICATE OF COMPLETION**

Race Program # 20-745377 and VHMA Course

## KIM KUHLMANN

This non interactive-distance, non medical program has been approved for 2 hours of continuing education credit in jurisdictions that recognize RACE approval. The Veterinary Hospital Managers Association has approved this course for 2.0 (two) continuing education credits (Online Delivery).


**Veterinary Medical Records (2 hours)** 

Date: 2025-01-02

Serial No.

cert\_66bl97zs









## Kim Kuhlmann

## VETERINARIAN

Alamo, CA 94507

Methodical with extensive experience in diagnosing, treating, and preventing animal diseases. Skilled in advanced medical procedures, conducting thorough examinations, and developing customized treatment plans. Strong background in veterinary pharmacology and exemplary problem-solving abilities. Passionate about continual learning and scientific research. Treated or examined approximately 1.7 million patients during a time spanning over four decades. During that time period performed approximately five thousand surgical procedures involving the musculoskeletal and respiratory systems in racing age thoroughbreds which constituted a majority of all surgeries in Northern California racing thoroughbreds.

## **EXPERIENCE**

#### VETERINARIAN

Pleasanton, CA

San Francisco Equine Inc.

September 1991 - Present

- Educated owners regarding proper nutrition, preventative health care measures and potential risks associated with racing thoroughbreds
- Maintained accurate medical records and updated patient histories regularly.
- Managed emergencies efficiently, providing critical care for injured and sick animals.
- Performed orthopedic, soft tissue and respiratory system surgery.
- Monitored anesthesia during surgical procedures to ensure safety of animal patients.
- Attended lectured, conferences, and continuing education courses.

#### PRESIDENT

Pleasanton , CA

September 1991 - Present

VETERINARIAN

San Francisco Equine Inc.

San Mateo, CA

February 1983 - September 1991

Equine Veterinary Services

## **EDUCATION**

## DOCTOR OF VETERINARY MEDICINE (D.V.M.) IN VETERINARY

Jan 1983

SCIENCE

Colorado State University, Fort Collins, CO, US

## BACHELOR OF SCIENCE (B.S.) IN VETERINARY SCIENCE

May 1980

Colorado State University, Fort Collins, CO, US

## CERTIFICATIONS

California Veterinary Medical Board

License #8208



BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY - GAVIN NEWSOM, GOVERNOR
DEPARTMENT OF CONSUMER AFFAIRS • CALIFORNIA VETERINARY MEDICAL BOARD
1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2978
P (916) 515-5220 | Toll-Free (866) 229-0170 | www.vmb.ca.gov



#### PROBATION COMPLIANCE REPORT

PETITIONER: Kim Lewis Kuhlmann, DVM, VET 8208

REPORT TYPE: Early Termination of Probation

CASE NUMBER: 4602018000299

PROBATIONARY TERM: Four years: December 30, 2022 – December 29, 2026

## PROBATION TERMS AND CONDITIONS AND STATUS:

Obey All Laws: Compliant.

The Board has not received any notices of arrest or criminal conviction concerning Petitioner. The Board has not taken any action against Petitioner for violations of the Veterinary Medicine Practice Act.

2. Quarterly Reports: Non-Compliant.

All Quarterly Reports except for quarter 1 of 2023 was submitted in a timely manner.

On May 26, 2023, Petitioner was issued a Probation Violation letter. This letter informed Petitioner that he did not submit a Quarter Report for quarter 1 of 2023. Petitioner submitted the late Quarter Report on or about May 30, 2023.

On June 25, 2024, Petitioner was issued a Probation Violation letter. This letter informed Petitioner that he did not submit a Quarter Report for quarter 3 of 2023. Petitioner had submitted the Quarter Report on October 5, 2023 via email, therefore, this quarter report is not considered late.

#### Interview with the Board: Compliant.

Petitioner appeared for his interview on December 30, 2022, to review the terms and conditions of probation.

## Cooperation with Board Staff: Compliant.

Petitioner has responded and cooperated with probation surveillance in a timely manner when requested to respond.

## Probation Monitoring Costs: Compliant.

The probation monitoring total, \$4,800, is Probationer's total for four years of probation. Probation monitoring costs were paid in full as of September 23, 2024.

Changes of Employment or Address: Compliant.

# Probation Compliance Report Kim Lewis Kuhlmann, DVM

Petitioner notified to Board of a change in address for San Francisco Equine on May 26, 2025. Starting on June 1, 2025, the new address for San Francisco Equine became 15 Augusta Ct., Alamo, CA 94507.

## 7. No Supervision of Students, Interns, or Residents: Compliant.

No evidence has been received that Petitioner has supervised any students, interns, or residents.

## 8. Notice to Employers.

The Board has not requested a Notice to Employers form from Petitioner as he identified himself as the co-owner of San Francisco Equine.

## 9. Notice to Employees.

The Board has not requested a Notice to Employees form from Petitioner as he indicated San Francisco Equine does not employ any staff veterinarians, registered veterinary technicians, or controlled substance permit holders.

## 10. Tolling of Probation.

Petitioner has not entered tolling status during his probationary period.

## 11. Maintain a Current and Active License: Compliant.

Petitioner has maintained a valid license during probation.

## 12. Violation of Probation.

Since the effective date of the Decision, no Accusation or Petition to Revoke Probation has been filed against Petitioner for a probation violation.

As discussed in more detail in Condition 2, Petitioner was issued Probation Violation Letter on May 26, 2023. However, this violation did not result in the Board filing a Petition to Revoke Probation.

As discussed in more detail in Condition 17, Petitioner was issued Probation Violation Letters on January 30, 2023, and June 25, 2024. However, these violations did not result in the Board filing a Petition to Revoke Probation.

#### 13. License Surrender While on Probation/Suspension.

Petitioner has not requested to surrender his license.

## 14. Completion of Probation.

To date, all probation related costs have been paid.

## **15. Cost Recovery**: Compliant.

## Probation Compliance Report Kim Lewis Kuhlmann, DVM

Petitioner has made timely payments towards his Cost Recovery total, \$71,001.01 at a rate of \$4,900 per month for 14 months and a final monthly payment of \$2,401.01. Petitioner paid the final payment of the \$71,001.01 in Cost Recovery on April 1, 2024.

## 16. Inspections:

Petitioner is co-owner of San Francisco Equine, HSP 6179, and is not responsible for inspection fees for inspections completed on August 12, 2024, as Petitioner was not the MGL of the facility.

## 17. Medical Record Review: Non-Compliant.

On January 30, 2023, Petitioner was issued a Probation Violation letter. This letter informed Petitioner that he did not have a Board-approved reviewer. Petitioner provided the name and qualifications of the reviewer, Casille Batten, DVM, and received approval on or about January 31, 2023.

On June 25, 2024, a Probation Violation Letter was sent to Petitioner. This letter informed Petitioner the Board had not received Medical Record Review Reports for the months of January through June 2024. Petitioner's Medical Record Reviewer supplied January, February, and March's Medical Record Reports on or about June 26, 2024. Since this letter was issued to Petitioner on June 25, 2024, Medical Record Reviews for the months of April, May, and June were not due until July 7, 2024, so they were not considered late at the time of this letter. April, May, and June 2024 reviews were submitted on or about July 6, 2024.

The Board has now received all Medical Record Review reports; however, the unsatisfactory pages of the reports are missing. An email was sent to the reviewer, Casille Batten, DVM, to inform her that these pages were missing and to include them in future reports. Casille Batten responded stating that she would be sure to attach the missing page in the future. There is no indication that the reviewer was notified of the missing pages previously.

## 18. Continuing Education: Compliant.

Petitioner is required to submit CE courses related to medical record keeping for eight (8) hours for each year of probation.

December 30, 2022 - December 29, 2023:

Medical record keeping: 8 hours with approval and certificates received.

December 30, 2023 – December 29, 2024:

Medical record keeping: 8 hours with approval and certificates received.

## **19. Fine**: Compliant.

Petitioner's \$5,000 Fine was paid in full on January 12, 2023. No other costs related to fines are outstanding.

Probation Compliance Report Kim Lewis Kuhlmann, DVM

Completed by: Rachel McKowen Signature: SIGNATURE ON FILE Date: August 18, 2025



BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY • GAVIN NEWSOM, GOVERNOR

DEPARTMENT OF CONSUMER AFFAIRS • VETERINARY MEDICAL BOARD

1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2978

P (916) 515-5220 | Toll-Free (866) 229-0170 | www.vmb.ca.gov



## **VIA ELECTRONIC, CERTIFIED & REGULAR US MAIL**

January 30, 2023

Dr. Kim Kuhlmann c/o San Francisco Equine Inc 865 Marina Bay Parkway #39 Richmond, CA 94804 sfequine.office@gmail.com

Re: PROBATION VIOLATION LETTER Case No. 4602018000299

Dear Dr. Kuhlmann:

The following item requires your immediate attention:

## MEDICAL RECORDS REVIEW

Within 30 calendar days of the effective date of this Decision, Respondent Kuhlmann shall provide to the Board or its designee the name and qualifications of one or more proposed reviewer of the medical records of animal patients created and maintained by Respondents. If Respondent Kuhlmann's terms of probation include Supervised Practice, that supervisor also may served as the medical records reviewer. Each reviewer shall be a licensed veterinarian in California, have held a valid California license for at least five (5) years, and have never been subject to any disciplinary action by the Board.

The Board or its designee shall provide the approved reviewer with copies of this Decision. Within fifteen (15) calendar days of the reviewer's receipt of this Decision, the reviewer shall sign an affirmation that they have reviewed the terms and conditions of this Decision and fully understands the role of the reviewer.

If Respondent Kuhlmann fails to obtain the Board's or its designee's approval of a reviewer within sixty (60) calendar days of the effective date of this Decision, Respondent Kuhlmann shall receive a notification from the Board or its designee to cease practicing veterinary medicine within three (3) calendar days after being notified. Respondent Kuhlmann shall cease practice until a reviewer is approved to provide medical records review services.

The reviewer shall review a minimum of ten percent (10%) of Respondents' animal patient medical records or fifteen (15) records (whichever is greater), a minimum of twelve (12) times per year. The reviewer shall determine the method of random selection of medical records to review and shall access the medical records directly from where the medical records are being kept. Review of

Respondents' medical records shall not be delegated to Respondents or Respondents' staff. The reviewer's random selection of medical records shall include medical records that correlate to the animal patient care issues or other issues identified in the disciplinary action that resulted in this Decision. Respondents are required to make all animal patient medical records available for immediate inspection and copying by the reviewer at all times during business hours. The reviewer shall immediately notify the Board's Probation Monitor if Respondents fail or refuse to make the medical records available for inspection and/or copying.

Any potential costs associated with conducting the medical records review shall be borne by Respondents.

The reviewer shall evaluate the medical records to assess: 1) The medical necessity and appropriateness of Respondents' treatment; 2) Respondents' compliance with minimum standards of practice in the diagnosis and treatment of animal patients; 3) Respondents' maintenance of necessary and appropriate treatment; 4) Respondents' maintenance of necessary and appropriate records and chart entries; and 5) Respondents' compliance with existing statues and regulations governing the practice of veterinary medicine.

The reviewer shall submit quarterly reports to the Board on a form designated by the Board. The reports shall be submitted by the reviewer directly to the Board's Probation Monitor within seven (7) calendar days after the end of the preceding quarter. The quarterly reporting periods and due dates are as follows: January 1 to March 31 (Quarter I) due no later than April 7; April 1 to June 30 (Quarter II) due no later than July 7; July 1 to September 30 (Quarter III) due no later than October 7; October 1 to December 31 (Quarter IV) due no later than January 7.

Pursuant to the Medical Records Review term of probation included in the Stipulated Settlement which became effective on December 30, 2022, you are required to maintain an approved reviewer. You do not have a Board-approved reviewer.

Failure to comply with the terms and conditions of your disciplinary order will result in the Board filing a Petition to Revoke Probation with the Attorney General's Office.

If you have any questions or concerns, please contact me via email at <a href="mailto:jeffrey.weiler@dca.ca.gov">jeffrey.weiler@dca.ca.gov</a>

Regards,

SIGNATURE ON FILE

Jeffrey Weiler Lead Probation Monitor Veterinary Medical Board



BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY • GAVIN NEWSOM, GOVERNOR

DEPARTMENT OF CONSUMER AFFAIRS • VETERINARY MEDICAL BOARD

1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2978

P (916) 515-5220 | Toll-Free (866) 229-0170 | www.vmb.ca.gov



# PROBATION SUPERVISOR APPROVAL FORM

**INSTRUCTIONS:** Complete all sections below. If you work at multiple locations where you will have more than one supervisor, a separate form must be completed for each supervisor. The supervisor shall be independent, with no prior business or personal relationship with you and the supervisor shall not be in a familial relationship with or be an employee, partner, or associated with you. Do not enter into any Agreement until you have received approval by the Board. Please type or print clearly.

Probationer's Name KIM L. KYWMANN Case # 440201800000
Proposed Supervisor's Information
Supervisor's Name CASILLE BATTER VET# 18833
Mailing Address
Phone number: E-mail address:
Area of Practice: EDUNE Regulatory Votor ray AO (Please list the type of veterinary medicine the proposed supervisor practices)
Duration of Supervision $1-1-33 \rightarrow 12-31-27$
Type of Supervision: OlRECT (Please list a start and end date)  MEDICAL RECORD REVIEW SPECIFIC PROCEDURE (list the type of procedures to be supervised)
I hereby submit this signed form, as required by the Veterinary Medical Board's Disciplinary Order, to obtain approval for a supervisor during my probation.
I declare under penalty of perjury under the laws of the State of California that all statements given here are true and correct.
Probationer's Signature:
How is the supervisor known to you? Regulatory vet at Coldulatificas
(For Board use only)
APPROVEDX DENIED
Probation Monitor Signature SIGNATURE ON FILE Date: January 31, 2023



BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY • GAVIN NEWSOM, GOVERNOR

DEPARTMENT OF CONSUMER AFFAIRS • VETERINARY MEDICAL BOARD

1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2978

P (916) 515-5220 | Toll-Free (866) 229-0170 | www.vmb.ca.gov



#### VIA ELECTRONIC MAIL

May 26, 2023

Dr. Kim Kuhlmann sfequine.office@gmail.com

Re: PROBATION VIOLATION LETTER Case No. 4602018000299

Dear Dr. Kuhlmann:

The following item requires your immediate attention:

## **QUARTERLY REPORTS**

Respondent Kuhlmann hall report quarterly to the Board or its designee, under penalty of perjury, on forms provided by the Board, stating whether there has been compliance with all terms and conditions of probation. Omission or falsification in any manner of any information on these reports shall constitute a violation of probation and shall result in the filing of an accusation and/or a petition to revoke probation against Respondents' license registration or permit. If the final written quarterly report is not made as directed, the period of probation shall be extended until the final report is received by the Board. Any period(s) of delinquency in submission of reports may be added to the total period of probation.

The quarterly report for the first quarter of 2023 has not been received. The deadline to submit that report was April 5, 2023. Please submit the missing quarterly report and ensure all future quarterly reports are submitted timely to the Board.

Failure to comply with the terms and conditions of your disciplinary order will result in the Board filing a Petition to Revoke Probation with the Attorney General's Office.

If you have any questions or concerns, please contact me via email at <a href="mailto:jeffrey.weiler@dca.ca.gov">jeffrey.weiler@dca.ca.gov</a>

Regards,

SIGNATURE ON FILE
Jeffrey Weiler
Lead Probation Monitor
Veterinary Medical Board



DEPARTMENT OF CONSUMER AFFAIRS • VETERINARY MEDICAL BOARD
1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2978
P (916) 515-5220 | Toll-Free (866) 229-0170 | www.vmb.ca.gov

EDMINERAL CORRESPONDED IN A PROMOTO DESIGNATION OF A GRANDER WASHINGTON DIRECT



## **Quarterly Probation Report**

**INSTRUCTIONS:** Please type or print neatly. <u>ALL</u> requested information and questions on this form must be answered. When space provided is insufficient, attach additional sheets of paper. All attachments are considered part of the Declaration, Submit your completed report to the Veterinary Medical Board's Probation Unit via email to your Probation Monitor, or via U.S. mail to the office address above. Please retain a completed copy for your records.

C	heck Appropriat	te Box Below for Re	eporting Period								
1st Quarter (January, February	y, March)	Postmark date Ap	ril 5 <sup>th</sup>								
2 <sup>nd</sup> Quarter (April, May, June)		Postmark date July 5 <sup>th</sup>									
3 <sup>rd</sup> Quarter (July, August, Sep		Postmark date October 5th									
4 <sup>th</sup> Quarter (October, Novemb		Postmark date Jar									
	,,										
First Name	Middle Name		Last Name								
Kim	Lew	115	Kuhlmanu								
Case Number	License/Registra	ation Number	Primary Email Address								
	80	208									
Hours Worked	Days Worked		Mobile Fliorie National Troute	FIIONON	amper						
Per Week:	Per Week: 7										
Principle Place of Practice											
Golden Coute 7161 Address of Principle Place of Practice	S ENET	BACK									
100 EASTSHORE H *You must list all practice locations locations or employers, you must list	wy So and changes in			ractice							
	COMPL	LIANCE REPOR	Т								
The questions below refer to the tim supporting documentation as reque			Quarterly Report. Please pro	vide any							
(Check ONE box for each question be			And the second s	YES	NO						
Have you had any disciplinary ac		•			V						
against any professional or vocat	ional license yo	u now hold? if yes,	attach an explanation.		$\sim$						

Have you had any disciplinary action taken by any federal, state, other governmental agency against any professional or vocational license you now hold? If yes, attach an explanation.		X
Since the last quarterly report have you been arrested, charged, or convicted of any violation of any federal, state or local laws? If yes, attach a detailed explanation.	grant to be a second second	X
Have you complied with every term and condition of your probation? If no, provide an explanation.	Х	

(Check ONE box for each question below)	AES	NO
Have you maintained a current and valid license/registration? If no, provide an explanation.	X	
Are you current with your probation monitoring costs? If no, provide an explanation.	X	

## **DECLARATION AND SIGNATURE**

I hereby submit this Quarterly Report as required by the Veterinary Medical Board and thereof and declare under penalty of perjury under the laws of the State of California the foregoing report and any attachments in their entirety and know their contents and that are true in every respect and I understand and acknowledge that any misstatements, no omissions of material fact may be cause for further disciplinary action.	nat I have read the tall statements made
Executed on April 2 , 2023 , at Alawo City	, <u>CA</u> State
Probationer (print name):	
Probationer's Signature:	




BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY • GAVIN NEWSOM, GOVERNOR
DEPARTMENT OF CONSUMER AFFAIRS • VETERINARY MEDICAL BOARD
1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2978
P (916) 515-5220 | Toll-Free (866) 229-0170 | www.vmb.ca.gov



## VIA ELECTRONIC, CERTIFIED & US MAIL

June 25, 2024



Re: PROBATION VIOLATION LETTER Case No. 4602018000299

Dear Dr. Kuhlmann:

A comprehensive review of your probation file was conducted. The following items require your immediate attention:

## **QUARTERLY REPORTS**

The Respondent Kuhlmann shall report quarterly to the Board or its designee, under penalty of perjury, on forms provided by the Board, stating whether there has been compliance with all terms and conditions of probation. Omission or falsification in any manner of any information on these reports shall constitute a violation of probation and shall result in the filing of an accusation and/or a petition to revoke probation against Respondents' license registration or permit. If the final written quarterly report is not made as directed, the period of probation shall be extended until the final report is received by the Board. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation.

After review of the Board's records, the Board has not received a Quarterly Report for Quarter 3 of 2023. Quarterly Reports are due on the 5<sup>th</sup> day after each quarter of the calendar year.

#### MEDICAL RECORDS REVIEW

The reviewer shall review a minimum of ten percent (10%) of Respondent's animal patient medical records or fifteen (15) records (whichever is greater), a minimum of twelve (12) times per year. The reviewer shall submit quarterly reports to the Board on a form designated by the Board. The reports shall be submitted by the reviewer directly to the Board's Probation Monitor within seven (7) calendar days after the end of the preceding quarter.

After review of the Board's records, the Board has not received reports for the months of January 2024 through June 2024. Medical Records Review reports are due on (at least) a quarterly basis.

Please submit a written letter of explanation in answer to the above-described violation along with a proposed plan to correct the violation by **July 9**, **2024**. Failure to rectify any and/or all of the violations may be considered violations of your probation.

If you have any questions or concerns, please contact me via email at <u>Alexander.Juarez@dca.ca.gov</u>.

Regards,

Alexander A. Juarez Probation Monitor Veterinary Medical Board

## McKowen, Rachel@DCA

From: Juarez, Alexander@DCA

**Sent:** Friday, August 29, 2025 1:11 PM

To: McKowen, Rachel@DCA
Subject: FW: Quarterly report letter

Here you go.



## Alexander A. Juarez Probation Monitor

California Veterinary Medical Board Department of Consumer Affairs 1747 N. Market Blvd, Suite 230 Sacramento, CA 95834

Direct: 916-905-5434 Toll Free: 866-229-0170

| | X | Join Our Email List! | VMB Customer
| Satisfaction Survey

From: Kimkuhlmann

Sent: Wednesday, June 26, 2024 12:38 PM

To: Juarez, Alexander@DCA <Alexander.Juarez@dca.ca.gov>

Subject: Quarterly report letter

#### This Message Is From an Untrusted Sender

Warning: This email originated from outside of the organization! Do not click links, open attachments, or reply, unless you recognize the sender's email.

Report Suspicious

## Dear Mr Juarez;

I was informed today by my office staff of a letter from your office informing us that you are missing the first quarter report as well as reviews of our billing records. I spoke with Dr Batten and she informed me that she sent in the report for our March records today and you should have received January and February records reviews already.

In regards to the first quarter report, it was sent the first week of April. It includes attachments and when it was sent we received an automated response that you were out of the office so the email address should have been correct. They will resend it today, hopefully including the time stamp showing the original submission. Please confirm receipt of the documents so we will know you received them. Thank you.

Sincerely,

Kim Kuhlmann, DVM

## McKowen, Rachel@DCA

From: Juarez, Alexander@DCA

Sent: Tuesday, September 2, 2025 9:40 AM

To: McKowen, Rachel@DCA

Subject: FW: Automatic reply: 3rd Quarterly Probation Report - Dr. Kim Kuhlmann



## Alexander A. Juarez Probation Monitor

California Veterinary Medical Board Department of Consumer Affairs 1747 N. Market Blvd, Suite 230 Sacramento, CA 95834

Direct: 916-905-5434 Toll Free: 866-229-0170

| | X | Join Our Email List! | VMB Customer
| Satisfaction Survey

From: sf equine <sfequine.office@gmail.com> Sent: Wednesday, June 26, 2024 1:36 PM

To: Juarez, Alexander@DCA <Alexander.Juarez@dca.ca.gov>

Subject: Re: Automatic reply: 3rd Quarterly Probation Report - Dr. Kim Kuhlmann

## This Message Is From an Untrusted Sender

Warning: This email originated from outside of the organization! Do not click links, open attachments, or reply, unless you recognize the sender's email.

Report Suspicious

I understand you didn't request the QUARTER 1 2024 in your letter from yesterday, I was just covering my bases, since the same automatic email response was received for the missing QUARTER 3 2023. I don't want it to happen again in the future that you are missing a Quarterly report, when I get an automatic email response from you.

Thank you for your understanding.

Chris

On Wed, Jun 26, 2024 at 1:03 PM Juarez, Alexander@DCA <<u>Alexander.Juarez@dca.ca.gov</u>> wrote:

Hello.

## McKowen, Rachel@DCA

From: Juarez, Alexander@DCA

Sent: Friday, August 29, 2025 1:12 PM

To: McKowen, Rachel@DCA

Subject: FW: Allison and Kuhlman reviews

Attachments: ALLISON JAN 24 MEDICAL RECORD REVIEW OVERALL EXAMINATION ASSESSMENT.pdf;

Kuhlman JAN24 MEDICAL RECORD REVIEW OVERALL EXAMINATION ASSESSMENT - Page 2.pdf; ALLISON MAR 24 MEDICAL RECORD REVIEW OVERALL EXAMINATION ASSESSMENT.pdf; Kuhlman JAN 24 Monthly Supervision VET Report Packet.pdf; Allison JAN 24 Monthly Supervision VET Report Packet Fillable.pdf; Kuhlman MAR MEDICAL RECORD REVIEW OVERALL EXAMINATION ASSESSMENT.pdf; Allison MARCH 24 Monthly Supervision VET Report Packet Fillable.pdf; Kuhlman MARCH 24 Monthly

Supervision VET Report Packet.pdf

## Here you go.



## Alexander A. Juarez Probation Monitor

California Veterinary Medical Board Department of Consumer Affairs 1747 N. Market Blvd, Suite 230 Sacramento, CA 95834

Direct: 916-905-5434 Toll Free: 866-229-0170

| | X | Join Our Email List! | VMB Customer
| Satisfaction Survey

From: Casille Batten <

Sent: Wednesday, June 26, 2024 9:07 AM

To: Juarez, Alexander@DCA <Alexander.Juarez@dca.ca.gov>

Subject: Allison and Kuhlman reviews

## This Message Is From an Untrusted Sender

Warning: This email originated from outside of the organization! Do not click links, open attachments, or reply, unless you recognize the sender's email.

Report Suspicious

Hi Alex,

Here are the record reviews for Drs Allison and Kuhlman. Sorry for the delay in getting these to you. I will have some more coming soon.

Thanks

Casille

\_\_

Casille Batten, DVM

I received the Quarter 1 2024 Quarterly Report. That report was not requested in the letter I sent yesterday. Dr. Batten sent reports for January and March 2024, but has not sent over a report for February 2024. Dr. Batten stated a report for February 2024 will be sent over later today.
Thank you.
From: sf equine <sfequine.office@gmail.com> Sent: Wednesday, June 26, 2024 12:51 PM To: Juarez, Alexander@DCA <alexander.juarez@dca.ca.gov> Subject: Re: Automatic reply: 3rd Quarterly Probation Report - Dr. Kim Kuhlmann</alexander.juarez@dca.ca.gov></sfequine.office@gmail.com>
Did you receive the 1ST QUARTER 2024 email? I got an OUT OF OFFICE response when I sent that email.
I am not sure what you are looking for as far as Medical Records Reviewer report. Dr. Batten resent them this morning and you confirmed receipt.
Please let me know if this is satisfactory.
Chris
San Francisco Equine, Inc. 510-412-3660
**** PLEASE NOTE OUR NEW LOCATION ADDRESS ****

7026 KOLL CENTER PARKWAY SUITE 205 PLEASANTON, CA 94566



Feb

nstructions:

Veterinarian Name: Kim Kuhlman

Report for the Month of: (circle one)

March April May

BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY • GAVIN NEWSOM, GOVERNOR DEPARTMENT OF CONSUMER AFFAIRS • VETERINARY MEDICAL BOARD 1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2978



Dec

Case No: 4602018000299

VET # 8208

Sept

Oct

August

P (916) 515-5220 | Toll-Free (866) 229-0170 | www.vmb.ca.gov

July

## MONTHLY SUPERVISION REPORT

June

(1) Please review the supervision agreement which includes the percentage and frequency of records that

need to be reviewed.
(2) Make additional copies of this page and two types of Supervision Review logs to be turned in
monthly (Satisfactory/Unsatisfactory).
(3) Fill this page completely with all up-to-date information and turn in monthly by the 5 <sup>th</sup> of each month of
supervision with corresponding logs.
(4) Please fill out UNSATISFACTORY TREATMENT OR DOCUMENATION review log for all patient care reviewed that required discussion, concerns or recommendations and provide your feedback to the
Board (e.g. did you discuss the concerns with the probationer, were any changes made, what was the
outcome, etc.)
(5) Please fill out SATISFACTORY TREATMENT AND DOCUMENTATION for all patient care reviewed that was in total compliance.
•
The BOX below is to be filled out AFTER all necessary logs are filled out.
I HEREBY SUBMIT THIS REPORT OF COMPLIANCE AS REQUIRED BY THE VETERINARY
MEDICAL BOARD AND THE TERMS AND CONDITIONS OF THE DISCIPLINARY ORDER IN THE
MATTER REGARDING THE ABOVE REFERENCE PROBATIONER. I HEREBY CERTIFY UNDER
PENALTY OF PERJURY UNDER THE LAW OF THE STATE OF CALIFORNIA THAT ALL
STATEMENTS GIVEN HERE ARE TRUE AND CORRECT.
SUPERVISOR NAME: Casille Batten VET # 18833
PROBATIONER'S EMPLOYER OR HOSPITAL:
San Francisco Equine, Inc
ADDRESS: 865 Marina Bay Pkwy Ste 39, Richmond, CA 94804 TELEPHONE #: (510)867-5871
NUMBER OF HOURS YOU SPEND REVIEWING PATIENT RECORDS: PER WEEK PER
MONTH 4
CARL NA
SUPERVISOR'S SIGNATURE: Costle Batter, M REVIEW DATE: 04.15.24

Patient Name	Yes He C	Can (1)	Treatment Date	01.21.24
Medical Care P	rovided	Post race fluid th	erapy	
Patient Name	Ann (2)		Treatment Date	01.21.24
Medical Care P	rovided	Post race flyuid t	herapy	
	90		) / ·	
<b>Patient Name</b>	Algeria (	3)	Treatment Date	01.21.24
Medical Care P	rovided	Diagnostic analg	esia right hind limb	
Patient Name	HersABi	gGirl (4)	Treatment Date	01.21.24
Medical Care P	rovided	Lasix		
	70	18-26	2	
<b>Patient Name</b>	North Co	ountry (5)	Treatment Date	01.21.24
Medical Care P	rovided	Lasix		
		•		
<b>Patient Name</b>	Miss Wil	I (6)	Treatment Date	01.21.24
Medical Care P	rovided	Lasix	•	
		NOTAL STREET		
Patient Name	Orderly 7	Transition (7)	Treatment Date	01.21.24
Medical Care P	rovided	Lasix		
		•		
Patient Name	Acero (8	)	Treatment Date	01.21.24
Medical Care P	rovided	Lasix		
Patient Name	Acclider	(9)	Treatment Date	01.21.24
Medical Care P	rovided	Post race fluid ar	nd electrolyte supple	mentation
	100			
<b>Patient Name</b>	Bronze (	Girl (10)	Treatment Date	01.21.24
Medical Care P	rovided	Post race fluid ar	nd electrolyte supple	mentation
			, , ,	
<b>Patient Name</b>	Conejo M	Malo (11)	Treatment Date	01.21.24
Medical Care P	A 100 TO	7 - 2 - 2	nd electrolyte supple	mentation
<b>Patient Name</b>	Galopin	Gourmet (12)	Treatment Date	01.21.24
Medical Care P			nd electrolyte supple	mentation
and the second s	erecental transmission (Contragation)	1		Reviewing Vet Initials CB

Patient Name	La Prime	r Estrella (13)	Treatment Date	01.21.24
Medical Care P	rovided	Post race fluid a	nd electrolyte supple	mentation
Patient Name	Lord WIm	borne (14)	Treatment Date	01.21.24
Medical Care P	rovided	Post race fluid a	nd electrolyte supple	mentation
	186		4	
Patient Name	Uncle Jua	an (15)	Treatment Date	01.21.24
Medical Care P	rovided	Post race fluid a	nd electrolyte supple	mentation
		•		
<b>Patient Name</b>	Senor De	l Campo (16)	Treatment Date	01.21.24
Medical Care P	rovided	Post race fluid a	nd electrolyte supple	mentation
	10	9		
<b>Patient Name</b>	Port O Ca	all (17)	Treatment Date	01.21.24
Medical Care P	rovided	Dispense medica	ation for pastern der	natitis
		-		
<b>Patient Name</b>	Tigersun	(18)	Treatment Date	01.21.24
Medical Care P	rovided	Lasix		
		100		
<b>Patient Name</b>	Elwood R	Road (19)	Treatment Date	01.21.24
Patient Name Medical Care P		Road (19) Lasix	Treatment Date	01.21.24
			Treatment Date	01.21.24
	rovided		Treatment Date  Treatment Date	01.21.24
Medical Care P	rovided Hops For	Lasix		
Medical Care P	rovided Hops For	Pops (20)		
Medical Care P	rovided Hops For	Pops (20) Prework exam		
Medical Care P  Patient Name  Medical Care P	Hops For rovided  Beau Bru	Pops (20) Prework exam	Treatment Date	01.21.24
Medical Care P  Patient Name  Medical Care P  Patient Name	Hops For rovided  Beau Bru	Pops (20) Prework exam me (21)	Treatment Date	01.21.24
Medical Care P  Patient Name  Medical Care P  Patient Name	Hops For rovided  Beau Bru	Pops (20) Prework exam me (21) Lasix	Treatment Date	01.21.24
Medical Care P  Patient Name  Medical Care P  Patient Name  Medical Care P	Hops For rovided  Beau Bru rovided  Mars Mag	Pops (20) Prework exam me (21) Lasix	Treatment Date  Treatment Date	01.21.24
Medical Care Property Patient Name  Medical Care Property Patient Name  Medical Care Property Patient Name	Hops For rovided  Beau Bru rovided  Mars Mag	Pops (20) Prework exam me (21) Lasix gic (22)	Treatment Date  Treatment Date	01.21.24
Medical Care Property Patient Name  Medical Care Property Patient Name  Medical Care Property Patient Name	Hops For rovided  Beau Bru rovided  Mars Mag	Pops (20) Prework exam me (21) Lasix gic (22) Lasix	Treatment Date  Treatment Date	01.21.24
Medical Care Property Patient Name Medical Care Property Property Property Name	Hops For rovided  Beau Bru rovided  Mars Magrovided  Seaver W	Pops (20) Prework exam me (21) Lasix gic (22) Lasix	Treatment Date  Treatment Date  Treatment Date	01.21.24
Medical Care Property Patient Name	Hops For rovided  Beau Bru rovided  Mars Magrovided  Seaver W	Lasix  Pops (20)  Prework exam  me (21)  Lasix  gic (22)  Lasix  /ay (23)	Treatment Date  Treatment Date  Treatment Date	01.21.24
Medical Care Property Patient Name	Hops For rovided  Beau Bru rovided  Mars Mag rovided  Seaver W rovided	Lasix  Pops (20)  Prework exam  me (21)  Lasix  gic (22)  Lasix  /ay (23)	Treatment Date  Treatment Date  Treatment Date	01.21.24
Medical Care Property Patient Name	Hops For rovided  Beau Bru rovided  Mars Magrovided  Seaver Wrovided  Lookin For	Pops (20) Prework exam me (21) Lasix gic (22) Lasix /ay (23) Lasix	Treatment Date  Treatment Date  Treatment Date	01.21.24 01.21.24 01.21.24
Patient Name Medical Care P	Hops For rovided  Beau Bru rovided  Mars Magrovided  Seaver Wrovided  Lookin For	Lasix  Pops (20)  Prework exam  me (21)  Lasix  gic (22)  Lasix  /ay (23)  Lasix  or Revenge (24)	Treatment Date  Treatment Date  Treatment Date	01.21.24 01.21.24 01.21.24

Patient Name	Good Lov	/in (25)	Treatment Date	01.21 - 01.23.24						
Medical Care P			liagnostics for respira	atory infection						
Patient Name	Hot And	Spicy (26)	Treatment Date	01.21.24						
Medical Care P	rovided	Prerace entry ex	Prerace entry exam							
	ľ		T							
Patient Name	Harcyn (2	T .	Treatment Date	01.21.24						
Medical Care P	rovided	Diagnostic analg	gesia left front							
Patient Name	LLL Cool	(20)	Treatment Date	04.24.24						
Medical Care P	LLL Cool	T -		01.21.24						
Medical Care F	roviueu	Prerace entry ex	am							
<b>Patient Name</b>	Long Jac	ket (29)	Treatment Date	01.21.24						
Medical Care P	30	Radiograph	2	01.21.21						
		rtadiograph								
<b>Patient Name</b>	Lord She	ldon (30)	Treatment Date	01.21.24						
Medical Care P	rovided	Prerace entry ex	kam							
			T 20 20 20 20 20 20 20 20 20 20 20 20 20							
Patient Name	Mobou (3	31)	Treatment Date	01.21.24						
Medical Care P	rovided	Dental								
***			Two stars and Data							
Patient Name	- 22	ot Lucky (32)	Treatment Date	01.21.24						
Medical Care P	rovided	Prerace entry ex	am							
<b>Patient Name</b>	Alphabati	inal Order (22)	Treatment Date	01.21.24						
Medical Care P		cal Order (33)	THE STATE OF THE S	0.121.21						
Wicultar Care F	TOVIUCU	Endoscopic exa	Ш							
<b>Patient Name</b>	Lammas	(34)	Treatment Date	01.21.24						
Medical Care P	The state of the s	Prework exam		1 Table 10 T						
and the second s										
<b>Patient Name</b>	Oops (35	)	Treatment Date	01.21.24						
Medical Care P	rovided	Prework exam								
New York Assessed										
Patient Name	Sunglass	es (36)	Treatment Date	01.21.24						
Medical Care P	rovided	Lasix								
				Reviewing Vet Initials CB						

<b>Patient Name</b>	Tessa (3	7)	Treatment Date	01.22.24
Medical Care P	The second secon	111	nd electrolyte supple	mentation
Patient Name	TopAntic	ipation (38)	Treatment Date	01.23.24
Medical Care P	rovided	Dispense steroid	l for mild dermatitis	
	ř		T ( 1 )	
Patient Name	Cat Band		Treatment Date	01.23.24
Medical Care P	rovided	Dispense steroid	I for mild dermatitis	
Dadiana Nama			Treatment Date	24 24 24
Patient Name	120,000 (200)	Paycheck (40)	Treatment Date	01.21.24
Medical Care P	roviaea	Lasix		
<b>Patient Name</b>	Juliet's K	(itchen (41)	Treatment Date	01.23.24
Medical Care P		Prework exam	2	01.20.21
		i Towork oxam		
<b>Patient Name</b>	Contrary	Chieftain (42)	Treatment Date	01.23.24
Medical Care P	rovided	Endoscopic exar	n	
<u>.</u>			•	
Patient Name	Dontim (	43)	Treatment Date	01.21.24
Medical Care P	rovided	Prerace entry ex	am	
			T ( ) P (	N 4 2 2 200
Patient Name		ver Bells (44)	Treatment Date	01.21.24
Medical Care P	rovided	Prerace entry ex	am	
Patient Name	Deles Al	: /45)	Treatment Date	04.04.04
E TO SEAS THE DESCRIPTION OF THE PROPERTY OF T	Poker Al	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	The second secon	01.21.24
Medical Care P	rovided	Prerace entry ex	am	
<b>Patient Name</b>	Champa	gne Pegasus (46)	Treatment Date	01.21.24
Medical Care P	The second of the second of the second of	Prerace entry ex		01.21.21
1,100,100,1		i rorado onay ox	di i	
<b>Patient Name</b>	Church H	Harbor (47)	Treatment Date	01.21 -01.22.24
Medical Care P	A STATE OF THE STA	Treatment for Ell	PH	
	10			
Patient Name			Treatment Date	
Medical Care P	rovided			
				Reviewing Vet Initials CB

MEDICAL RECORD REVIEW. Record #	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	
OVERALL EXAMINATION ASSESSMENT																							
Diagnosis complied with minimum standards.	$\checkmark$										$\checkmark$			$\overline{\mathbf{v}}$								$\overline{\mathbf{v}}$	
Treatment was necessary, appropriate, and complied with minimum standards.	$\checkmark$	abla				$\checkmark$	$ \vee $		abla		<b>V</b>										abla	$\overline{\mathbf{v}}$	
Maintained necessary and appropriate treatment.	$\checkmark$											$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$		$\overline{\mathbf{v}}$							abla	
Maintained necessary and appropriate records and chart entries.	<b>~</b>	$\checkmark$	$\vee$	abla		$\vee$		$\vee$		$\overline{\mathbf{v}}$	$\vee$		$\overline{\mathbf{v}}$	abla	$\vee$	<b>V</b>	$\vee$	abla		$\vee$	$\overline{\mathbf{v}}$	abla	
Complied with existing statutes and regulations governing the practice of veterinary medicine.	$\vee$	$\overline{\mathbf{v}}$	~	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\vee$		~			$\overline{\mathbf{v}}$	~	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	~	$\sim$	~	~	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	
CCR SECTION 2032.3 (a) RECORD REVIEW																							
Legible	~	~	<b>V</b>	~	$\vee$	~	~	$\vee$	~	~	~	~	~	<b>V</b>	~		<b>V</b>	~	~	~	~	$\vee$	
Name or initials of the person responsible for entries.	<	$\overline{\mathbf{v}}$		$\overline{\mathbf{v}}$			abla			$\overline{\mathbf{v}}$					$\vee$			$\overline{\mathbf{v}}$				<b>~</b>	
Name, address and phone number of the client.	$\checkmark$	$\overline{\mathbf{z}}$	$\overline{\mathbf{v}}$																			$\vee$	
Name or identity of the animal, herd or flock.	<b>~</b>		$\vee$	$\overline{\mathbf{v}}$			$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$			$\checkmark$				~	$\vee$	$\overline{\mathbf{v}}$			$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\sim$	
Except for herds or flocks, age, sex, breed, species.	$\checkmark$		$\overline{\mathbf{v}}$																			$\overline{\mathbf{v}}$	
Dates (beginning and ending) of custody of the animal, if applicable.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
A history or pertinent information as it pertains to each animal, herd, or flock's medical status.	N/A	$\checkmark$	N/A	$\sim$	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A		$\overline{\mathbf{v}}$	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
Data, including that obtained by instrumentation, from the physical examination.	~	$\overline{\mathbf{v}}$	~				$\checkmark$	~			$\checkmark$		$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	~		~	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\checkmark$	$\overline{\mathbf{v}}$	~	
Treatment and intended treatment plan, including medications, dosages, route of administration, and frequency of use.	N/A	N/A	N/A	N/A	N/A		N/A		N/A	N/A					~	N/A		N/A	N/A	N/A	N/A		
Records for surgical procedures include a description of the procedure, the name of the surgeon, the type of sedative/anesthetic agents used, their route of administration, and their strength if available in more than one strength.	N/A		N/A		N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
Diagnosis or assessment prior to performing a treatment or procedure.	N/A	$\vee$	N/A		N/A		N/A	abla	N/A	N/A	abla		abla	$\vee$		N/A	~	N/A	N/A	N/A	N/A		
If relevant, a prognosis of the animal's condition.	N/A		N/A		N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
All medications and treatments prescribed and dispensed, including strength, dosage, route of administration, quantity, and frequency of use.	N/A	$\overline{\mathbf{v}}$	N/A	abla	N/A	$\vee$	N/A	N/A	N/A	N/A	$\overline{\vee}$		abla			N/A	N/A	N/A	N/A	N/A	N/A		
Daily progress, if relevant, and disposition of the case.	N/A	~	N/A	~	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	



Feb

**Instructions:** 

Veterinarian Name: Kim Kuhlman

Report for the Month of: (circle one)

March

April

May

BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY • GAVIN NEWSOM, GOVERNOR DEPARTMENT OF CONSUMER AFFAIRS • VETERINARY MEDICAL BOARD 1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2978



Dec

Case No: \_4602018000299

VET # 8208

Sept

Oct

P (916) 515-5220 | Toll-Free (866) 229-0170 | www.vmb.ca.gov

July

August

## MONTHLY SUPERVISION REPORT

June

(1) Please review the supervision agreement which includes the percentage and frequency of records that

need to be reviewed.						
(2) Make additional copies of this page and two types of Supervision Review logs to be turned in						
monthly (Satisfactory/Unsatisfactory).						
(3) Fill this page completely with all up-to-date information and turn in monthly by the 5th of each month of						
supervision with corresponding logs.						
(4) Please fill out UNSATISFACTORY TREATMENT OR DOCUMENATION review log for all patient						
care reviewed that required discussion, concerns or recommendations and provide your feedback to the						
Board (e.g. did you discuss the concerns with the probationer, were any changes made, what was the						
outcome, etc.)						
(5) Please fill out SATISFACTORY TREATMENT AND DOCUMENTATION for all patient care						
reviewed that was in total compliance.						
The BOX below is to be filled out AFTER all necessary logs are filled out.						
The Box below is to be inied out All TEX an necessary logs are inied out.						
I HEREBY SUBMIT THIS REPORT OF COMPLIANCE AS REQUIRED BY THE VETERINARY						
MEDICAL BOARD AND THE TERMS AND CONDITIONS OF THE DISCIPLINARY ORDER IN THE						
MATTER REGARDING THE ABOVE REFERENCE PROBATIONER. I HEREBY CERTIFY UNDER						
PENALTY OF PERJURY UNDER THE LAW OF THE STATE OF CALIFORNIA THAT ALL						
STATEMENTS GIVEN HERE ARE TRUE AND CORRECT.						
SUPERVISOR NAME: Casille Batten VET # 18833						
PROBATIONER'S EMPLOYER OR HOSPITAL:						
San Francisco Equine, Inc						
Carrirancioso Equino, mo						
ADDRESS: 865 Marina Bay Pkwy Ste 39, Richmond, CA 94804 TELEPHONE #: (510)867-5871						
NUMBER OF HOURS YOU SPEND REVIEWING PATIENT RECORDS: PER WEEK PER						
MONTH 4						
SUPERVISOR'S SIGNATURE: Costle Batter, M. REVIEW DATE: 05.01.24						
SUPERVISOR'S SIGNATURE:						

TO			T (D)			
Patient Name	Original (	1)	Treatment Date	3.24.24		
Medical Care Provided Scope						
Patient Name	Beat of N	My Heart (2)	Treatment Date	3.25.24		
Medical Care P	Provided Prerace entry ex		am			
v	94		30			
<b>Patient Name</b>	Good Lovin (3)		Treatment Date	3.24.24		
Medical Care P	Provided Castration					
Patient Name	Greatful	Attitude (4)	Treatment Date	3.23.24		
Medical Care P	Provided Fluid administrate		ion post race			
	70	iblodi	2	·		
Patient Name	Hot and	Spicy (5)	Treatment Date	3.23 - 3.25.24		
Medical Care P	rovided	Blood work and	antibiotics for respira	atory disease		
<b>Patient Name</b>	Infinite L	ove (6)	Treatment Date	3.7.24		
Medical Care P	rovided	Prerace entry ex	am			
0		sactive .				
			177 N. 17			
Patient Name	Alibi Terl	hune (7)	Treatment Date	3.23.24		
Patient Name Medical Care P		hune (7) Lasix for work	Treatment Date	3.23.24		
		1	Treatment Date	3.23.24		
	rovided	1	Treatment Date  Treatment Date	3.23.24		
Medical Care P	Cry Me	Lasix for work				
Medical Care P	Cry Me	Lasix for work A Runner (8)				
Medical Care P	Cry Me	Lasix for work  Runner (8)  Lasix for work				
Medical Care P  Patient Name  Medical Care P	Cry Me A rovided  Slewscio	Lasix for work  A Runner (8)  Lasix for work  on (9)	Treatment Date  Treatment Date	3.24.24		
Medical Care P  Patient Name  Medical Care P  Patient Name	Cry Me A rovided  Slewscio	Lasix for work  A Runner (8)  Lasix for work  on (9)	Treatment Date	3.24.24		
Medical Care P  Patient Name  Medical Care P  Patient Name	Cry Me A rovided  Slewscio	Lasix for work  A Runner (8)  Lasix for work  on (9)  Prerace entry ex	Treatment Date  Treatment Date	3.24.24		
Medical Care Programme  Patient Name  Medical Care Programme  Patient Name  Medical Care Programme	Cry Me A rovided Slewscic rovided Bettor Be	Lasix for work  A Runner (8)  Lasix for work  on (9)  Prerace entry ex  et'r (10)	Treatment Date Treatment Date am and prerace me Treatment Date	3.24.24 3.25.24 dication		
Medical Care P  Patient Name Medical Care P  Patient Name Medical Care P  Patient Name	Cry Me A rovided Slewscic rovided Bettor Be	Lasix for work  A Runner (8)  Lasix for work  on (9)  Prerace entry ex	Treatment Date Treatment Date am and prerace me Treatment Date	3.24.24 3.25.24 dication		
Medical Care P  Patient Name Medical Care P  Patient Name Medical Care P  Patient Name	Cry Me A rovided Slewscic rovided Bettor Be	Lasix for work  A Runner (8)  Lasix for work  on (9)  Prerace entry ex  et'r (10)  Prerace entry ex	Treatment Date Treatment Date am and prerace me Treatment Date	3.24.24 3.25.24 dication		
Medical Care P  Patient Name Medical Care P  Patient Name Medical Care P  Patient Name Medical Care P	Cry Me A rovided  Slewscic rovided  Bettor Be rovided  Berry Va	Lasix for work  A Runner (8)  Lasix for work  on (9)  Prerace entry ex  et'r (10)  Prerace entry ex	Treatment Date Treatment Date am and prerace me Treatment Date am	3.24.24 3.25.24 dication 3.25.24		
Medical Care P  Patient Name Medical Care P	Cry Me A rovided  Slewscic rovided  Bettor Be rovided  Berry Va	Lasix for work  A Runner (8)  Lasix for work  on (9)  Prerace entry ex  et'r (10)  Prerace entry ex	Treatment Date Treatment Date am and prerace me Treatment Date am	3.24.24 3.25.24 dication 3.25.24		
Medical Care P  Patient Name Medical Care P	Cry Me A rovided  Slewscio rovided  Bettor Be rovided  Berry Va rovided	Lasix for work  A Runner (8)  Lasix for work  on (9)  Prerace entry ex  et'r (10)  Prerace entry ex	Treatment Date Treatment Date am and prerace me Treatment Date am	3.24.24 3.25.24 dication 3.25.24		
Medical Care Property Patient Name	Cry Me A rovided  Slewscic rovided  Bettor Be rovided  Berry Va rovided  Cowboy	Lasix for work  A Runner (8)  Lasix for work  on (9)  Prerace entry ex  et'r (10)  Prerace entry ex  illey (11)  Prework exam	Treatment Date  Treatment Date  am and prerace me  Treatment Date  am  Treatment Date	3.24.24 3.25.24 dication 3.25.24		
Patient Name Medical Care P	Cry Me A rovided  Slewscic rovided  Bettor Be rovided  Berry Va rovided  Cowboy	Lasix for work  A Runner (8)  Lasix for work  on (9)  Prerace entry ex  et'r (10)  Prerace entry ex  alley (11)  Prework exam  Kisses (12)	Treatment Date  Treatment Date  am and prerace me  Treatment Date  am  Treatment Date	3.24.24 3.25.24 dication 3.25.24		

<b>Patient Name</b>	Mr Duff (	13)	Treatment Date	3.25.24
Medical Care P			am	
Patient Name	Not My R	todeo (14)	Treatment Date	3.24.24
Medical Care P	rovided	Prework exams		
- 1	ľ		T ( 1 )	0.04.04
Patient Name	Stormy Kiss (15)		Treatment Date	3.24.24
Medical Care P	rovided	Prework exam		
Patient Name	D	10 (40)	Treatment Date	3.23.24
200 CONTROL OF THE CO	12000000 00000	el Campo (16)		0.20.24
Medical Care P	roviaea	Ultrasound tendo	on	
<b>Patient Name</b>	What's In	A Name (17)	Treatment Date	3.24.24
Medical Care P	20	Upper airway sco	nne	0.27.27
With the same is	1011464	Topper an way see	орс	
<b>Patient Name</b>	Dontim (*	18)	Treatment Date	3.25.24
Medical Care P	rovided	Prerace entry ex	am	
Patient Name	No More	Ding Dongs (19)	Treatment Date	3.24.24
Medical Care P	rovided	Upper airway sco	оре	
	ľ		T / / P /	
Patient Name	Poker Ali	T .	Treatment Date	3.25.24
Medical Care P	rovided	Prerace entry ex	am	
<b>Patient Name</b>	Drasfile	Dides (24)	Treatment Date	2.22.24
Medical Care P	- 1/2	Rides (21)		3.23.24
Medical Care F	Tovided	Upper Airway sc	ope	
<b>Patient Name</b>	Rivermar	k (22)	Treatment Date	3.24.24
Medical Care P		Upper Airway sc	one	0.21.21
		Topper 7 iii way ee		
<b>Patient Name</b>	Beau Bru	me (23)	Treatment Date	3.25.24
Medical Care P	A STATE OF THE PARTY OF THE PAR	Prerace entry ex	am	
NAME AND ADDRESS OF				
Patient Name	Begin Ag	ain (24)	Treatment Date	3.24.24
Medical Care P	rovided	Lasix for work		
				Reviewing Vet Initials CB

Patient Name	_	Sweetly (25)	Treatment Date	03.23.24
Medical Care P	rovided	Lasix for work		
				<b>.</b>
Patient Name	Baby Kris	sten (26)	Treatment Date	3.23.24
Medical Care P	rovided	Lasix for work		
	24			
Patient Name	Tamaran	do Star (27)	Treatment Date	3.24.24
Medical Care P	rovided	Medication dispe	ensed - medication for	or gastric ulcers
	_		_	
Patient Name	Explain T	his Audit (28)	Treatment Date	3.24.24
<b>Medical Care P</b>	rovided	Upperairway sco	рре	
		1504	2	
Patient Name	Along Ca	me Joann (29)	Treatment Date	3.24.24
<b>Medical Care P</b>	rovided	Post race fluids		
Patient Name	Bid On T	he Prize (30)	Treatment Date	3.23.24
<b>Medical Care P</b>	rovided	Radiograph shin		
<u> </u>	_	2000		
Patient Name	We Can	(31)	Treatment Date	3.25.24
<b>Medical Care P</b>	rovided	Prerace entry ex	am	
Patient Name	Steve's E	Big Ticket (32)	Treatment Date	3.25.24
Medical Care P	rovided	Prerace entry ex	kam	
	_			
Patient Name	Gerlachs	(33)	Treatment Date	3.23.24
Medical Care P	rovided	Lasix for work		
		-		
Patient Name	Monsieur	(34)	Treatment Date	3.24.24
<b>Medical Care P</b>	rovided	Lasix for work		
<b>Patient Name</b>	Consilies or A	Molly (35)	Treatment Date	3.24.24
	Smiling	nony (oo)		
Medical Care P		Lasix for work		
The second secon		1		
The second secon		Lasix for work	Treatment Date	3.19; 3.21.23
Medical Care P	rovided  Juniors K	Lasix for work	Treatment Date	3.19; 3.21.23

Patient Name	Luna Lind	da (37)	Treatment Date	3.24.24
Medical Care Pr	ovided	Prework exam		
Patient Name	*		Treatment Date	
<b>Medical Care Pr</b>	ovided			
			( 1904	
Patient Name			Treatment Date	
Medical Care Pr	ovided			
		4		
Patient Name			Treatment Date	
Medical Care Pr	ovided			
		55.45		
Patient Name		_	Treatment Date	
Medical Care Pr	ovided	Ye		
Patient Name			Treatment Date	
Medical Care Pr	ovided			
			T ( ) ( D (	
Patient Name		1	Treatment Date	
Medical Care Pr	ovided	St.		
- · · ·			T 4 4 D 4	
Patient Name		E.	Treatment Date	
Medical Care Pr	ovided			
D 4: 4 N			Treatment Date	
Patient Name		Ī	ттеминени дане	
Medical Care Pr	ovided	of the state of th		
Detient Name			Treatment Date	
Patient Name			Treatment Date	
Medical Care Pr	ovided			
Patient Name			Treatment Date	
	- L. L.	l	Transment Date	
Medical Care Pr	ovided			
Patient Name			Treatment Date	
Medical Care Pr	ovided		Trument Dute	
Medical Care Pr	ovided			Dariania Validation
				Reviewing Vet Initials CB

MEDICAL RECORD REVIEW. Record #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25
OVERALL EXAMINATION ASSESSMENT																									
Diagnosis complied with minimum standards.	$\overline{\mathbf{v}}$	$\checkmark$	$\checkmark$	$\checkmark$	$\overline{\checkmark}$	$\checkmark$	abla	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\overline{\checkmark}$	$\sim$	$\overline{\mathbf{v}}$	$\checkmark$	$\checkmark$	$\overline{\mathbf{v}}$								
Treatment was necessary, appropriate, and complied with minimum standards.			$\overline{\checkmark}$	$\checkmark$						$\overline{\mathbf{v}}$	$\overline{\checkmark}$	$\overline{\checkmark}$		abla	$\checkmark$		$\checkmark$			abla	$\overline{\mathbf{v}}$				
Maintained necessary and appropriate treatment.	abla	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	abla	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	abla	$\checkmark$	$\checkmark$	$\checkmark$
Maintained necessary and appropriate records and chart entries.	abla	$\checkmark$	$\checkmark$	$\checkmark$	$\overline{\checkmark}$	$\overline{\mathbf{v}}$	$\checkmark$	$\overline{\mathbf{v}}$	$\checkmark$	$\checkmark$	$\overline{\checkmark}$	$\overline{\checkmark}$	$\checkmark$	$\checkmark$	$\checkmark$	$\overline{\checkmark}$	$\checkmark$	$\checkmark$	$\checkmark$	abla	$\checkmark$	$\overline{\checkmark}$		$\overline{\checkmark}$	
Complied with existing statutes and regulations governing the practice of veterinary medicine.			$\checkmark$	$\checkmark$		$\checkmark$	$\overline{\mathbf{v}}$				$\checkmark$	abla	$\checkmark$		$\overline{\mathbf{v}}$		$\checkmark$				$\checkmark$		$\checkmark$	$\checkmark$	
CCR SECTION 2032.3 (a) RECORD REVIEW																									
Legible		$\overline{\checkmark}$	$\sim$	$\checkmark$			$\checkmark$		$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\checkmark$	$\overline{\mathbf{v}}$	$\checkmark$				$\checkmark$	$\overline{\mathbf{v}}$	$\checkmark$	$\overline{\mathbf{v}}$	$\checkmark$		$\checkmark$	$\checkmark$	abla
Name or initials of the person responsible for entries.		$\checkmark$	$\checkmark$	$\checkmark$			abla			$\checkmark$	$\checkmark$	$\checkmark$		$\overline{\mathbf{v}}$	$\overline{\checkmark}$		$\checkmark$			$\overline{\mathbf{v}}$	$\checkmark$				ightharpoons
Name, address and phone number of the client.	$\overline{\mathbf{v}}$	$\checkmark$	$[\checkmark]$	$\checkmark$	$\checkmark$	~	$\sim$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\overline{\mathbf{v}}$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$[\checkmark]$	$[\checkmark]$	$\sim$
Name or identity of the animal, herd or flock.	abla	$\checkmark$	$\overline{\checkmark}$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\vee$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	~	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	
Except for herds or flocks, age, sex, breed, species.		$\checkmark$	$\checkmark$	$\checkmark$	abla	$\checkmark$		abla	ightharpoons	$\checkmark$	$\checkmark$	$\checkmark$	$\overline{\mathbf{v}}$		abla	$\checkmark$	<b>~</b>	abla	ightharpoons	$\overline{\mathbf{v}}$	$\checkmark$	$\checkmark$	$\overline{\mathbf{v}}$	$\checkmark$	
Dates (beginning and ending) of custody of the animal, if applicable.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
A history or pertinent information as it pertains to each animal, herd, or flock's medical status.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Data, including that obtained by instrumentation, from the physical examination.			$\overline{\checkmark}$	$\checkmark$		abla	w			$\overline{\mathbf{v}}$	$\overline{\checkmark}$	$\overline{\checkmark}$	$\overline{\mathbf{z}}$	$\square$	abla	$\overline{\checkmark}$	$\checkmark$					$\overline{\mathbf{v}}$		$\overline{\mathbf{v}}$	
Treatment and intended treatment plan, including medications, dosages, route of administration, and frequency of use.		N/A	<b>~</b>	<b>~</b> ]		N/A				N/A	N/A	N/A	N/A	N/A	N/A		$\checkmark$	$\overline{\mathbf{v}}$		N/A			N/A		
Records for surgical procedures include a description of the procedure, the name of the surgeon, the type of sedative/anesthetic agents used, their route of administration, and their strength if available in more than one strength.	N/A	N/A	NIA	NI/A	NI/A	NI/A	NI/A	NI/A	N/A	NI/A	NI/A	N/A	NI/A	NI/A	N/A	N/A	N/A	NI/A	N/A	NI/A	N/A	NIA	N/A	NI/A	N/A
Diagnosis or assessment prior to performing a treatment or procedure.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
If relevant, a prognosis of the animal's condition.	N/A	N/A	✓	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	✓	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
All medications and treatments prescribed and dispensed, including strength, dosage, route of administration, quantity, and frequency of use.	N/A	N/A		~		N/A	$\overline{\mathbf{v}}$			N/A	N/A	N/A	N/A	N/A	N/A		N/A		N/A	N/A	N/A	N/A	N/A		
Daily progress, if relevant, and disposition of the case.	N/A	N/A	<b>~</b>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A		N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<del>-</del>																									

CONTRACTOR OF THE CONTRACTOR O		500000	(5.70%)	200014	(C)(X)	N. Carlo	Visibility	N 900 C	122599	GODGO.	0.00	130892	Children	T00000	9992	610000	10020	Barrie	250000	2000	X2000		
MEDICAL RECORD REVIEW. Record #	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	
OVERALL EXAMINATION ASSESSMENT																							
Diagnosis complied with minimum standards.	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$												
Treatment was necessary, appropriate, and complied with minimum standards.		$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$												
Maintained necessary and appropriate treatment.	$\overline{\mathbf{v}}$	$\overline{\checkmark}$	$\checkmark$	$\overline{\mathbf{v}}$		$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\overline{\mathbf{V}}$												
Maintained necessary and appropriate records and chart entries.	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\overline{}$	$\overline{\checkmark}$	$\checkmark$	$\checkmark$	$\checkmark$												
Complied with existing statutes and regulations governing the practice of veterinary medicine.	$[\checkmark]$	$[\checkmark]$	$\checkmark$	$\overline{\ }$	$\overline{\checkmark}$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$												
CCR SECTION 2032.3 (a) RECORD REVIEW																							
Legible	~	$\checkmark$	<b>/</b>		~	<b>/</b>	$\checkmark$	~	~	$\checkmark$	$\checkmark$												
Name or initials of the person responsible for entries.	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$		$\checkmark$	$\overline{\checkmark}$	$\overline{\checkmark}$	$\checkmark$	$\checkmark$	$\checkmark$												
Name, address and phone number of the client.	$\sim$	$\checkmark$	$[\checkmark]$	$\overline{\mathbf{v}}$	abla	$[\checkmark]$	$\checkmark$	$\checkmark$	$\checkmark$	$[\checkmark]$	$\leq$												
Name or identity of the animal, herd or flock.	~	$[\checkmark]$	$\checkmark$	$\checkmark$	$[\checkmark]$	$\checkmark$		$\checkmark$	$\checkmark$	$\sim$	$\checkmark$												
Except for herds or flocks, age, sex, breed, species.	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$												
Dates (beginning and ending) of custody of the animal, if applicable.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A												
A history or pertinent information as it pertains to each animal, herd, or flock's medical status.	N/A	$\overline{\checkmark}$	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A											
Data, including that obtained by instrumentation, from the physical examination.	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$		$\checkmark$	$[\checkmark]$	$\checkmark$	$\checkmark$											
Treatment and intended treatment plan, including medications, dosages, route of administration, and frequency of use.		abla	$\checkmark$	abla	abla	N/A	N/A		~	~	N/A	$\checkmark$											
Records for surgical procedures include a description of the procedure, the name of the surgeon, the type of sedative/anesthetic agents used, their route of administration, and their																							
strength if available in more than one strength.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A											
Diagnosis or assessment prior to performing a treatment or procedure.	$\sim$	$\checkmark$	$\checkmark$	$\overline{\checkmark}$	$\checkmark$	N/A	N/A	$\checkmark$	$\checkmark$	$\checkmark$	N/A	$\overline{\mathbf{V}}$											
If relevant, a prognosis of the animal's condition.	N/A	N/A	N/A	N/A	$\overline{\mathbf{v}}$	N/A	N/A	N/A	N/A	N/A	N/A	N/A											
All medications and treatments prescribed and dispensed, including strength, dosage, route of administration, quantity, and frequency of use.	$\checkmark$	$\checkmark$	N/A	$\checkmark$	abla	N/A	N/A	$\checkmark$	$\overline{\mathbf{v}}$	$\checkmark$	N/A	$\checkmark$											
Daily progress, if relevant, and disposition of the case.	N/A	N/A	N/A	N/A	<	N/A	N/A	N/A	N/A	N/A	N/A	N/A											

#### McKowen, Rachel@DCA

From: Juarez, Alexander@DCA

Sent: Friday, August 29, 2025 1:13 PM

To: McKowen, Rachel@DCA

Subject: FW: Allison and Kuhlman reviews

Attachments: ALLISON FEB 24 MEDICAL RECORD REVIEW OVERALL EXAMINATION ASSESSMENT.pdf;

Allison FEB 24 Monthly Supervision VET Report Packet Fillable.pdf; Kuhlman FEB24 MEDICAL RECORD REVIEW OVERALL EXAMINATION ASSESSMENT.pdf; Kuhlman FEB 24

Monthly Supervision VET Report Packet.pdf

#### Here you go.



### Alexander A. Juarez Probation Monitor

California Veterinary Medical Board Department of Consumer Affairs 1747 N. Market Blvd, Suite 230

Sacramento, CA 95834

Direct: 916-905-5434 Toll Free: 866-229-0170

| | X | Join Our Email List! | VMB Customer

Satisfaction Survey

From: Casille Batten

Sent: Wednesday, June 26, 2024 5:41 PM

To: Juarez, Alexander@DCA <Alexander.Juarez@dca.ca.gov>

Subject: Re: Allison and Kuhlman reviews

#### This Message Is From an Untrusted Sender

Warning: This email originated from outside of the organization! Do not click links, open attachments, or reply, unless you recognize the sender's email.

Report Suspicious

Hi Alex,

Here are the reviews for February.

Casille

On Wed, Jun 26, 2024 at 10:40 AM Juarez, Alexander@DCA < Alexander.Juarez@dca.ca.gov > wrote:

Hello,

You have provided reports for January 2024 and March 2024. Do you have reports for February 2024?
Thank you,
From: Casille Batten  Sent: Wednesday, June 26, 2024 9:07 AM  To: Juarez, Alexander@DCA < Alexander.Juarez@dca.ca.gov > Subject: Allison and Kuhlman reviews
Hi Alex,
Here are the record reviews for Drs Allison and Kuhlman. Sorry for the delay in getting these to you. I will have some more coming soon.
Thanks
Casille
Casille Batten, DVM
 Casille Batten, DVM



Instructions:

Veterinarian Name: Kim Kuhlman

Report for the Month of: (circle one)

BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY • GAVIN NEWSOM, GOVERNOR DEPARTMENT OF CONSUMER AFFAIRS • VETERINARY MEDICAL BOARD 1747 North Market Blvd., Suite 230, Sacramento, CA 95834-2978



Dec

Case No: \_4602018000299

VET# 8208

Sept

Oct

P (916) 515-5220 | Toll-Free (866) 229-0170 | www.vmb.ca.gov

#### MONTHLY SUPERVISION REPORT

March April May June July August

(1) Please review the supervision agreement which includes the percentage and frequency of records that
need to be reviewed.  (2) Make additional copies of this page and two types of Supervision Review logs to be turned in
monthly (Satisfactory/Unsatisfactory).
(3) Fill this page completely with all up-to-date information and turn in monthly by the 5 <sup>th</sup> of each month of supervision with corresponding logs.
(4) Please fill out UNSATISFACTORY TREATMENT OR DOCUMENATION review log for all patient care reviewed that required discussion, concerns or recommendations and provide your feedback to the Board (e.g. did you discuss the concerns with the probationer, were any changes made, what was the outcome, etc.)
(5) Please fill out SATISFACTORY TREATMENT AND DOCUMENTATION for all patient care reviewed that was in total compliance.
The BOX below is to be filled out AFTER all necessary logs are filled out.
I HEREBY SUBMIT THIS REPORT OF COMPLIANCE AS REQUIRED BY THE VETERINARY
MEDICAL BOARD AND THE TERMS AND CONDITIONS OF THE DISCIPLINARY ORDER IN THE
MATTER REGARDING THE ABOVE REFERENCE PROBATIONER. I HEREBY CERTIFY UNDER
PENALTY OF PERJURY UNDER THE LAW OF THE STATE OF CALIFORNIA THAT ALL
STATEMENTS GIVEN HERE ARE TRUE AND CORRECT.
SUPERVISOR NAME: Casille Batten VET # 18833
PROBATIONER'S EMPLOYER OR HOSPITAL: San Francisco Equine, Inc
ADDRESS: 865 Marina Bay Pkwy Ste 39, Richmond, CA 94804 TELEPHONE #: (510)867-5871
NUMBER OF HOURS YOU SPEND REVIEWING PATIENT RECORDS: PER WEEK PER MONTH _3.5
SUPERVISOR'S SIGNATURE: Costle Batter, M. REVIEW DATE: 04.23.24

	100			
Patient Name	Peter Flie	es (1)	Treatment Date	2.18.24
Medical Care P	rovided	Prerace entry ex	am	
	_			
Patient Name	Moonrise	e (2)	Treatment Date	2.18 - 2.19.24
Medical Care P	rovided	Diagnostics and	treatment for fever	
	Bar			
Patient Name	Union Ex	rpress (3)	Treatment Date	2.18.24
Medical Care P	rovided	Post race electro	lyte and vitamin supp	olementation
	_			
Patient Name	Buttonwo	ood Tree (4)	Treatment Date	2.18.24
Medical Care P	rovided	Post race electro	olyte and vitamin supp	olementation
·	10	3804		
Patient Name	Lord She	eldon (5)	Treatment Date	2.18.24
Medical Care P	rovided	Post race electro	lyte and vitamin sup	olementation
<b>Patient Name</b>	MacLear	ns Rhyme (6)	Treatment Date	2.18.24
Medical Care P	rovided	Post race electro	lyte and vitamin supp	olementation
	_	2000		
<b>Patient Name</b>	Super El	lie (7)	Treatment Date	2.18.24
Medical Care P	rovided	Post race electro	lyte and vitamin supp	olementation
		•		
Patient Name	Sir Greys	son (8)	Treatment Date	2.18.24
Medical Care P	rovided	Prerace entry ex	am	
Patient Name	Slewscio	on (9)	Treatment Date	2.18.24
<b>Medical Care P</b>	rovided	Lasix		
	- 27	•		
Patient Name	Dulas (1	0)	Treatment Date	2.18.24
<b>Medical Care P</b>	rovided	Lasix		
<b>Patient Name</b>	Lammas	(11)	Treatment Date	2.18.24
<b>Medical Care P</b>	rovided	Prerace entry ex	am	
	70			
<b>Patient Name</b>	Naughty	Nadine (12)	Treatment Date	2.18.24
Medical Care P	rovided	Post race electro	lyte and vitamin sup	olementation
			-	Reviewing Vet Initials CB

ATTA APP WHITE												
Patient Name	Shana Ma	adel (13)	Treatment Date	2.18.24								
Medical Care P	rovided	Post race electro	olyte and vitamin sup	pplementation								
	-											
Patient Name	Sunglass	es (14)	Treatment Date	2.18.24								
Medical Care P	rovided	Prerace entry ex	am									
Patient Name	Tessa (15	5)	Treatment Date	2.18.24								
Medical Care P	rovided	Post race electro	olyte and vitamin sup	pplementation								
		•										
Patient Name	TopAntici	pation (16)	Treatment Date	2.18.24								
<b>Medical Care P</b>	rovided	Post race electro	olyte and vitamin sup	pplementation								
	20		3									
Patient Name	My Bucke	et List (17)	Treatment Date	2.18.24								
Medical Care P	rovided	Prerace entry ex	am									
Patient Name	Sensation	nal ZZ (18)	Treatment Date	2.18.24								
<b>Medical Care P</b>	rovided	Diagnostics and	treatment for fever									
Patient Name	Momma I	Mocca (19)	Treatment Date	2.18.24								
<b>Medical Care P</b>	rovided	Radiographs										
<b>Patient Name</b>	Little Misc	chevious (20)	Treatment Date	2.18.24								
<b>Medical Care P</b>	rovided	Prerace entry ex	am									
Patient Name	Mischiefs	King (21)	Treatment Date	2.18.24								
<b>Medical Care P</b>		Preerace entry e	exam									
	9,0											
Patient Name	FastTrain	ToTexas (22)	Treatment Date	2.18.24								
<b>Medical Care P</b>	rovided	Dispense steroic	for cellulitis									
<b>Patient Name</b>	Cat Band	it (23)	Treatment Date	2.18.24								
Medical Care P	rovided	Lasix										
	70	•	2									
<b>Patient Name</b>	Warrens '	World (24)	Treatment Date	2.18 - 2.19.24								
Medical Care P	rovided	Treatment for ba	cterial dermatitis									
		1		Reviewing Vet Initials CB								
				<u></u>								

2120 V.O. 2000 00100	-			
Patient Name	Alexande	rs Dream (25)	Treatment Date	2.18.24
Medical Care P	rovided	Endoscopic exar	m	
Patient Name	Elwood R	oad (26)	Treatment Date	2.18.24
Medical Care P	rovided	Lasix for work		
	26			
Patient Name	TigerSun	(27)	Treatment Date	2.18.24
<b>Medical Care P</b>	rovided	Lasix for work	9	
		•		
<b>Patient Name</b>	River Of A	Ambition (28)	Treatment Date	2.18.24
<b>Medical Care P</b>	rovided	Upper airway sc	ope	
	20	Å4:	2	
<b>Patient Name</b>	Hartman	(29)	Treatment Date	2.18.24
<b>Medical Care P</b>	rovided	Lasix		
<b>Patient Name</b>	Rose Of I	Mooncoin (30)	Treatment Date	2.18.24
<b>Medical Care P</b>	rovided	Prerace entry ex	am	
. <del>.</del>	,	***		
<b>Patient Name</b>	ShezaLud	ckyCharm (31)	Treatment Date	2.18.24
<b>Medical Care P</b>	rovided	Dispense steroic	for soft tissue inflar	nmation
				-
Patient Name	Do It For	Dave (32)	Treatment Date	2.18.24
<b>Medical Care P</b>	rovided	Prework exam		
Commission was a commission of the commission of	Special control of security design to 1250 seek ob-	Secure and contraction of the co		
<b>Patient Name</b>	Hops For	Pops (33)	Treatment Date	2.18.24
<b>Medical Care P</b>		Prework exam		
2		No. 2007 To Committee Comm		
Patient Name	Gerlachs	(34)	Treatment Date	2.19.24
<b>Medical Care P</b>	rovided	Preventative me	dication for osteoart	hritis
Patient Name	Silver Flir	t (35)	Treatment Date	2.18.24
<b>Medical Care P</b>		Prerace entry ex	am	
		,	2	
<b>Patient Name</b>	Sparkle S	Sweetly (36)	Treatment Date	2.18.24
Medical Care P	rovided	Prerace entry ex	am	
AND TRANSPORT (1997)		, , , , , , , , , , , , , , , , , , , ,		Reviewing Vet Initials CB
				<u>-</u>

<b>Patient Name</b>	Druidic (	37)	Treatment Date	2.18.24
Medical Care P		Prerace entry ex	kam	
SAMOTO CONTRACTOR TO CONTRACTO		, , , , , , , , , , , , , , , , , , , ,		
<b>Patient Name</b>	Lil Bit Th	irsty (38)	Treatment Date	2.18.24
Medical Care P	rovided	Lasix		
	ľ			
Patient Name	Daddy's	1111	Treatment Date	2.18-2.19.24
Medical Care P	rovided	Treatment for ce	ellulitis	
D-4:4 N			Treatment Date	10.40.040.04
Patient Name	V 120/09 9-74	ehearsal (40)		2.18 - 2.19.24
Medical Care P	roviaea	Treatment for ce	ellulitis	
<b>Patient Name</b>	Wine and	d Whisky (41)	Treatment Date	2.18.24
Medical Care P	7/3	Upper airway en	doscopy	2.10.21
		Toppor an may on	шестру	
Patient Name			Treatment Date	
Medical Care P	rovided		•	
Patient Name			Treatment Date	
Medical Care P	rovided	F1 (9)		
Patient Name			Treatment Date	
	u svidad	1	Treatment Date	
Medical Care P	roviaea			
<b>Patient Name</b>	8		Treatment Date	
Medical Care P	rovided			
1,200,200,200,200,200,200,200,200,200,20		\$ K		
<b>Patient Name</b>			Treatment Date	
Medical Care P	rovided	20.00		
Patient Name	E TOPINE SURF	1	Treatment Date	
Medical Care P	rovided			
Dationt Name			Treatment Date	
Patient Name	uovid - J	1	Treatment Date	
Medical Care P	rovided			Danianian XI-4 Taiti I
				Reviewing Vet Initials CB

MEDICAL RECORD REVIEW. Record #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25
OVERALL EXAMINATION ASSESSMENT																									
Diagnosis complied with minimum standards.	$\checkmark$	$\overline{\mathbf{v}}$	$\overline{\checkmark}$	abla	$\overline{\mathbf{v}}$		$\overline{\mathbf{v}}$	$\sim$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	abla	$\checkmark$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$		$\sim$	abla	$\overline{\checkmark}$	$\overline{\mathbf{v}}$	$\overline{\checkmark}$	$\sim$		$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$
Treatment was necessary, appropriate, and complied with minimum standards.				~		$\overline{\mathbf{v}}$				$\overline{\mathbf{v}}$	abla	abla				abla	~				$\vee$				
Maintained necessary and appropriate treatment.	$\checkmark$	$[\checkmark]$	<	$\vee$		<	$\vee$	$\checkmark$	abla	$\overline{\mathbf{v}}$	$\vee$	abla	$\vee$	$\overline{\mathbf{v}}$	$\checkmark$	$\overline{\mathbf{v}}$	$\checkmark$	$\overline{\mathbf{v}}$			$\vee$				
Maintained necessary and appropriate records and chart entries.		$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	abla	abla	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\vee$	$\overline{\mathbf{v}}$		$\overline{\mathbf{v}}$	abla	abla	$\overline{\mathbf{v}}$	abla		<b>V</b>	$\overline{\mathbf{v}}$	abla				<b>V</b>	<b>V</b>	
Complied with existing statutes and regulations governing the practice of veterinary medicine.	$\overline{\mathbf{v}}$		$\overline{\mathbf{v}}$					~		$\overline{\mathbf{v}}$			$\overline{\mathbf{v}}$						$\overline{\mathbf{v}}$						
CCR SECTION 2032.3 (a) RECORD REVIEW																									
Legible		$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\vee$					$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\vee$						$\overline{\checkmark}$	abla			$\overline{\mathbf{v}}$			$\overline{\vee}$	
Name or initials of the person responsible for entries.	$\checkmark$		abla	abla			$\overline{\mathbf{v}}$							$\overline{\mathbf{v}}$			$\overline{\vee}$								
Name, address and phone number of the client.	$\overline{\checkmark}$	$\checkmark$	abla	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	abla		abla	$\overline{\mathbf{v}}$	$\vee$		$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\checkmark$	$\overline{\mathbf{v}}$			$\overline{\mathbf{v}}$		$\overline{\mathbf{v}}$	$\overline{\checkmark}$	
Name or identity of the animal, herd or flock.	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$		~	abla					~		$\overline{\mathbf{v}}$	abla			~	$\vee$	$\overline{\mathbf{v}}$	$\vee$		~			$\overline{\mathbf{v}}$	
Except for herds or flocks, age, sex, breed, species.	$\overline{\mathbf{v}}$							$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\sim$						$\overline{\mathbf{v}}$	$\vee$	$\sim$	~		~	abla	$\sim$	$\sim$	
Dates (beginning and ending) of custody of the animal, if applicable.	N/A																								
A history or pertinent information as it pertains to each animal, herd, or flock's medical status.	N/A	~	N/A	N/A		N/A	N/A	N/A																	
Data, including that obtained by instrumentation, from the physical examination.	$\overline{\checkmark}$						$\sim$			$\overline{\mathbf{v}}$			$\sim$			$\sim$	$\overline{\mathbf{v}}$				$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$		$\sim$	
Treatment and intended treatment plan, including medications, dosages, route of administration, and frequency of use.	N/A							N/A		~	N/A	N/A		N/A			N/A		N/A	N/A	N/A				
Records for surgical procedures include a description of the procedure, the name of the surgeon, the type of sedative/anesthetic agents used, their route of administration, and their strength if available in more than one strength.	N/A	$\geq$	N/A	N/A	N/A	N/A	N/A	N/A																	
Diagnosis or assessment prior to performing a treatment or procedure.	N/A		$\overline{\mathbf{v}}$					N/A			N/A	N/A		N/A			N/A			N/A	N/A	$\overline{\mathbf{v}}$			
If relevant, a prognosis of the animal's condition.	N/A		N/A	N/A	N/A	N/A	N/A	N/A																	
All medications and treatments prescribed and dispensed, including strength, dosage, route of administration, quantity, and frequency of use.	N/A		<b>V</b>		$\sim$		~	N/A	< >		N/A	N/A		N/A	<b>V</b>		N/A		~	N/A	N/A	< >		~	N/A
Daily progress, if relevant, and disposition of the case.	N/A		N/A	N/A	N/A	N/A	N/A	N/A																	

MEDICAL RECORD REVIEW. Record #	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	
OVERALL EXAMINATION ASSESSMENT																							
Diagnosis complied with minimum standards.	$\vee$																						
Treatment was necessary, appropriate, and complied with minimum standards.	<b>~</b>					abla	$\overline{\mathbf{v}}$		abla					$\vee$	$\overline{\mathbf{v}}$								
Maintained necessary and appropriate treatment.	$\checkmark$					$\overline{\mathbf{v}}$			$\overline{\mathbf{v}}$				$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$									
Maintained necessary and appropriate records and chart entries.	<b>~</b>	$\checkmark$	$\vee$	abla		$\vee$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$	<b>V</b>		$\overline{\mathbf{v}}$		$\overline{\mathbf{v}}$	<b>V</b>							
Complied with existing statutes and regulations governing the practice of veterinary medicine.	$\vee$	$\overline{\mathbf{v}}$	$\overline{\mathbf{v}}$			$\overline{\mathbf{v}}$		$\overline{\mathbf{v}}$	~	$\overline{\mathbf{v}}$		~	$\overline{\mathbf{v}}$										
CCR SECTION 2032.3 (a) RECORD REVIEW																							
Legible	<b>&gt;</b>	~	~	~	$\checkmark$	~	$\vee$	~	~	~	$\vee$	~	$\checkmark$	~	~	$\overline{\mathbf{v}}$							
Name or initials of the person responsible for entries.		$\overline{\mathbf{v}}$		$\overline{\mathbf{v}}$										$\overline{\mathbf{z}}$	$\overline{\checkmark}$								
Name, address and phone number of the client.	~	abla				$\overline{\mathbf{z}}$			abla			$\overline{\mathbf{v}}$	$ \vee $	$\checkmark$	~								
Name or identity of the animal, herd or flock.	<b>~</b>	$\overline{\mathbf{v}}$							$\overline{\mathbf{v}}$						$\vee$								
Except for herds or flocks, age, sex, breed, species.	$\checkmark$	$\overline{\mathbf{v}}$													$\overline{\mathbf{v}}$								
Dates (beginning and ending) of custody of the animal, if applicable.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A							
A history or pertinent information as it pertains to each animal, herd, or flock's medical status.	N/A	N/A	N/A	N/A	N/A		N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A							
Data, including that obtained by instrumentation, from the physical examination.	<b>V</b>	~	~						~	$\checkmark$	<b>V</b>	$\vee$	~	~	~	$\overline{\mathbf{v}}$							
Treatment and intended treatment plan, including medications, dosages, route of administration, and frequency of use.	< >				N/A		N/A	N/A		N/A	N/A	N/A		~	N/A	N/A							
Records for surgical procedures include a description of the procedure, the name of the surgeon, the type of sedative/anesthetic agents used, their route of administration, and their strength if available in more than one strength.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A							
Diagnosis or assessment prior to performing a treatment or procedure.	<b>V</b>	$\overline{\mathbf{v}}$			N/A		N/A	N/A		N/A	N/A	N/A			N/A	N/A							
If relevant, a prognosis of the animal's condition.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A							
All medications and treatments prescribed and dispensed, including strength, dosage, route of administration, quantity, and frequency of use.	<b>V</b>		N/A		N/A		N/A	N/A		N/A	N/A	N/A			N/A	N/A							
Daily progress, if relevant, and disposition of the case.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A							

#### McKowen, Rachel@DCA

From: Casille Batten <

Sent: Wednesday, August 27, 2025 2:37 PM

To: McKowen, Rachel@DCA

Cc: Kim Kuhlmann

Subject: Re: CVMB - Medical Record Review for Dr. Kuhlmann

#### This Message Is From an Untrusted Sender

Warning: This email originated from outside of the organization! Do not click links, open attachments, or reply, unless you recognize the sender's email.

Report Suspicious

Hi Rachel,

Thanks for the heads up! I'll make sure the form is attached for the next quarters reviews.

Casille

Casille Batten, DVM

On Wed, Aug 27, 2025 at 2:23 PM McKowen, Rachel@DCA < Rachel.McKowen@dca.ca.gov > wrote:

Good Afternoon Dr. Batten,

I hope you are doing well! I wanted to touch base with you in regards to the medical record review services that you provide for Dr. Kuhlmann.

It appears that the forms you have been submitting to the Board are missing the "unsatisfactory treatment or documentation" page of the report packet (please see attachment). Going forward, please make sure you are submitting this page as well, even if there wasn't any unsatisfactory treatment. There are two small boxes that say "compliant" and "noncompliant" on this page. If there isn't any unsatisfactory treatment, you would mark the "compliant" box and initial the bottom right of the page. If there is unsatisfactory treatment, then you would mark the "noncompliant" box and explain whatever was unsatisfactory and initial the bottom.

If you have any questions regarding the packet or the information given today, please feel free to reach out.